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Myelodysplastic	   syndrome	  with	   ring	  sideroblasts	   (MDS-­‐RS)	   is	  a	  clonal	  hematopoietic	   stem	  
cell	  disorder	  characterized	  by	  hyperplastic	  and	  ineffective	  erythropoiesis,	  ring	  sideroblasts	  in	  
the	  bone	  marrow,	  and	  anemia.	  Heterozygous	  mutations	  in	  the	  spliceosome	  gene	  SF3B1	  are	  
found	   in	   a	   majority	   of	   MDS-­‐RS	   cases	   and	   are	   associated	   with	   the	   ring	   sideroblast	  
phenotype	  and	  a	  favorable	  prognosis.	  MDS-­‐RS	  is	  a	  usually	  slowly	  progressing	  disease	  of	  the	  
elderly	  distinguished	  by	  an	  initial	  phase	  of	  erythroid	  hyperplasia	  and	  macrocytic	  anemia	  that	  
can	   remain	   stable	   for	   several	   years,	   but	   which	   usually	   evolve	   into	   progressive	   erythroid	  
failure	  and	  a	  need	  for	  regular	  red	  blood	  cell	  transfusions.	  	  
The	  focus	  of	  this	  thesis	  was	  to	  study	  the	  genotype-­‐phenotype	  relations	  in	  MDS-­‐RS	  patients	  
in	   order	   to	   understand	   the	   abnormal	   iron	   accumulation	   and	   erythroid	   failure,	   and	   in	  
particular	  the	  role	  of	  SF3B1	  in	  MDS	  pathogenesis.	  	  
In	  study	  I,	  we	  tested	  whether	  ABCB7	  was	  a	  key	  mediator	  of	  the	  aberrant	  iron	  accumulation,	  
by	   modulating	   its	   expression	   in	   normal	   bone	   marrow.	   ABCB7	   down-­‐regulation	   reduced	  
erythroid	  differentiation,	  growth	  and	  colony	   formation,	  and	  resulted	   in	  a	  gene	  expression	  
pattern	   similar	   to	   that	   observed	   in	   MDS-­‐RS	   erythroblasts,	   and	   in	   the	   accumulation	   of	  
mitochondrial	   ferritin.	   Conversely,	   forced	   ABCB7	   expression	   restored	   erythroid	   colony	  
growth	   and	   decreased	  mitochondrial	   ferritin	   in	  MDS-­‐RS	   CD34+	   progenitor	   cells.	   Also,	   we	  
showed	  altered	  exon	  usage	  of	  ABCB7	  as	  possible	  explanation	  of	  the	  reduced	  expression	  in	  
MDS-­‐RS	  and	  a	  potential	  link	  of	  this	  gene	  with	  SF3B1.	  
In	   study	   II	   we	   sought	   to	   identify	   potential	   downstream	   targets	   of	   SF3B1	   mutations	   and	  
understand	  how	  these	  affect	  RNA	  splicing	  and	  gene	  expression	  profile	  of	  MDS-­‐RS	  patients.	  
In	   particular,	   we	   detected	   a	   significant	   up-­‐regulation	   of	   genes	   involved	   in	   hemoglobin	  
synthesis	   and	   in	   the	   oxidative	   phosphorylation	   process,	   and	   down-­‐regulation	   of	  
mitochondrial	   ABC	   transporters	   compared	   to	   normal	   bone	   marrow.	   These	   findings	  
together	   with	   mis-­‐splicing	   of	   hemoglobin	   genes	   indicated	   a	   compromised	  
hemoglobinization	   during	   MDS-­‐RS	   erythropoiesis.	   Importantly,	   we	   demonstrated	   that	  
anemia	  in	  MDS-­‐RS	  patients	  develops	  during	  terminal	  differentiation	  into	  reticulocytes.	  
Ultimately	  in	  study	  III,	  we	  investigated	  the	  mechanistic	  effects	  of	  SF3B1	  mutation	  in	  MDS-­‐RS	  
pathogenesis	   and	  explored	   if	   the	  most	   frequent	  SF3B1	  mutation	  K700E	   confers	   a	   loss-­‐of-­‐
function	   with	   regard	   to	   gene	   expression	   and	   splicing	   of	   key	   genes	   in	   MDS-­‐RS.	   Loss	   or	  
reduction	  of	  SF3B1	  normal	  protein	  in	  human	  myeloid	  cells	  resulted	  unexpectedly	  in	  an	  MDS-­‐
RS-­‐like	  phenotype	  with	  reduced	  ABCB7	  expression	  and	  altered	  exon	  usage,	  increased	  levels	  
of	  ALAS2	  and	  mis-­‐splicing	  of	  TMEM14C.	  Identical	  effects	  were	  observed	  when	  we	  expressed	  
SF3B1	  K700E	  mutation	  at	  physiological	  levels.	  Additionally,	  loss	  of	  SF3B1	  compromised	  cell	  
growth	   but	   did	   not	   increase	   apoptosis.	   Overall,	   our	   findings	   support	   an	   essential	   role	   of	  
ABCB7	   in	   the	   MDS-­‐RS	   phenotype	   and	   offer	   insights	   into	   the	   mechanistic	   role	   of	   SF3B1	  
mutations.	   Via	   altered	   gene	   expression	   or	   mis-­‐splicing	   of	   key	   genes	   in	   the	   heme	   and	  
hemoglobin	  synthesis,	  these	  mutations	  disturb	  mitochondrial	   iron	  handling	  in	  a	  way	  that	  
lead	  to	  mitochondrial	  iron	  accumulation	  in	  MDS-­‐RS.	  	   	  
LIST	  OF	  PUBLICATIONS	  
	  
	  I. Nikpour	  M.*,	   Scharenberg	   C.*,	   Liu	   A.,	   Conte	   S.,	   Karimi	  M.,	   Mortera-­‐
Blanco	  T.,	  Giai	  V.,	  Fernandez-­‐Mercado	  M.,	  Papaemmanuil	  E.,	  Hogstrand	  
K.,	   Jansson	   M.,	   Vedin	   I.,	   Wainscoat	   J.S.,	   Campbell	   P.,	   Cazzola	   M.,	  
Boultwood	   J.,	   Grandien	   A.,	   Hellström-­‐Lindberg	   E.	   (2013).	   The	  
transporter	   ABCB7	   is	   a	   mediator	   of	   the	   phenotype	   of	   acquired	  
refractory	  anemia	  with	  ring	  sideroblasts.	  Leukemia,	  27,	  889-­‐896.	  
	  
II. Conte	  S.,	   Katayama	  S.,	  Vesterlund	   L.,	   Karimi	  M.,	  Dimitriou	  M.,	   Jansson	  
M.,	  Mortera-­‐Blanco	  T.,	  Unneberg	  P.,	  Papaemmanuil	  E.,	  Sander	  B.,	  Skoog	  
T.,	   Campbell	   P.,	   Walfridsson	   J.,	   Kere	   J.,	   Hellström-­‐Lindberg	   E.	   (2015).	  
Aberrant	   splicing	   of	   genes	   involved	   in	   haemoglobin	   synthesis	   and	  
impaired	   terminal	   erythroid	   maturation	   in	   SF3B1	   mutated	   refractory	  
anaemia	  with	  ring	  sideroblasts.	  Br	  J	  Haematol.	  2015	  Nov;171(4):478-­‐90	  
	  
III. Conte	   S.,	   Heshmati	   Y.,	   Harisankar	   A.,	   Dimitriou	   M.,	   Jansson	   M.,	  
Vesterlund	  L.,	  Elvarsdottir	  E.,	  Mortera-­‐Blanco	  T.,	  Larsson	  J.,	  Shiozawa	  Y.,	  
Ogawa	  S.,	  Karimi	  M.,	  Walfridsson	   J.,	  Hellström-­‐Lindberg	  E.	  Mechanistic	  
role	  of	  SF3B1	  in	  MDS-­‐RS.	  Manuscript	  
	  
	  




Related	  publications	  not	  included	  in	  the	  thesis	  
	  
	  
I.	  . Malcovati	   L.*,	   Papaemmanuil	   E.*,	   Bowen	   D.T.,	   Boultwood	   J.,	   Della	  
Porta	   M.G.,	   Pascutto	   C.,	   Travaglino	   E.,	   Groves	   M.J.,	   Godfrey	   A.L.,	  
Ambaglio	  I.,	  Galli	  A.,	  Da	  Via	  M.C.,	  Conte	  S.,	  Tauro	  S.,	  Keenan	  N.,	  Hyslop	  
A.,	   Hinton	   J.,	   Mudie	   L.J.,	   Wainscoat	   J.S.,	   Futreal	   P.A.,	   Stratton	   M.R.,	  
Campbell	   P.J.,	   Hellström-­‐Lindberg	   E.,	   Cazzola	   M.	   (2011).	   Clinical	  
significance	   of	   SF3B1	   mutations	   in	   myelodysplastic	   syndromes	   and	  
myelodysplastic/myelo-­‐proliferative	  neoplasms.	  Blood,	  118,	  6239-­‐6246	  
	  
II.	  
II. Malcovati	   L.,	   Karimi	   M.,	   Papaemmanuil	   E.,	   Ambaglio	   I.,	   Jädersten	   M.,	  
Jansson	  M.,	   Elena	   C.,	   Gallì	   A.,	  Walldin	  G.,	   Della	   Porta	  M.G.,	   Raaschou-­‐
Jensen	  K.,	  Travaglino	  E.,	  Kallenbach	  K.,	  Pietra	  D.,	   Ljungström	  V.,	  Conte,	  
S.,	   Boveri	   E.,	   Invernizzi	   R.,	   Rosenquist	   R.,	   Campbell	   P.J.,	   Cazzola	   M.,	  
Hellström	  Lindberg	  E.	  (2015).	  SF3B1	  mutation	  identifies	  a	  distinct	  subset	  




TABLE	  OF	  CONTENTS	  
 
1 INTRODUCTION	  ....................................................................................................................	  1 
1.1 Erythropoiesis	  ...............................................................................................................	  1 
1.2 Iron	  metabolism	  and	  heme	  synthesis	  ..........................................................................	  3 
1.3 Myelodysplastic	  Syndromes	  .........................................................................................	  6 
1.4 Myelodysplastic	  Syndromes	  with	  Ring	  Sideroblasts	  ....................................................	  9 
1.4.1 Morphological	  and	  clinical	  features	  of	  MDS-­‐RS	  ....................................................	  9 
1.4.2 Treatment	  of	  MDS-­‐RS	  ..........................................................................................	  12 
1.4.3 Mutational	  landscape	  in	  MDS-­‐RS	  ........................................................................	  13 
1.4.4 Spliceosome	  as	  the	  “indicted	  conspirator”	  in	  MDS-­‐RS	  .......................................	  15 
1.4.5 Mutations	  in	  the	  splicing	  factor	  SF3B1	  ................................................................	  16 
1.4.6 Functional	  impact	  of	  SF3B1	  mutations	  in	  MDS-­‐RS	  .............................................	  19 
1.4.6.1 Mouse	  models	  of	  SF3B1	  mutations	  .............................................................	  19 
1.4.6.2 Effects	  of	  SF3B1	  mutations	  on	  splicing	  ........................................................	  21 
1.4.6.3 Gene	  expression	  profile	  in	  SF3B1	  mutated	  cells	  ..........................................	  24 
2 AIM	  OF	  THE	  THESIS	  ............................................................................................................	  26 
3 METHODOLOGICAL	  APPROACHES	  .....................................................................................	  27 
3.1 CD34+	  cells	  isolation	  and	  erythroblast	  culture	  ...........................................................	  27 
3.2 Colony	  forming	  unit	  assay	  ..........................................................................................	  27 
3.3 q-­‐PCR	  ...........................................................................................................................	  28 
3.4 Taqman	  low	  density	  array	  ..........................................................................................	  28 
3.5 Pyrosequencing	  ..........................................................................................................	  29 
3.6 RNA	  sequencing	  ..........................................................................................................	  30 
3.7 Lentiviral	  transduction	  ................................................................................................	  31 
3.8 short	  hairpin	  RNA	  .......................................................................................................	  32 
3.9 CRISPR/Cas9	  genome	  editing	  .....................................................................................	  33 
4 RESULTS	  AND	  DISCUSSIONS	  ..............................................................................................	  36 
4.1 Study	  I	  .........................................................................................................................	  36 
4.2 Study	  II	  ........................................................................................................................	  39 
4.3 Study	  III	  .......................................................................................................................	  43 
5 CONCLUDING	  REMARKS	  AND	  FUTURE	  DIRECTIONS	  .........................................................	  46 
6 ACKNOWLEDGEMENTS	  .....................................................................................................	  49 
7 REFERENCES	  .......................................................................................................................	  53 
	  
  
LIST	  OF	  ABBREVIATIONS	  
ABCB7	  	   ATP	  Binding	  Cassette	  B7	  
ALA	   Aminolevulinic	  Acid	  	  
ALAS2	   Aminolevulinic	  Acid	  Synthase	  2	  
AML	   Acute	  Myeloid	  Leukemia	  
ATG	   Anti-­‐Thymocyte	  Globulin	  
BFU-­‐E	   Burst	  Forming	  Unit-­‐Erythroid	  
BM	   Bone	  Marrow	  
CFU-­‐E	   Colony	  Forming	  Unit-­‐Erythroid	  
CLL	  	   Chronic	  Lymphocytic	  Leukemia	  
CMML	   Chronic	  Myelomonocytic	  Leukemia	  
CRISPR	   Clustered	  Regularly	  Interspaced	  Short	  Palindromic	  Repeats	  
DMT1	   Divalent	  Metal	  Transporter	  1	  
EPO	   Erythropoietin	  	  
ESA	   Erythropoiesis	  Stimulating	  Agents	  	  
ET	   Essential	  Thrombocythemia	  
FAB	   French	  American	  British	  	  
Fe-­‐S	   Iron-­‐Sulphur	  
FPKM	   Fragments	  Per	  Kilobase	  of	  Exon	  per	  Million	  of	  Fragments	  Mapped	  
FTMT	   Mitochondrial	  Ferritin	  
G-­‐CSF	   Granulocyte	  Colony-­‐Stimulating	  Factor	  
GFP	   Green	  Fluorescent	  Protein	  
GLRX5	   Glutaredoxin	  5	  
GMP	   Granulocytes	  Macrophage	  Progenitors	  
GPA	  	   Glycophorin	  A	  
GSEA	   Gene	  Set	  Enrichment	  Analysis	  
HEAT	  	   Huntingtin	  Elongation	  Factor	  EF2	  Protein	  Phosphatase	  PP2A	  yeast	  kinase	  
TOR1	  
HMA	   Hypomethylating	  Agents	  	  
HSC	   Hematopoietic	  Stem	  Cells	  
IL-­‐3	   Interleukin-­‐3	  
IPSS	   International	  Prognostic	  Scoring	  System	  
IRP	   Iron	  Regulatory	  Proteins	  
JAK	   Janus	  Kinases	  
MAPK	   Mitogen-­‐Activated	  Protein	  Kinases	  
MDS	  	  	   Myelodysplastic	  Syndromes	  
MDS-­‐RS	  	   Myelodysplastic	  Syndromes	  with	  Ring	  Sideroblasts	  	  
	   	  
  
MDS/MPN	   Myelodysplastic	  Syndromes/Myeloproliferative	  Neoplasms	  
MNC	   Mononuclear	  Cells	  
mTOR	   Mechanistic	  Target	  Of	  Rapamycin	  
NBM	   Normal	  Bone	  Marrow	  
NMD	  	   Nonsense	  Mediated	  Decay	  
NSG	   Nod	  Scid	  Gamma	  
PAM	  	   Protospacer	  Adjacent	  Motif	  
PB	   Peripheral	  Blood	  
PMF	   Primary	  Myelofibrosis	  
qPCR	   Quantitative	  Real	  Time	  PCR	  
RAEB	   Refractory	  Anemia	  with	  Excess	  of	  Blasts	  
RARS	   Refractory	  Anemia	  with	  Ring	  Sideroblasts	  
RARS-­‐T	  	   Refractory	  Anemia	  with	  Ring	  Sideroblast	  with	  Thrombocytosis	  
RBC	  	   Red	  Blood	  Cell	  
RCMD	  	   Refractory	  Cytopenia	  with	  Multilineage	  Dysplasia	  
ROS	   Reactive	  Oxygen	  Species	  
RS	   Ring	  Sideroblasts	  
SA	  	   Sideroblastic	  Anemia	  
SCF	   Stem	  Cell	  Factor	  
SF1	   Splicing	  Factor	  1	  
SF3B1	   Splicing	  Factor	  3b	  subunit	  1	  
shRNA	   short	  hairpin	  RNA	  
SLC25A37	  	   Mitoferrin-­‐1	  
snRNP	  	   small	  nuclear	  Ribonucleic	  Protein	  
SOLiD	   Sequencing	  by	  Oligo	  Ligation	  Detection	  
SS	   Splice	  Site	  
STAT	   Signal	  Transducer	  and	  Activator	  of	  Transcription	  
STEAP3	   Ferroreductase	  3	  
TF	   Transferrin	  
TFCP2	   Transcription	  Factor	  CP2	  
TGF-­‐β	   Transforming	  Growth	  Factor	  β	  
TLDA	   Taqman	  Low	  Density	  Array	  
TMEM14C	   Transmembrane	  protein	  14C	  
TPO	   Thrombopoietin	  
WHO	   World	  Health	  Organization	  
WT	  	   Wild-­‐Type	  
XLSA	   X-­‐Linked	  Sideroblastic	  Anemia	  
	  
	   	  











  1 
1 INTRODUCTION	  
1.1 ERYTHROPOIESIS	  
The	   process	   of	   erythropoiesis	   entails	   the	   generation	   of	   mature	   red	   blood	   cells	   from	  
multipotent	   stem	  cells.	   The	  erythrocyte	   is	   the	  most	   common	  cell	   type	   in	  blood.	  Mature	  
erythrocytes	   have	   a	   life	   span	   of	   approximately	   120	   days	   and	   need	   to	   be	   continuously	  
produced	   in	  order	  to	  renew	  the	  red	  cell	  mass.	   In	  mammals,	  definitive	  erythropoiesis	  first	  
occurs	  in	  the	  fetal	  liver	  with	  progenitor	  cells	  from	  the	  yolk	  sac	  (Palis	  et	  al.	  1999).	  Within	  the	  
fetal	  liver	  and	  the	  adult	  bone	  marrow,	  hematopoietic	  cells	  are	  formed	  continuously	  from	  a	  
small	  population	  of	  pluripotent	  stem	  cells	  that	  generate	  progenitors	  committed	  to	  one	  or	  a	  
few	  hematopoietic	  lineages	  (Hattangadi	  et	  al.	  2011).	  	  
The	   erythroid	   lineage	   consists	   of	   erythroid	   progenitors	   and	   precursors.	   Erythroid	  
progenitors	   can	   be	   divided	   in	   early	   or	   late	   progenitors	   based	   on	   their	   colony	   forming	  
capacity	  in	  vitro.	  The	  earliest	  committed	  progenitors,	  the	  burst	  forming	  unit-­‐erythroid	  (BFU-­‐
E),	   are	   the	   first	   solely	  erythroid	   restricted	  cells	   and	  give	   rise	   to	  multi-­‐clusters	   colonies	   (or	  
bursts)	   comprising	   200	   to	   many	   thousands	   of	   erythroblasts	   (Testa	   2004).	   The	   late	  
progenitors	   are	   the	   colony	   forming	   unit-­‐erythroid	   (CFU-­‐E),	   more	   differentiated	   than	   the	  
BFU-­‐E	  and	  able	   to	  generate	  smaller	  colonies	   in	  one	  or	   few	  separate	  clusters.	   Importantly,	  
BFU-­‐E	   and	   CFU-­‐E	   can	   be	   distinguished	   based	   on	   their	   differential	   growth	   factor	  
requirements.	  The	  proliferation	  and	  survival	  of	  BFU-­‐E	  is	  dependent	  on	  the	  stem	  cell	  factor	  
(SCF)	  and	   interleukin-­‐3	   (IL-­‐3)	   signaling,	  while	  CFU-­‐E	  progenitors	  are	  exclusively	  dependent	  
on	  erythropoietin	  (EPO).	  CFU-­‐Es	  differentiate	  into	  morphologically	  distinguishable	  erythroid	  
precursor,	   which	   in	   contrast	   to	   the	   erythroid	   progenitors,	   are	   less	   EPO	   responsive,	   but	  
strongly	   iron	   dependent	   (Camaschella	   et	   al.	   2016).	   The	   first	   recognizable	   precursors,	  
proerythroblasts,	  undergo	  3-­‐5	  cell	  divisions	  and	  give	  rise	  to	  basophilic,	  polychromatic	  and	  
orthochromatic	   erythroblasts.	   These	   cell	   divisions	   are	   characterized	   by	   a	   rapid	   G1	   cell	  
phase	   resulting	   in	   a	   progressive	  decrease	   in	   cell	   size	   (von	   Lindern	  2006).	   Simultaneously,	  
maturating	   precursors	   undergo	   to	   substantial	   changes	   in	   morphology	   due	   to	   the	  
accumulation	  of	  erythroid-­‐specific	  proteins	  and	  chromatin	  condensation	  (Hattangadi	  et	  al.	  
2011).	  Then,	  orthochromatic	  erythroblasts	  form	  reticulocytes	  by	  extruding	  their	  nuclei	  and	  
reticulocytes	   lose	  their	  mitochondria	  and	  ribosomes	  within	  a	  couple	  of	  days	  before	  finally	  
maturing	  into	  erythrocytes	  (Testa	  2004)	  (Figure	  1).	  	  
Each	  stage	  of	   the	  erythroid	  maturation	  process	  can	  be	  distinguished	  by	   the	  expression	  of	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surface	  markers/receptors,	  transcription	  factors	  and	  effector	  molecules.	  The	  main	  hormone	  
involved	  in	  erythropoiesis	  is	  EPO,	  which	  interacts	  with	  cells	  carrying	  its	  receptor	  EpoR,	  i.e.	  all	  
cells	  of	  the	  erythroid	  lineage	  except	  for	  reticulocytes.	  SCF	  is	  the	  ligand	  for	  the	  c-­‐kit	  receptor,	  
which	  it	   is	  present	  on	  a	   large	  spectrum	  of	  hematopoietic	  stem	  and	  progenitors	  cells.	  Both	  
BFU-­‐E	   and	   CFU-­‐E	   exhibit	   high	   levels	   of	   c-­‐kit	   (or	   CD117)	   and	   the	   levels	   decrease	   at	   the	  
proerythroblast	   stage.	   The	   expression	   of	   glycoprotein	   CD36,	   transferrin	   receptor	   (TFR	   or	  
CD71)	   and	   glycophorin	   A	   (GPA	   or	   CD235a)	   divide	   erythroid	   precursors	   into	   three	  
erythroblasts	  populations:	  basophilic/polychromatic	  (CD36+	  CD71+	  GPA+),	  orthochromatic	  
(CD36-­‐	  CD71+	  GPA+)	  and	  reticulocytes/red	  blood	  cells	  (CD36-­‐	  CD71-­‐	  GPA+)	  (Merryweather-­‐
Clarke	   et	   al.	   2011).	   GATA1	   is	   the	   main	   transcription	   factor	   driving	   terminal	   erythroid	  
differentiation,	  while	  GATA2	  is	  highly	  expressed	  in	  hematopoietic	  stem	  and	  progenitor	  cells.	  
Finally,	  the	  hemoglobin	  production	  that	  starts	  gradually	  at	  the	  erythroblast	  stage	  reaches	  its	  













Figure	  1	  Outline	  of	  the	  erythroid	  differentiation.	  SCF,	  IL-­‐3,	  EPO	  are	  the	  growth	  factors	  required	  
during	  the	  erythroid	  maturation	  process.	  Each	  stage	  is	  distinguished	  by	  the	  expression	  of	  surface	  
marker/receptors	  (grey)	  and	  transcription	  factors	  (black).	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1.2 IRON	  METABOLISM	  AND	  HEME	  SYNTHESIS	  	  
	  
The	  second	  phase	  of	  the	  erythropoiesis	  from	  proerythroblasts	  to	  erythrocytes	  is	  strongly	  
iron	  dependent.	  Iron	  is	  essential	  for	  heme	  and	  iron-­‐sulfur	  cluster	  synthesis	  in	  every	  cell	  of	  
the	   body	   but	   is	   required	   in	   larger	   amounts	   for	   hemoglobin	   synthesis	   in	   maturing	  
erythroblasts	   (Camaschella	  et	  al.	  2016).	  To	  produce	  about	  200	  billion	  erythrocytes	  every	  
day,	  approximately	  25	  mg	  of	  iron	  must	  be	  supplied	  to	  the	  bone	  marrow.	  The	  vast	  majority	  
is	  provided	  by	  macrophages,	  who	  recycle	  hemoglobin-­‐derived	  iron	  from	  the	  breakdown	  of	  
senescent	  erythrocytes,	  while	  in	  the	  absence	  of	  anemia,	  <1–2	  mg	  iron	  daily	  derives	  from	  
intestinal	  absorption	  (Camaschella	  et	  al.	  2011).	  As	  we	  recycle	  much	  more	  iron	  than	  what	  
we	  absorb,	  iron	  has	  a	  very	  conservative	  metabolism.	  	  
Iron	   enters	   the	   body	   through	   the	   diet	   and	   most	   iron	   absorption	   takes	   place	   in	   the	  
duodenum	  (Figure	  2).	   In	  the	  enterocytes,	   iron	  is	  solubilized	  and	  converted	  from	  trivalent	  
into	   bivalent	   by	   the	   duodenal	   cytochrome	   B	   (DcytB).	   Iron	   is	   transported	   across	   the	  
enterocyte’s	   cell	   membrane	   by	   the	   divalent	   metal	   transporter	   1	   (DMT1)	   into	   the	   cell	  
where	  heme	  is	  degraded	  by	  heme	  oxygenase	  and	  iron	  is	  either	  stored	  in	  cellular	  ferritin	  or	  
released	  into	  the	  portal	  circulation	  by	  the	  ferroportin	  (Figure	  2A).	  The	  hepatocyte	  serves	  
as	  the	  main	  storage	  for	  the	  iron	  surplus,	  but	  most	  body	  iron	  is	  present	  in	  erythrocytes	  and	  
macrophages.	  In	  the	  hepatocyte,	  hepcidin	  controls	  and	  regulates	  the	  entry	  of	   iron	  in	  the	  
circulation	  (Figure	  2B).	  The	  macrophage	  recycles	  hemoglobin-­‐derived	  iron	  from	  senescent	  
erythrocytes.	  This	  iron	  can	  either	  be	  stored	  in	  the	  macrophage	  as	  hemosiderin	  or	  ferritin	  
or	  be	  delivered	  to	  the	  erythroid	  progenitor	  as	  an	  ingredient	  for	  new	  erythrocytes	  (Figure	  
2C).	  The	  iron	  exporter	  ferroportin	  is	  responsible	  for	  the	  efflux	  of	  Fe	  into	  the	  circulation.	  In	  
the	  erythroid	  progenitor,	   transferrin	   saturated	  with	  2	   iron	  molecules	   is	   endocytosed	  via	  
the	   transferrin	   receptor	   1.	   After	   endocytosis,	   the	   iron	   is	   released	   from	   transferrin,	  
converted	  from	  trivalent	  to	  divalent	  Fe	  by	  the	  ferroreductase	  STEAP3	  and	  transported	  to	  
the	   cytosol	   by	   DMT1,	   where	   it	   is	   available	   mainly	   for	   the	   heme	   synthesis	   (Figure	   2D)	  
(Donker	   et	   al.	   2014).	   Iron	   is	   transported	   within	   the	   serum	   bound	   to	   transferrin	   (TF).	  
Cellular	   Fe	   homeostasis	   is	   maintained	   by	   iron	   regulatory	   proteins	   (IRP1	   and	   IRP2)	   that	  
recognize	  the	  iron	  responsive	  elements	  (IREs)	  located	  in	  untranslated	  regions	  of	  a	  subset	  
of	  mRNA	  involved	  in	  Fe	  homeostasis	  (Hentze	  et	  al.	  2010).	  Within	  the	  mitochondrion	  iron	  
can	   be	   used	   to	   synthesize	   heme	   and	   Fe-­‐S	   clusters,	   or	   incorporated	   into	   mitochondrial	  




Heme	  synthesis	   in	  erythroid	  cells	   is	  finely	  coordinated	  with	  that	  of	  alpha	  (α)	  and	  beta	  (β)-­‐
globin,	  resulting	  in	  the	  production	  of	  hemoglobin,	  and	  heme	  as	  the	  prosthetic	  group.	  Heme	  
is	  not	  only	   the	  structural	  component	  of	  hemoglobin,	  but	   it	  plays	  multiple	  regulatory	  roles	  
during	   the	   differentiation	   of	   erythroid	   precursors	   since	   it	   controls	   its	   own	   synthesis	   and	  
regulates	  the	  expression	  of	  several	  erythroid-­‐specific	  genes	  (Chiabrando	  et	  al.	  2014).	  Heme	  
is	  synthesized	  in	  developing	  erythroid	  progenitors	  by	  the	  stage	  of	  proerythroblast,	  through	  a	  
series	  of	  eight	  enzymatic	   reactions	  divided	  between	  mitochondria	  and	   cytosol.	   The	  heme	  
synthesis	   begins	   with	   the	   formation	   of	   the	   aminolevulinic	   acid	   (ALA)	   from	   glycin	   and	  
succinyl-­‐CoA,	  catalyzed	  by	  ALAS2	  in	  the	  mitochondrial	  matrix	  (Figure	  2E).	  ALA	  is	  exported	  to	  
the	  cytosol	  to	  be	  converted	  into	  porphobilinogen,	  hydroxymethylbilane,	  uroporphyrinogen	  
III	   and	   finally	   coporphyrinogen	   III	   through	   a	   series	   of	   enzymatic	   reactions	   (Figure	   3).	  
Figure	  2	  Iron	  homeostasis	  and	  heme	  synthesis.	  Figure	  reprinted	  with	  permission	  from	  the	  
publisher	  (Donker	  et	  al.	  2014)	  
1. Disorders due to low iron availability
for erythropoiesis
1A. Iron-refractory iron deficiency anemia (IRIDA) due to
defects in TMPRSS6
Pathogenesis and epidemiology. TMPRSS6 (OMIM 609862) en-
codes matriptase-2 (a type II plasma membrane serine protease) that
senses iron deﬁciency and blocks hepcidin transcription by cleaving
HJV. Consequently, pathogenic TMPRSS6 defects result in un-
inhibited hepcidin production, causing IRIDA.17-19At the population
level, genome-wide association studies show that TMPRSS6 is
polymorphic with a relatively large number of high-frequency poly-
morphisms, some ofwhich (particularly p.Ala736Val) are associated
with signiﬁcant decrease in the concentrations of iron, Hb, andMCVof
the red blood cell.20,21 The prevalence of pathogenic mutations leading
to IRIDA is unknown, but underdiagnosis seems likely. Patients with
IRIDA due to a suspected homozygous or compound heterozygous
TMPRSS6 defect are described in 61 patients in 39 families. Because
functional studies are not always performed, it is unclear whether
all these mutations are pathogenic. A few patients with microcytic
anemia, low TSAT, and low-normal ferritin are reported to be
heterozygous for TMPRSS6 defects (supplemental Data 1).
Figure 1. Cells and proteins involved in iron homeostasis and heme synthesis. (A) The enterocyte: iron enters the body through the diet. Most iron absorption takes place in
the duodenum and proximal jejunum. The absorption of iron takes place in different phases. In the luminal phase, iron is solubilized and converted from trivalent iron into bivalent iron
by duodenal cytochrome B (DcytB). Heme is released by enzymatic digestion of hemoglobin and myoglobin during the mucosal phase, iron is bound to the brush border and
transported into the mucosal cell by the iron transporter divalent metal transporter 1 (DMT1). Heme enters the enterocyte presumably through the heme carrier protein (HCP). In the
cellular phase, heme is degraded by heme oxygenase and iron is released. Iron is either stored in cellular ferritin or transported directly to a location opposite the mucosal side. In the
last phase of iron absorption, Fe21 is released into the portal circulation by the basolateral cellular exporter ferroportin. Enterocytic iron export requires hephaestin, a multicopper
oxidase homologous to ceruloplasmi (CP), which oxidizes Fe21 to Fe31 for loading onto transferrin. This cellular efflux of iron is inhibited by the peptide hormone hepcidin binding to
ferroportin and subsequent degradation of the ferroportin-hepcidin complex. (B) The hepatocyte serves as the main storage for the iron surplus (most body iron is present in
erythrocytes and macrophages). Furthermore, this cell, as the main producer of hepcidin, largely controls systemic iron regulation. The signal transduction pathway runs from the
membrane to the nucleus, where bone morphogenetic protein (BMP) receptor, the membrane protein hemojuvelin (HJV), the hemochromatosis (HFE) protein, transferrin receptors
1 and 2, and matriptase-2 play an essential role. Through intracellular pathways, a signal is given to hepcidin transcription. The membrane-ass ciated protease matriptase-2
(encoded by TMPRSS6) detects iron deficiency and blocks hepcidin transcription by cleaving HJV. (C) The macrophage belongs to the group of reticuloendothelial cells and breaks
down senescent red blood cells. During this process, iron is releas d from heme p oteins. Thi iron can either be st red in the macrophage as hemosi erin or ferritin or it may be
delivered to the erythroid progenitor as an ingredient for new erythrocytes. The iron exporter ferroportin is responsible for the efflux of Fe21 into the circulation. In both hepatocytes
and macrophages, this transport r quires th multicopper oxida CP, which oxidases Fe21 to Fe31 for loading onto tr sferrin. (D) The erythroid prog nitor: transferrin saturated
with 2 iron molecules is endocytosed via the transferrin receptor 1. After endocytosis, the iron is released from transferrin, converted from Fe31 to Fe21 by the ferroreductase
STEAP3, and transported to the cytosol by DMT1, where it is available mainly for the heme synthesis. Erythropoiesis has been reported to communicate with the hepatocyte by the
proteins TWSG1, GDF15, and erythroferrone (Erfe) that inhibit signaling to hepcidin.7,14,30 (E) The mitochondria of the erythroid progenitor: in the mitochondria the heme synthesis
and Fe-S cluster synthe is takes place. In th first rate-limiting step f heme synthesis, 5-aminolevulinic a id (ALA) is sy thesized fr m glycine and succinyl-coenzyme A by the
enzyme d-ALA synthase 2 (ALAS2) in the mitochondrial matrix. The protein SLC25A38 is located in the mitochondrial membrane and is probably responsible for the import of glycine
into the mitochondria and mig t also export ALA to the cytosol. In the heme synthesis pathway, the uroporphyrinogen III synthase (UROS) in the cytosol is the fourth enzyme. It is
responsible for the conversion of hydroxymethylbilane (HMB) to uroporphyrinogen III, a physiologic precursor of heme. In the last step, ferrochelatase (FECH), located in the
mitochondrial intermembrane space, is responsible for the incorporation of Fe21 into PPIX to form heme. GATA1 is critical for normal erythropoiesis, gl bin gene expression, and
megakaryocyte development; it also regulates expression of UROS and ALAS2 in erythroblasts. The enzyme glutaredoxin-5 (GLRX5) plays a role in the synthesis of the Fe-S
clusters, which are transported to the cytoplasm, probably via the trans orter ABCB7. Figure adapted from van Rooijen et al.2 Professional illustration created by Debra T. Dartez.
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Coporphyrinogen	   III	   is	   transferred	   into	  mitochondrial	   intermembrane	   space	   to	  where	   it	   is	  
modified	   to	   form	   protoporphyrinogen	   IX.	   Fe	   is	   inserted	   into	   protoporphyrinogen	   IX	   by	  
ferrochetalase	  (FECH)	  to	  produce	  heme	  (Chiabrando	  et	  al.	  2014).	  Fe-­‐S	  clusters	  are	  required	  
in	  the	  heme	  synthesis	  when	  a	  large	  amount	  of	  heme	  is	  needed	  for	  hemoglobinazation.	  The	  
enzyme	  glutaredoxin-­‐5	  (GLRX5)	  plays	  a	  role	  in	  the	  synthesis	  of	  the	  Fe-­‐S	  clusters,	  which	  are	  
transported	   via	   the	   transmembrane	   transporter	   ABCB7	   (Donker	   et	   al.	   2014),	   however	   its	  
substrate	   is	   unknown	   (Bekri	   et	   al.	   2000).	   Fe-­‐S	   clusters	   serve	   as	   cofactors	   for	   molecules	  
involved	   in	   electron	   transfer,	   catalysis,	   redox	   reactions,	   ribosome	  assembly,	  DNA	  damage	  
repair,	  telomere	  maintenance,	  DNA	  replication	  and	  other	  processes	  (Lill	  et	  al.	  1999).	  	  
	  
Figure	  3	  Schematic	  representation	  of	  the	  heme	  biosynthetic	  pathway.	  Heme	  synthesis	  starts	  in	  the	  
mitochondrion	  with	  the	  condensation	  of	  succynil-­‐CoA	  and	  glycine	   to	   form	  ALA,	  catalyzed	  by	  ALAS.	  
There	   are	   two	   isoforms	  of	  ALAS,	   ALAS1	   and	  ALAS2,	  ALAS1	   is	  ubiquitously	   expressed	  and	  provides	  
heme	  in	  non-­‐erythroid	  tissues	  while	  ALAS2	  gene	  is	  located	  is	  expressed	  exclusively	  in	  erythroid	  cells.	  
ALA	  is	  transported	  into	  the	  cytosol	  where	  it	  is	  converted	  to	  coporphyrinogen	  III	  through	  a	  series	  of	  
enzymatic	   reactions.	   Then,	   coporphyrinogen	   III	   is	   transferred	   into	   mitochondrial	   intermembrane	  
space	   to	  where	   it	   is	  modified	   to	   form	  protoporphyrinogen	   IX.	  Finally,	   ferrous	   iron	   is	   incorporated	  
into	  PPIX	  to	  form	  heme	   in	   the	  mitochondrial	  matrix,	  a	  reaction	  catalyzed	  by	  FECH.	  Figure	  adapted	  
from	  (Chiabrando	  et	  al.	  2014)	  and	  reprinted	  with	  permission	  from	  Haematologica	  Journal.	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1.3 MYELODYSPLASTIC	  SYNDROMES	  	  
The	  term	  myelodysplastic	  syndromes	  (MDS)	  encompass	  a	  heterogeneous	  group	  of	  myeloid	  
neoplasms	  characterized	  by	  ineffective	  clonal	  hematopoiesis	  and	  dysplasia	   in	  one	  or	  more	  
cell	  lineages,	  resulting	  in	  peripheral	  blood	  cytopenia(s).	  MDS	  is	  a	  disease	  of	  the	  elderly,	  with	  
a	  median	   age	  of	   75	   years	   and	  with	   less	   than	  10%	  of	   the	  patients	   being	   younger	   than	  50	  
years	   of	   age.	   The	   incidence	   in	   Europe	   is	   4	   cases/100	   000	   inhabitants/year	   with	   a	   slight	  
dominance	  of	  men	  (Greenberg	  et	  al.	  2012)	  and	  no	  known	  ethnic	  differences;	  however,	  MDS	  
in	  Asia	  tend	  to	  occur	  at	  an	  earlier	  age	  (Fenaux	  et	  al.	  2014).	  	  
MDS	   pathophysiology	   is	   a	   multistep	   process	   involving	   cytogenetic	   changes,	   somatic	  
mutations,	   and	   epigenetic	   alterations	   (Jiang	   et	   al.	   2009).	   Ninety	   percent	   of	   MDS	   are	  
idiopathic	   and	   approximately	   10%	   of	   cases	   occur	   secondary	   to	   previous	   treatment	   with	  
cytostatic	  drugs	  or	  radiotherapy	  (Neukirchen	  et	  al.	  2011).	  Epidemiological	  studies	  identified	  
occupational	  exposure	  to	  solvents	  or	  agricultural	  chemicals	  and	  tobacco	  use	  as	  risk	  factors;	  
however	  these	  factors	  have	  a	  poor	  association	  with	  the	  disease	  (Nisse	  et	  al.	  1995,	  Strom	  et	  
al.	   2005).	   Interestingly,	   the	   risk	   of	   MDS	   increases	   in	   different	   bone	   marrow	   failure	  
syndromes	  such	  as	  Fanconi	  Anemia,	  Diamond-­‐Blackfan	  anemia	  and	  dyskeratosis	  congenital	  
(Holme	   et	   al.	   2012,	  West	   et	   al.	   2014).	   Importantly,	   the	  MDS	   classification	   from	  2008	  has	  
recently	   been	   revised	   and	   the	   2016	   update	   contains	   several	   changes	   (i.e.	   refinements	   in	  
morphologic	   interpretation,	   cytopenia	   assessment	   and	  genetic	   information),	   not	   the	   least	  
with	  importance	  for	  MDS	  with	  ring	  sideroblasts,	  Table	  1,	  (Arber	  et	  al.	  2016).	  
The	   clinical	   presentation	   and	   the	   natural	   course	   of	   MDS	   vary	   between	   subgroups	   and	  
individuals.	   Symptoms	   are	   often	   related	   to	   the	   cytopenia(s),	   in	   the	   vast	   majority	  
represented	   by	   anemia,	   often	  macrocytic,	   but	   also	   leukopenia	   and/or	   thrombocytopenia.	  
Half	  of	  the	  patients	  have	  severe	  anemia	  (<100	  g/L)	  at	  diagnosis	  (Greenberg	  et	  al.	  1997)	  and	  
anemia	  related	  symptoms	  such	  as	  fatigue,	  dyspnea	  and	  headache.	  Other	  symptoms	  include	  
infections	   and	   bleedings	   as	   a	   result	   of	   leukopenia	   and	   thrombocytopenia.	   A	   minority	   of	  
patients	  suffers	  for	  autoimmune	  manifestations	  such	  as	  arthritis,	  pulmonary	  effusions	  and	  
vasculitis	  (Billstrom	  et	  al.	  1995,	  Marisavljevic	  et	  al.	  2006).	  Approximately	  30%	  of	  the	  patients	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Table	  1	  The	  2016	  revision	  to	  the	  WHO	  classification	  of	  MDS	  
Name	   Dysplastic	  lineages	   Cytopenias*	  









MDS	  with	  single	  
lineage	  dysplasia	  
(MDS-­‐SLD)	  
1	   1	  or	  2	   <15%/<5%**	  
BM	  <5%,	  PB	  
<1%,	  no	  Auer	  
rods	  
Any,	  unless	  fulfills	  all	  
criteria	  for	  MDS	  with	  
isolated	  del(5q)	  
MDS	  with	  multilineage	  
dysplasia	  (MDS-­‐MLD)	  
2	  or	  3	  
	   1-­‐3	   <15%/<5%**	  
BM	  <5%,	  PB	  
<1%,	  no	  Auer	  
rods	  
Any,	  unless	  fulfills	  all	  
criteria	  for	  MDS	  with	  
isolated	  del(5q)	  
MDS	  with	  ring	  sideroblasts	  (MDS-­‐RS)	  
MDS-­‐RS	  with	  single	  
lineage	  dysplasia	  
(MDS-­‐RS-­‐SLD)	  
1	   1	  or	  2	   ≥15%/≥5%**	  
BM	  <5%,	  PB	  
<1%,	  no	  Auer	  
rods	  
Any,	  unless	  fulfills	  all	  
criteria	  for	  MDS	  with	  





2	  or	  3	   1-­‐3	   ≥15%/≥5%**	  
BM	  <5%,	  PB	  
<1%,	  no	  Auer	  
rods	  
Any,	  unless	  fulfills	  all	  
criteria	  for	  MDS	  with	  
isolated	  del(5q)	  
MDS	  with	  isolated	  
del(5q)	   1-­‐3	   1-­‐2	   None	  or	  any	  
BM	  <5%,	  PB	  
<1%,	  no	  Auer	  
rods	  
del(5q)	  alone	  or	  with	  
1	  additional	  
abnormality	  except	  
−7	  or	  del(7q)	  
MDS	  with	  excess	  blasts	  (MDS-­‐EB)	  
MDS-­‐EB-­‐1	   0-­‐3	   1-­‐3	   None	  or	  any	  
BM	  5%-­‐9%	  or	  
PB	  2%-­‐4%,	  no	  
Auer	  rods	  
Any	  
MDS-­‐EB-­‐2	   0-­‐3	   1-­‐3	   None	  or	  any	  
BM	  10%-­‐19%	  
or	  PB	  5%-­‐19%	  
or	  Auer	  rods	  
Any	  
MDS,	  unclassifiable	  (MDS-­‐U)	  
with	  1%	  blood	  blasts	   1-­‐3	   1-­‐3	   None	  or	  any	  
BM	  <5%,	  PB	  =	  
1%,	  ‡no	  Auer	  
rods	  
Any	  
with	  single	  lineage	  
dysplasia	  and	  
pancytopenia	  
1	   3	   None	  or	  any	  
BM	  <5%,	  PB	  
<1%,	  no	  Auer	  
rods	  
Any	  
based	  on	  defining	  
cytogenetic	  
abnormality	  
0	   1-­‐3	   <15%	  §	  
BM	  <5%,	  PB	  





of	  childhood	   1-­‐3	   1-­‐3	   None	  
BM	  <5%,	  PB	  
<2%	   Any	  
(*)	  Cytopenias	  defined	  as:	  hemoglobin,	  <10	  g/dL;	  platelet	  count,	  <100	  ×	  109/L;	  and	  absolute	  neutrophil	  
count,	   <1.8	   ×	   109/L.	   Rarely,	  MDS	  may	   present	   with	  mild	   anemia	   or	   thrombocytopenia	   above	   these	  
levels.	  PB	  monocytes	  must	  be	  <1	  ×	  109/L;	  (**)	  If	  SF3B1	  mutation	  is	  present;	  (‡)	  One	  percent	  PB	  blasts	  
must	  be	  recorded	  on	  at	  least	  2	  separate	  occasions;	  (§)	  Cases	  with	  ≥15%	  ring	  sideroblasts	  by	  definition	  
have	  significant	  erythroid	  dysplasia,	  and	  are	  classified	  as	  MDS-­‐RS-­‐SLD.	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MDS	  diagnosis	   is	   based	  on	  peripheral	   blood	   counts	   including	   a	   full	   differential	   count	   and	  
cytomorphology,	   bone	  marrow	   aspiration	   and	   biopsy,	   and	   cytogenetics	   of	   bone	  marrow	  
cells.	  The	  bone	  marrow	  in	  MDS	  patients	   is	  typically	  hypercellular	  with	  significant	  dysplasia	  
(≥10%	   of	   all	   nucleated	   cells)	   in	   at	   least	   one	   of	   the	   hemopoietic	   lineages	   (i.e.	   erythroid,	  
myeloid	  or	  megakaryocytic).	  The	  percentage	  of	  bone	  marrow	  blasts	  may	  be	   increased	  but	  
should	  not	  amount	  to	  20%	  or	  more.	  Morphological	  features	  of	  dysplasia(s)	  are	  summarized	  
in	   Table	   2.	   Cytogenetic	   abnormalities	   have	   an	   important	   impact	   on	   therapeutic	   decision-­‐
making	  in	  individual	  patients	  (Pozdnyakova	  et	  al.	  2008). Karyotypic	  abnormalities	  are	  seen	  in	  
approximately	   50%	   of	   patients	   (Malcovati	   et	   al.	   2013).	   Unbalanced	   chromosomal	  
abnormalities	   reflecting	   gain	   or	   loss	   of	   chromosomal	   material	   are	   more	   prevalent	   in	  
comparison	  to	  AML,	  while	  balanced	  translocations	  are	  rare.	  The	  most	  frequent	  abnormality	  
is	   the	   deletion	   of	   the	   long	   arm	   of	   chromosome	   5,	   with	   or	   without	   additional	   karyotypic	  
abnormalities	  (Schanz	  et	  al.	  2012).	  Finally,	  laboratory	  values	  such	  as	  lactate	  dehydrogenase	  
(LDH),	   ferritin,	   transferrin,	   reticulocytes	   counts,	   haptoglobin,	   vitamin	   B12,	   folate	  
concentrations,	   endogenous	   erythropoietin	   (EPO)	   and	   creatinine	   levels,	   are	   important	   to	  
support	  or	  exclude	  the	  diagnosis	  of	  MDS	  from	  iron	  deficiency	  anemia,	  hemolytic	  anemia	  or	  
vitamin	  B12	  or	  folate	  deficiency	  (Fenaux	  et	  al.	  2014).	  	  
Due	  to	  the	  variable	  natural	  history	  of	  MDS,	  risk	  stratification	  is	  critical	  for	  both	  prognostic	  
assessment	  and	  treatment	  goals.	  Prognosis	  is	  based	  on	  the	  revised	  International	  Prognostic	  
Scoring	  System	  (IPSS-­‐R)	  (Greenberg	  et	  al.	  2012),	  although	  the	  conventional	  IPSS	  (Greenberg	  
et	   al.	   1997)	   still	   remains	   widely	   used.	   Based	   on	   the	   percentage	   of	   bone	   marrow	   blasts,	  
number	  of	  cytopenias	  and	  karyotype,	  the	  IPSS	  stratifies	  patients	  in	  four	  risk	  categories:	  low,	  
intermediate-­‐1	  (Int-­‐1),	  intermediate	  2	  (Int-­‐2),	  and	  high.	  
Table	  2	  Morphological	  features	  of	  dysplasia	  in	  MDS	  	  










Periodic	  acid-­‐Schiff	  positivity	  
	  
	  
Small	  or	  unusual	  large	  size	  	  
Nuclear	  hypolobation	  (pseudo	  
Pelger	  Huet	  anomaly)	  	  
Irregular	  hypersegmentation	  
Decreased	  granules	  	  
Agranularity	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1.4 MYELODYSPLASTIC	  SYNDROMES	  WITH	  RING	  SIDEROBLASTS	  	  
The	  MDS	  umbrella	  includes	  a	  subgroup	  called	  MDS	  with	  ring	  sideroblasts	  (MDS-­‐RS),	  initially	  
described	  by	  Bjorkman	  (Bjorkman	  1956)	  in	  1956	  and	  subsequently	  categorized	  as	  idiopathic	  
acquired	  sideroblastic	  anemia	  in	  the	  French	  American	  British	  (FAB)	  classification	  (Bennett	  et	  
al.	  1982).	  The	  same	  subgroup	  of	  disease	  was	   later	  defined	  as	   refractory	  anemia	  with	   ring	  
sideroblasts	  (RARS)	  or	  refractory	  cytopenia	  with	  multi-­‐lineage	  dysplasia	  and	  ring	  sideroblasts	  
(RCMD-­‐RS)	   by	   the	   International	   Agency	   for	   Research	   and	   Cancer	   in	   2011	   (www.iarc.fr	  
9982/3)	  (Jaffe	  et	  al.	  2001).	  According	  to	  the	  WHO	  2016	  Classification,	  if	  an	  SF3B1	  mutation	  is	  
identified,	  a	  diagnosis	  of	  MDS-­‐RS	  may	  be	  made	  if	  ring	  sideroblasts	  comprise	  as	  few	  as	  5%	  of	  
nucleated	  erythroid	  cells,	  whereas	  at	   least	  15%	  ring	  sideroblasts	  are	  still	   required	   in	  cases	  
lacking	   SF3B1	  mutation	   (Arber	   et	   al.	   2016).	   As	   shown	   in	   Table	   1,	   MDS-­‐RS	   subgroup	   is	  
subdivided	  into	  cases	  with	  single	  lineage	  dysplasia,	  MDS-­‐SLD	  (previously	  classified	  as	  RARS)	  
and	  cases	  with	  multi-­‐lineage	  dysplasia,	  MDS-­‐MLD	  (previously	  classified	  as	  RCMD).	  
	  
1.4.1 MORPHOLOGICAL	  AND	  CLINICAL	  FEATURES	  OF	  MDS-­‐RS	  
MDS-­‐RS	  is	  a	  low-­‐risk	  subtype	  of	  myelodysplastic	  syndromes	  and	  it	  accounts	  for	  around	  10%	  
of	   all	  MDS	   cases.	  Ninety	   percent	   of	  MDS-­‐RS	   patients	   have	   no	   cytogenetic	   abnormalities,	  
while	  10%	  may	  have	  various	  but	  not	  high-­‐risk	  aberrations	  (Komrokji	  et	  al.	  2003).	  	  
Ring	  sideroblasts	  (RS)	  are	  erythroid	  precursors	  with	  iron-­‐loaded	  mitochondria	  visualized	  as	  a	  
perinuclear	   ring	   of	   blue	   granules	   by	   Prussian	   blue	   staining	   (Cazzola	   et	   al.	   2003).	   A	   cell	   is	  
defined	   as	   ring	   sideroblast,	  when	   there	   is	   a	  minimum	  of	   5	   siderotic	   granules	   covering	   at	  
least	  a	  third	  of	  the	  nuclear	  circumference	  (Mufti	  et	  al.	  2008)	  (Figure	  4A).	  Ring	  sideroblasts	  
are	   found	   exclusively	   in	   pathological	   conditions	   and	   should	   not	   be	   confused	  with	   ferritin	  
sideroblasts	  (Figure	  4B),	  which	  are	  present	  in	  normal	  bone	  marrow.	  These	  latter	  are	  normal	  
erythroblasts	   that,	  after	  Prussian	  blue	  staining,	   show	  a	   few	  blue	  granules	  scattered	   in	   the	  
cytoplasm,	  representing	  endosomes	  or	  siderosomes,	  filled	  with	  excess	  iron	  not	  utilized	  for	  
heme	  synthesis	  (Harrison	  et	  al.	  1996).	  Although	  the	  presence	  of	  ring	  sideroblasts	  is	  one	  of	  
the	  hallmarks	  of	  MDS-­‐RS,	  none	  of	  the	  liquid	  culture	  systems	  reported	  so	  far	  have	  been	  able	  





In	   MDS-­‐RS,	   aberrant	   iron	   accumulation	   in	   erythroblasts	   is	   present	   in	   the	   form	   of	  
mitochondrial	   ferritin	   (FTMT),	   while	   normal	   erythroblasts	   lack	   this	   protein	   (Cazzola	   et	   al.	  
2003).	  Data	   suggested	   that	   the	  expression	  of	  FTMT	  was	  a	   response	   to	  mitochondrial	   iron	  
accumulation,	  but	   the	   finding	  that	  bone	  marrow	  cells	  of	  MDS-­‐RS	  patients	  start	   to	  express	  
FTMT	   in	   the	   early	   stages	   of	   erythroid	   differentiation,	   before	   evident	   iron	   accumulation,	  
indicated	  a	  more	  complex	  mechanism	  of	  gene	   regulation	   (Invernizzi	   et	  al.	   2013),	  which	   is	  
not	  completely	  understood.	  The	  fact	  that	  in	  K562	  cell	  line,	  FTMT	  affects	  JAK/STAT	  pathway,	  
a	   significant	   regulator	  of	   erythropoiesis,	   supports	   the	  hypothesis	   that	   FTMT	  may	  have	   an	  
important	   role	   in	   the	   ineffective	   erythropoiesis	   (Santambrogio	   et	   al.	   2011).	   In	   the	   same	  
study,	  FTMT	  induced	  apoptosis	  in	  human	  CD34+	  cells.	  	  
Regardless	   the	   etiology,	   the	   presence	   of	   ring	   sideroblasts	   usually	   signifies	   ineffective	  
erythropoiesis	   and	   mitochondrial	   iron	   overload,	   in	   the	   form	   of	   mitochondrial	   ferritin.	  
However,	  for	  a	  correct	  diagnosis	  of	  MDS-­‐RS,	  it	  is	  important	  to	  exclude	  nonclonal	  conditions	  
associated	   with	   ring	   sideroblasts	   formation;	   excess	   of	   alcohol,	   lead	   toxicity,	   copper	   or	  
pyridoxine	  deficiency,	   isoniazid	  therapy	  and	  hereditary	  sideroblastic	  anemias	  (Camaschella	  
2009,	  Willekens	   et	   al.	   2013).	   The	  most	   frequent	  hereditary	   sideroblastic	   anemia	   is	   the	  X-­‐
linked	  sideroblastic	  anemia	  (XLSA)	  occurring	  secondary	  to	  missense	  mutations	  in	  conserved	  
amino	  acids	  in	  the	  aminolevulinate	  synthase	  2,	  ALAS2,	  a	  gene	  encoding	  the	  first	  enzyme	  of	  
the	  heme	  biosynthetic	  pathway.	  Loss	  of	  function	  mutation	  in	  SLC25A38	  has	  been	  shown	  to	  
cause	  a	  sideroblastic	  anemia	  similar	   to	  XLSA,	  but	  with	  an	  autosomal	   recessive	   inheritance	  
(Guernsey	  et	  al.	  2009).	   	  XLSA	  with	  ataxia	  (XLSA-­‐A)	   is	  another	  inherited	  disorder	  associated	  
Figure	  4	  (A)	  Bone	  marrow	  ring	  sideroblasts	  in	  MDS-­‐RS.	  Prussian	  blue	  staining	  shows	  
that	   most	   erythroblasts	   have	   five	   or	   more	   positive	   granules	   disposed	   in	   a	   ring	  
surrounding	   the	  nucleus	   and	  covering	  at	   least	  one-­‐third	   of	  nuclear	   circumference.	  
(B)	   Ferritin	   sideroblasts.	   Images	   A	   and	   B	   are	   adapted	   with	   permission	   from	   the	  
publisher	  (Malcovati	  et	  al.	  2016)	  (Cazzola	  et	  al.	  2013a),	  respectively.	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with	  sideroblastic	  anemia	  and	  non-­‐progressive	  spinocerebellar	  ataxia.	  This	  form	  is	  caused	  by	  
mutations	  involving	  the	  ATP	  binding	  cassette	  gene	  ABCB7	  (Steensma	  et	  al.	  2007)	  not	  found	  
in	   acquired	   cases.	   Similarly	   mutations	   in	   glutaredoxin-­‐5	   GLRX5,	   a	   gene	   that	   encodes	   a	  
mitochondrial	  protein	  involved	  in	  iron-­‐sulfur	  cluster	  biogenesis	  can	  give	  rise	  to	  sideroblastic	  
anemia	   (SA)	   (Rouault	   et	   al.	   2008).	   Additional	   rare	   causes	   of	   SA	   include	   mitochondrial	  
deletion	  syndromes,	  usually	  diagnosed	  in	  pediatric	  patients	  (Patnaik	  et	  al.	  2015).	  	  
MDS-­‐RS	   is	   a	   slowly	   progressing	   disease	   characterized	   by	   an	   initial	   phase	   of	   erythroid	  
hyperplasia	  and	   ineffective	  erythropoiesis	   that	  can	  remain	  stable	   for	  several	  years,	  and	   in	  
some	   cases	   for	   decades.	   Usually,	   however,	   the	   stable	   phase	   is	   followed	   by	   a	   phase	   of	  
increasing	   erythroid	   failure	   eventually	   resulting	   in	   a	   need	   for	   regular	   erythrocyte	  
transfusions	   (Cazzola	   et	   al.	   2013b).	  While	   pancytopenia	   and	   leukemic	   transformation	   is	   a	  
rare	  event,	  anemia,	  chronic	  transfusion	  need	  and	  a	  subsequent	  risk	  of	  iron	  overload	  are	  the	  
main	  clinical	  complications	  in	  MDS-­‐RS	  and	  quality	  of	  life	  is	  usually	  severely	  reduced	  due	  to	  
anemia	   (Bennett	   et	   al.	   1982,	   Greenberg	   et	   al.	   1997,	   Schmid	   2009).	   Anemia	   is	   the	   most	  
common	  cytopenia	  in	  all	  MDS,	  usually	  accompanied	  by	  increased	  apoptosis	  of	  bone	  marrow	  
precursors,	   low	  reticulocytes	  counts	  and	  mild	  hemolysis	   (Santini	  2015).	  Notably,	  defective	  
erythropoiesis	   is	  a	  common	  denominator	  for	  most	  subtypes	  of	  MDS.	  Whereas	  hypoplastic	  
erythropoiesis,	  characterized	  by	  a	  decreased	  relative	  number	  of	  erythroid	  progenitors	  in	  the	  
bone	   marrow,	   is	   typically	   seen	   in	   advanced	   MDS	   (i.e.	   in	   5q-­‐syndrome),	   hyperplastic	  
erythropoiesis,	  such	  as	   in	  MDS-­‐RS,	   is	  characterized	  by	  an	   increased	  percentage	  of	  marrow	  
erythroblasts,	  of	  which	  many	  undergo	  apoptosis	  before	  they	  mature	  into	  erythrocytes.	  This	  
latter	  is	  typically	  observed	  in	  lower	  risk	  MDS,	  but	  is	  also	  common	  in	  a	  subset	  of	  RA	  and	  RAEB	  
with	   a	  moderate	   increase	   of	  marrow	  blasts	   (Hellstrom-­‐Lindberg	   et	   al.	   2013).	   In	   the	   bone	  
marrow	   cells	   of	   patients	   with	   low-­‐risk	   MDS,	   the	   ineffective	   erythropoiesis	   has	   been	  
attributed	   to	   the	   an	   excess	   of	   apoptosis	   and	   to	   a	   significantly	   higher	   DNA	   instability	  
especially	   in	   the	   erythroid	   fraction,	   compared	  with	   age-­‐matched	   controls	   (Novotna	   et	   al.	  
2009).	  Previous	  studies	  have	  shown	  that	  erythroid	  apoptosis	  in	  low-­‐risk	  MDS	  is	  mediated	  via	  
mitochondrial	   release	   of	   cytochrome	   c	   (Figure	   5)	   and	   subsequent	   caspase	   activation	  
(Tehranchi	  et	  al.	  2003,	  Tehranchi	  et	  al.	  2005a).	  The	  same	  studies	  demonstrated	  that	  growth	  
factors	   such	   as	   erythropoietin	   and	   granulocyte	   colony-­‐stimulating	   factor	   (G-­‐CSF)	   can	   act	  
both	  via	  inhibition	  of	  apoptosis	  of	  myelodysplastic	  erythroid	  precursors	  and	  via	  selection	  of	  
cytogenetically	  normal	  progenitors.	  However,	  one	  of	  the	  aims	  of	  this	  thesis	  was	  to	  clarify	  at	  




1.4.2 TREATMENT	  OF	  MDS-­‐RS	  
 
The	  predominant	  problem	  in	  MDS-­‐RS	  is	  anemia,	  which	  alters	  quality	  of	  life	  in	  the	  elderly	  
patients.	  Erythropoiesis	  stimulating	  agents,	  ESAs	  (i.e.,	  recombinant	  erythropoietin,	  EPO	  or	  
darbepoetin,	   DAR)	   constitute	   the	   first-­‐line	   treatment	   of	   anemia	   (Fenaux	   et	   al.	   2013,	  
Malcovati	  et	  al.	  2013).	  The	  efficacy	  of	  ESA	  can	  be	  improved	  by	  adding	  granulocyte	  colony-­‐
stimulating	   factor.	   Indeed,	   G-­‐CSF	   in	   combination	   with	   EPO	   reduces	   the	   number	   of	  
apoptotic	  bone	  marrow	  precursors	  by	  blocking	  the	  cytochrome	  c	  release	  during	  all	  stages	  
of	   erythroid	   differentiation	   (Tehranchi	   et	   al.	   2003).	   The	   treatment	  with	   EPO	   and	   G-­‐CSF	  
improves	  anemia	  and	  therefore,	  survival	  of	  patients,	  with	  a	  median	  duration	  of	  response	  
of	   23	   months	   (Tehranchi	   et	   al.	   2003,	   Jadersten	   et	   al.	   2005,	   Jadersten	   et	   al.	   2008,	  
Hellstrom-­‐Lindberg	  et	  al.	  2013).	  When	  treatment	  after	  ESA	  fails	  due	  to	  primary	  resistance	  
or	  relapse	  after	  a	  response,	  patients	  are	  usually	  confined	  to	  long-­‐term	  red	  blood	  cell	  (RBC)	  
transfusions	  and	  second-­‐line	  treatments	  need	  to	  be	  considered.	  	  
Hypomethylating	   agents	   (HMAs),	   lenalidomide	   (LEN),	   and	   anti-­‐thymocyte	   globulin	   (ATG)	  
have	  been	  investigated	  as	  second-­‐line	  treatment	  for	  ESA-­‐refractory	  MDS-­‐RS,	  but	  with	  very	  
limited	  success.	  Hence,	  the	  main	  second-­‐line	  therapy	  is	  chronic	  transfusion	  therapy,	  which	  
will	   lead	  to	   iron	  overload,	  deleterious	  to	  organs	  such	  as	  heart	  and	   liver	   (Steensma	  et	  al.	  
Figure	  5	  Mitochondrial	  release	  of	  cytochrome	  c	   in	  MDS-­‐RS	  progenitors	  cells:	  inhibition	  by	  G-­‐
CSF.	   Mitochondria	   were	   stained	   with	   MitoTracker	   (red	   fluorescence),	   and	   cytochrome	   c	  
localization	   was	   revealed	   by	   indirect	   immunofluorescence	   (green	   fluorescence).	   The	   yellow	  
pattern	   denotes	   mitochondrial	   localization	   of	   cytochrome	   c,	   and	   the	   diffuse	   green	   pattern	  
indicates	  cytochrome	  c	  that	  has	  been	  released	  into	  the	  cytosol.	  Data	  are	  derived	  from	  normal	  
bone	   marrow	   (NBM;	   left	   panel),	   RARS	   progenitors	   (middle	   panel),	   and	   RARS	   progenitors	  
treated	  with	  G-­‐CSF	  (100	  ng/mL;	  right	  panel),	  at	  day	  7	  of	  culture.	  Original	  magnification	  ×	  40;	  
insets,	  ×	  100.	  Image	  adapted	  with	  permission	  from	  the	  publisher	  (Tehranchi	  et	  al.	  2003).	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2013).	   Therefore,	   chronic	   transfusion	   therapy	   is	   usually	   combined	   with	   iron	   chelation	  
agents	   such	   as,	   deferoxamine	   and	   deferasirox	   (Malcovati	   et	   al.	   2013,	   Steensma	   et	   al.	  
2013).	  Allogeneic	   stem	  cell	   transplantation	   is	  usually	  not	   indicated	   in	  MDS-­‐RS	  due	   to	   its	  
low	   risk	   for	  progression,	  but	  may	  be	  an	  option	   for	  patients	  who	  at	   relatively	   young	  age	  
develop	  a	  very	  high	  transfusion	  need.	  	  
Recently,	  studies	  have	   indicated	  Sotatercept	   (ACE-­‐011)	  and	  Luspatercept	   (ACE-­‐536),	  as	  a	  
new	   alternative	   to	   alleviate	   anemia	   (Dussiot	   et	   al.	   2014,	   Suragani	   et	   al.	   2014).	   These	  
molecules	  are	  ligand	  traps	  for	  the	  transforming	  growth	  factor	  (TGF-­‐β)	  superfamily,	  that	  by	  
targeting	  a	  pathway	  fundamentally	  distinct	  from	  EPO	  (Raje	  et	  al.	  2010),	  bind	  and	  block	  the	  
interaction	  of	   ligands	   to	   their	   receptors	  and	   therefore	   inhibit	   their	   signaling	   (Attie	   et	  al.	  
2014).	  Pre-­‐clinical	   studies	   in	  mice	  were	  associated	  with	  an	   increase	  of	  hemoglobin	   level	  
and	   red	   blood	   cell	   count	   making	   ACE-­‐011	   and	   ACE-­‐536,	   interesting	   novel	   compounds	  
currently	  evaluated	  in	  phase	  II	  clinical	  trials	  on	  low	  and	  intermediate-­‐1	  risk	  MDS	  patients	  
(Komrokji	  et	  al.	  2014,	  Giagounidis	  et	  al.	  2015).	  
	  
1.4.3 MUTATIONAL	  LANDSCAPE	  IN	  MDS-­‐RS	  
	  
The	   introduction	  of	  next	  generation	  sequencing	  technology	  has	  allowed	  us	  to	  define	  the	  
genetic	  landscape	  in	  MDS.	  In	  this	  scenario,	  spliceosome	  mutations	  were	  identified	  as	  the	  
most	   common	  molecular	   abnormalities,	   affecting	  mainly	   the	   initial	   steps	   of	   the	   splicing	  
process,	   such	  as	   the	   recognition	  of	   the	  3’	   SS	  of	   the	  pre-­‐mRNA	   target	   intron	   (SFSR2	  and	  
U2AF1)	  or	  the	  recruitment	  of	  the	  U2	  snRNP	  to	  the	  branch	  point	  proximal	  to	  the	  3’SS	  that	  
contains	  SF3B1	  (Hahn	  et	  al.	  2015).	  	  
Splicing	  mutations	  occur	  entirely	  as	  heterozygous	  missense	  mutations	  at	  highly	  restricted	  
residues	  and	  in	  a	  mutually	  exclusive	  manner	  with	  one	  another	  (Inoue	  et	  al.	  2016)	  making	  
them	   an	   hallmark	   of	   MDS.	   Among	   these,	   SF3B1	   mutations	   are	   the	   most	   common	   in	  
patients	  with	  MDS-­‐RS	  (Papaemmanuil	  et	  al.	  2011,	  Yoshida	  et	  al.	  2011,	  Patnaik	  et	  al.	  2012,	  
Papaemmanuil	  et	  al.	  2013,	  Haferlach	  et	  al.	  2014).	   Interestingly,	  splicing	  mutations,	  while	  
mutually	  exclusive	  with	  one	  another,	  show	  a	  tendency	  to	  co-­‐occur	  with	  mutations	  in	  DNA	  
methylators,	  chromatin	  modifiers	  and	  transcription	  factors.	  	  
A	   recent	   study	   by	  Malcovati	   et	   al.	   analyzed	   a	   cohort	   of	   243	   MDS	   patients	   with	   ring	  
sideroblasts	  and	  showed	  that	   the	  most	   frequent	  mutations	  were	  splicing	   factors	   (181	  of	  
243,	   74.5%),	   DNA	  methylators	   (TET2	   &	  DNMT3A,	   81	   of	   243,	   33%),	   chromatin	  modifiers	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(ASXL1	  &	  EZH2,	  35	  of	  243,	  14.4%),	  and	  the	  transcription	  factor	  RUNX1	  (28	  of	  243,	  11.5%).	  
In	   particular,	   a	   significantly	   higher	   prevalence	   of	   mutations	   in	   genes	   involved	   in	   DNA	  
methylation	   was	   observed	   in	   RARS/RCMD-­‐RS	   compared	   with	   RAEB.	   Conversely,	   a	  
significantly	  lower	  rate	  of	  mutations	  in	  chromatin	  modifiers	  and	  transcription	  factors	  was	  
found	  in	  sideroblastic	  categories	  compared	  with	  RAEB	  (17	  of	  159	  vs	  11	  of	  43,	  and	  9	  of	  159	  
vs	   13	   of	   43,	   respectively).	   In	   addition,	   a	   significantly	   higher	   prevalence	   of	  mutations	   in	  
TP53	  was	   found	   in	  RA/RCMD	   (4	  of	  34,	   11.8%)	  and	  RAEB	   (4	  of	  43,	   9.3%)	   compared	  with	  
RARS/RCMD-­‐RS	  (2	  of	  159,	  1.2%).	  Finally,	  a	  significantly	  higher	  prevalence	  of	  mutations	  in	  
genes	   involved	   in	   signaling	  was	   observed	   in	  MDS/MPN	  with	   ring	   sideroblasts	   compared	  










Figure	   6	   Mutations	   pattern	   in	   MDS	   patients.	   Figure	   adapted	   with	   permission	   from	   the	  
publisher	  (Malcovati	  et	  al.	  2015).	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1.4.4 SPLICEOSOME	  AS	  THE	  “INDICTED	  CONSPIRATOR”	  IN	  MDS-­‐RS	  
 
The	  discovery	  of	  mutations	   in	   components	  of	   the	   spliceosome,	  defined	  as	   the	   “indicted	  
conspirator”	  (Abdel-­‐Wahab	  et	  al.	  2011)	  of	  myeloid	  malignancies,	  has	  led	  to	  the	  necessity	  
of	  understanding	  the	  role	  of	  splicing	  and	  splicing	  factors	  in	  cancer.	  Splicing	  is	  an	  essential	  
process	   that	   allows	   the	   generation	   of	   mature	  mRNA	   from	   pre-­‐mRNA	   and	   where	   exon-­‐
intron	   junctions	   are	   recognized	   and	   intronic	   sequences	   removed.	   RNA	   splicing	   is	   highly	  
coordinated	   throughout	   different	   reactions	   catalyzed	   by	   the	   spliceosome,	   a	   complex	   of	  
five	   small	   ribonucleoproteins	   (snRNPs),	   U1,	   U2,	   U4/U6	   and	   U5	   together	   with	   several	  
associated	  proteins	  (Hahn	  et	  al.	  2015).	  In	  contrast,	  there	  are	  only	  two	  types	  of	  introns,	  U2	  
and	  U12,	  which	  are	  spliced	  by	  the	  U2-­‐type	  and	  U12	  type-­‐dependent	  spliceosome,	  referred	  
as	  major	  and	  minor	  spliceosomes,	  respectively.	  	  
The	  splicing	  process	  starts	  with	  the	  binding	  of	  the	  snRNP	  U1	  to	  the	  5’	  splice	  site	  of	  introns	  
and	  at	  the	  same	  time	  at	  the	  3’	  splice	  site,	  splicing	  factor	  1	  (SF1)	  binds	  to	  the	  branch	  point	  
(BP),	  and	  the	  serine/arginine	  (SR)	  rich	  proteins	  SRSF2	  and	  ZRSR2	  bind	  to	  the	  exon	  splicing	  
enhancer	   (ESE)	   site	   of	   the	   next	   exon	   to	   aid	   the	   binding	   and	   the	   stability	   of	   U2AF1	   and	  
U2AF2.	   Then,	  U2snRNP	   replaces	   SF1	   and	  binds	   to	   the	   branch	  point	   forming	   complex	  A.	  
SF3B1	  protein,	  part	  of	  the	  U2	  snRNP,	  is	  involved	  in	  the	  recognition	  of	  the	  branch	  point	  and	  
prevents	   the	  premature	  attack	  at	   the	  site,	  by	  the	  splicing	  machinery	   (Schellenberg	  et	  al.	  
2011).	  U4/U6.U5	  tri-­‐snRNPs	  are	  recruited	  to	  form	  the	  B	  complex.	  After	  release	  of	  U1	  and	  
U4	  snRNP,	  activated	  B	  complex	  performs	   the	  catalytic	  process	  of	   splicing	   (C	  complex)	   in	  
two	  steps:	  firstly,	  the	  5’	  splice	  site	  is	  cleaved	  and	  the	  5’	  residue	  of	  the	  intron	  is	   linked	  to	  
near	   the	  3’	   splice	   junction	   forming	   the	   lariat	   loop;	   secondly,	   the	  3’	   splice	   site	   is	   cleaved	  
releasing	   the	   lariat	   and	   joining	   the	   two	  exons	   together	   (Yoshida	   et	   al.	   2014),	   (Figure	  7).	  
After	   splicing	   is	   complete,	   the	   edited	  mRNA	   and	   introns	   are	   released,	   the	   spliceosome	  






1.4.5 MUTATIONS	  IN	  THE	  SPLICING	  FACTOR	  SF3B1	  
 
SF3B1	  is	  located	  at	  the	  chromosomal	  band	  2q33	  and	  encodes	  a	  core	  component	  of	  the	  U2	  
snRNP	  that	  binds	   the	  branch	  point	  sequences	   to	  stabilize	   the	   interaction	  between	  the	  U2	  
snRNP	  and	  the	  pre-­‐mRNA	  (Hahn	  et	  al.	  2015).	  Most	  mutations	   in	  SF3B1	   are	  heterozygous	  
substitutions	  and	  tend	  to	  cluster	  on	  the	  C-­‐terminal	  region	  consisting	  of	  22	  HEAT	  domains	  
between	  exon	  12	  and	  exon	  16	  of	  SF3B1	   (Papaemmanuil	  et	  al.	  2011).	  The	  most	  common	  
recurrent	  SF3B1	  mutation	  affects	  amino	  acid	  K700	  (45-­‐68%	  of	  reported	  cases)	  followed	  by	  
H662	  (10%),	  K666	  (10%),	  E622	  (7%)	  and	  R625	  (6%)	  (Malcovati	  et	  al.	  2011,	  Papaemmanuil	  et	  
al.	   2011,	   Damm	   et	   al.	   2012b,	   Papaemmanuil	   et	   al.	   2013)	   (Figure	   8).	   No	   significant	  
differences	   were	   reported	   in	   regards	   to	   WHO	   subtype,	   clinical	   features	   and	   other	  
hematologic	  parameters	  (Malcovati	  et	  al.	  2011).	  However,	  significant	  relationships	   in	  MDS	  
patients	  were	  found	  between	  SF3B1	  mutation	  and	  marrow	  erythroblasts,	  soluble	  transferrin	  
receptor	  and	  serum	  growth	  differentiation	  factor	  15.	  A	  multivariable	  analysis	  showed	  that	  
the	  hepcidin	  to	  ferritin	  ratio,	  a	  measure	  of	  adequacy	  of	  hepcidin	  levels	  relative	  to	  body	  iron	  
stores,	  was	  inversely	  related	  to	  the	  SF3B1	  mutation	  (Ambaglio	  et	  al.	  2013).	  
	  
Figure	  7	  	  The	  splicing	  process.	  Image	  from	  the	  Max	  Planck	  Institute	  
for	  Biophysical	  Chemistry	  http://www.mpibpc.mpg.de/	  





















Average	   SF3B1	   allele	   burden	   in	  MDS-­‐RS	   is	   approximately	   40%	  with	   a	   few	   cases	  with	   low	  
mutant	   allele	   burden.	   The	  median	   allele	   burden	   is	   similar	   in	   purified	  CD34+,	   granulocytes	  
and	  bone	  marrow	  GPA+	  cells,	  but	   the	  mutant	  clone	  confers	  a	  growth	  disadvantage	  at	   the	  
terminal	  maturation	  into	  reticulocytes,	  as	  will	  be	  discussed	  later	  (Conte	  et	  al.	  2015).	  Somatic	  
mutations	   in	   SF3B1	   were	   reported	   in	   14-­‐28%	   of	   MDS	   and	   19%	   of	   MDS/MPN	   cases	  
(Papaemmanuil	  et	  al.	  2011,	  Damm	  et	  al.	  2012a,	  Damm	  et	  al.	  2012b,	  Thol	  et	  al.	  2012,	  Mian	  
et	  al.	  2013,	  Papaemmanuil	  et	  al.	  2013),	  but	  also	  in	  other	  hematological	  malignancies	  such	  as	  
primary	   myelofibrosis	   (PMF)	   (4%),	   therapy	   related	   AML,	   de	   novo	   AML	   (5%),	   essential	  
thrombocythemia	  (ET)	  (3%),	  CLL	  (5%),	  multiple	  myeloma	  (3%)	  and	  chronic	  myelomonocytic	  
leukemia	   (CMML)	   (5%).	   Interestingly,	   SF3B1	   mutations	   in	   CLL	   confer	   a	   poor	   prognosis	  
(Quesada	   et	   al.	   2012).	  Mutations	  were	   also	   found	   in	   solid	   tumors	   such	   as	   breast	   cancer	  
(1%),	   renal	   cancer	   (3%)	   and	   adenoid	   cystic	   carcinoma	   (4%)	   (Papaemmanuil	   et	   al.	   2011).	  
Although	  SF3B1	  mutations	  were	  reported	  in	  a	  variety	  of	  myeloid	  malignancies,	  a	  remarkable	  
high	  mutation	   rate	   has	   been	   reported	   among	  MDS	   patients	  with	   RS,	   including	   RARS	   (64-­‐
Figure	   8	   Distribution	   of	   mutations	   in	   SF3B1.	   Image	   reproduced	   with	  
permission	  from	  (Papaemmanuil	  et	  al,	  2011),	  Copyright	  Massachusetts	  
Medical	  Society.	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90%)	  and	  RCMD-­‐RS	  (37-­‐76%)	  (Malcovati	  et	  al.	  2011,	  Yoshida	  et	  al.	  2011,	  Patnaik	  et	  al.	  2012,	  
Malcovati	   et	   al.	   2015)	   and	   in	   RARS	   associated	   with	   thrombocytosis,	   RARS-­‐T	   (67-­‐85%)	  
(Broseus	  et	  al.	  2013),	  classified	  as	  a	  unique	  form	  of	  MDS/MPN.	  	  
SF3B1	   mutated	   lower-­‐risk	   MDS	   patients	   present	   a	   distinct	   clinical	   and	   morphological	  
phenotype	   associated	   with	   the	   presence	   of	   RS	   (Malcovati	   et	   al.	   2011).	   SF3B1	   mutations	  
correlate	  with	  a	  favorable	  prognosis	  and	  confer	  a	  positive	  predictive	  value	  of	  97.7%	  for	  the	  
RS	  phenotype,	  whereas	  the	  absence	  of	  RS	  has	  a	  negative	  predictive	  value	  of	  98%	  (Malcovati	  
et	  al.	  2011).	  Importantly,	  MDS-­‐RS	  SF3B1	  wild	  type	  represents	  a	  subset	  with	  high	  prevalence	  
of	  TP53	  mutation	  and	  worse	  outcome	  (Malcovati	  et	  al.	  2015).	  Clinical	  correlation	  with	  SF3B1	  
mutation	  showed	  that	  MDS	  patients	  with	  the	  mutations	  have	  significantly	  lower	  incidence	  
of	  multilineage	  dysplasia,	  lower	  proportion	  of	  dysplastic	  myeloid	  cells	  and	  megakaryocytes,	  
higher	  white	  blood	  cell	  and	  platelets	  counts,	  marked	  erythroid	  hyperplasia	  and	  lower	  bone	  
marrow	   blasts	   and	   incidence	   of	   chromosomal	   abnormalities,	   compared	   to	   unmutated	  
patients	   (Malcovati	   et	   al.	   2015).	   In	   MDS-­‐RS	   patients,	   SF3B1	   mutations	   co-­‐occur	   with	  
mutations	  in	  genes	  involved	  in	  DNA	  methylation,	  chromatin	  modification,	  and	  transcription	  
factor	   (i.e.	  RUNX1).	   Interestingly,	   among	  SF3B1	  mutated	  patients,	   coexisting	  mutations	   in	  
DNA	  methylation	  genes	  were	  also	  associated	  with	  a	  higher	  degree	  of	  multilineage	  dysplasia.	  
On	   the	   contrary,	   exclusivity	   was	   observed	   between	   SF3B1	   mutations	   and	   other	   splicing	  
factors	  (SRSF2	  and	  U2AF1)	  and	  TP53	  (Malcovati	  et	  al.	  2015).	  	  
The	   prognostic	   impact	   of	   SF3B1	  mutations	   in	  MDS-­‐RS	   is	   slightly	   controversial,	  with	   some	  
studies	   demonstrating	   a	   favorable	   independent	   prognostic	   impact	   (Malcovati	   et	   al.	   2011,	  
Broseus	  et	  al.	  2013,	  Malcovati	  et	  al.	  2015)	  and	  with	  others	  not	  confirming	  this	  pattern.	  	  
In	  particular,	  an	  early	  study	  on	  161	  low-­‐risk	  MDS	  with	  RS	  (Malcovati	  et	  al.	  2011)	  and	  more	  
importantly,	   a	   recent	   multicenter	   study	   pursued	   by	   Hellström-­‐Lindberg	   and	   Cazzola	  
(Malcovati	  et	  al.	  2015),	  analyzed	  a	  large	  cohort	  of	  patients	  with	  1%	  or	  more	  RS	  and	  found	  
that	  SF3B1	  had	  a	  positive	  prognostic	  value	  on	  survival	  and	  risk	  of	  disease	  progression	  and	  
that	  this	  independent	  value	  was	  retained	  when	  the	  analysis	  was	  restricted	  to	  WHO	  subtypes	  
without	  excess	  of	  blasts	  or	  to	  sideroblastic	  categories.	  Conversely,	  in	  one	  of	  the	  studies	  not	  
confirming	  the	  prognostic	  relevance	  of	  SF3B1	  mutations,	  the	  presence	  of	  the	  mutation	  was	  
associated	  with	  better	  overall	  surival	  and	  leukemia-­‐free	  survival	  in	  univariable	  analysis,	  but	  
this	   prognostic	   value	   was	   lost	   in	   multivariable	   analysis	   (Patnaik	   et	   al.	   2012).	   In	   another	  
study,	  the	  disassociation	  between	  SF3B1	  mutation	  and	  good	  prognosis	  was	  partially	  related	  
to	  the	  heterogeneity	  of	  the	  cohort	   investigated	  and	  to	  the	  inclusion	  of	  a	   lower	  number	  of	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MDS-­‐RS	  cases	  (Damm	  et	  al.	  2012a).	  In	  the	  study	  conducted	  by	  Ebert	  et	  al.,	  SF3B1	  mutations	  
were	   under-­‐represented	   in	   category	   3	  with	   a	  median	   survival	   of	   1.11	   years	   and	   of	   note,	  
mutations	   were	   overlapping	   more	   than	   expected	   by	   chance	   with	   mutation	   in	  DNMT3A,	  
indicating	  an	  unappreciated	  molecular	  synergy	  between	  these	  two	  genetic	   lesions.	   In	  fact,	  
since	   SF3B1	   had	   a	   trend	   toward	   longer	   survival,	   co-­‐occurrence	   may	   have	   mitigated	   any	  
negative	   effect	   of	  DNMT3A,	   which	   showed	   longer	  median	   overall	   survival	   than	  DNMT3A	  
alone	  (Bejar	  et	  al.	  2012).	  
	  
1.4.6 FUNCTIONAL	  IMPACT	  OF	  SF3B1	  MUTATIONS	  IN	  MDS-­‐RS	  
Although	   substantial	  progress	  has	  been	  made	   in	  understanding	   the	   impact	  of	   several	  of	  
these	   splice	   factor	  mutations,	   functional	   connections	   linking	   the	  mechanistic	   changes	   in	  
splicing	   induced	   by	   these	   mutations	   to	   the	   phenotypic	   consequences	   of	   inefficient	  
erythropoiesis	  have	  not	  been	  elucidated	  yet.	  
1.4.6.1 Mouse	  models	  of	  SF3B1	  mutations	  
 
Several	  studies	  in	  mice	  have	  sought	  to	  understand	  the	  functional	  role	  of	  Sf3b1	  (Visconte	  et	  
al.	   2012,	   Matsunawa	   et	   al.	   2014,	   Visconte	   et	   al.	   2014,	   Wang	   et	   al.	   2014).	   Sf3b1	  
heterozygous	  (Sf3b1+/-­‐)	  mice	  had	  normal	  hematopoiesis	  and	  did	  not	  develop	  hematological	  
malignancies	  during	  a	  long	  observation	  period	  (Matsunawa	  et	  al.	  2014,	  Wang	  et	  al.	  2014).	  
Sf3b1+/-­‐	   cells	   had	   a	   significantly	   impaired	   capacity	   to	   reconstitute	   HSC	   in	   a	   competitive	  
setting,	  but	  showed	  normal	  homing	  capability,	  a	  mild	  increase	  in	  apoptosis	  and	  no	  defects	  in	  
differentiation.	   Additional	   depletion	   of	   Sf3b1	   using	   shRNAs	   compromised	   Sf3b1+/-­‐	   HSC	  
proliferative	   capacity	   compared	   to	   WT	   HSC	   in	   vitro	   and	   in	   vivo,	   implying	   that	   Sf3b1	   is	  
required	   for	   the	   self-­‐renewal	   capacity	   of	   HSC	   but	   not	   critical	   for	   the	   differentiation	  
capabilities	   of	   HSC	   (Wang	   et	   al.	   2014).	   Gene	   set	   enrichment	   analysis	   (GSEA)	   between	  
SF3B1+/-­‐	  and	  WT	  reported	  a	  negative	  enrichment	  of	  the	  non-­‐sense	  mediated	  mRNA	  decay	  
pathway,	   a	   system	   that	   surveys	   and	  degrades	   abnormal	   transcripts	   containing	  premature	  
stop	   codons	   (Maquat	   2004).	   This	   pathway	  was	   also	   reported	   as	   the	  mechanism	   through	  
which	   SF3B1	   mutant	   aberrant	   transcripts	   is	   degraded,	   causing	   a	   down-­‐regulation	   of	   key	  
genes	  (i.e.	  ABCB7)	  in	  MDS-­‐RS	  (Darman	  et	  al.	  2015,	  Yusuke	  2015).	  
Intriguingly,	   the	   correlation	   between	   Sf3b1	   mutations	   and	   the	   RS	   phenotype	   is	  
controversial.	   No	   changes	   were	   observed	   in	   the	   frequencies	   of	   sideroblasts	   in	   Sf3b1+/-­‐	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erythroblasts	  or	  cultured	  Sf3b1+/-­‐	  erythroblasts	  expressing	  shRNAs	  targeting	  Sf3b1	   (Wang	  
et	  al.	  2014),	  showing	  that	  Sf3b1	  haploinsufficiency	  in	  mice	  is	  not	  enough	  to	  induce	  a	  RARS-­‐
like	   phenotype.	   Conversely,	   in	   two	   studies	   from	   Visconte	   et	   al.	   (Visconte	   et	   al.	   2012,	  
Visconte	  et	  al.	  2014)	  BM	  aspirates	  from	  SF3B1+/-­‐	  compared	  to	  C57BL/6	  mice	  in	  one	  study	  
and	   Sf3b1+/-­‐	   mice	   compared	   to	   Sf3b1+/+	   showed	   the	   RS	   phenotype	   upon	   staining	   with	  
Prussian	  blue.	  Also	   in	   these	  mice,	  hematological	  parameters	  between	  heterozygous	  and	  
WT	   mice	   were	   comparable.	   In	   addition,	   the	   presence	   of	   RS	   has	   been	   preliminarily	  
reported	   in	  NOD	  scid	  gamma	  (NSG)	  mice	  engrafted	  with	  MDS-­‐RS	  purified	  HSC	  (Mortera-­‐
Blanco	  2016),	   suggesting	   that	   the	  bone	  marrow	  microenvironment	  may	  be	  essential	   for	  
the	   RS	   formation.	   Importantly,	   recent	   data	   from	   conditional	   knock-­‐in	  mouse	  models	   of	  
Sf3b1	  K700E	  (Mupo	  et	  al.	  2016,	  Obeng	  et	  al.	  2016)	  sought	  to	  explain	  how	  Sf3b1	  alterations	  
affect	  normal	  and	  malignant	  hematopoiesis.	  	  
Obeng	   et	   al.	   observed	   that	   Sf3b1K700E	   conditional	   knock-­‐in	   mice,	   had	   progressive	  
macrocytic	  anemia	  associated	  with	  a	   terminal	  block	   in	  erythroid	  maturation	  outlined	  by	  
the	   expression	   of	   CD71	   and	   Ter119,	   which	   subdivided	   cells	   into	   stages	   R1-­‐R4	   of	  
erythroblast	  maturation.	   As	   in	   previous	  mice	  models,	   no	   changes	  were	   observed	   in	   the	  
total	  count	  of	  WBC,	  platelet	  and	  reticulocytes	  and	  no	  animals	  developed	  acute	  leukemia.	  
Sf3b1+/K700E	   expression	   resulted	   in	   expansion	   of	   the	   long-­‐term	   stem	   cell	   (LT-­‐HSC)	  
compartment	   and	   a	   decrease	   of	   GMPs,	   but	   an	   impaired	   capacity	   to	   reconstitute	  
hematopoiesis	   in	   a	   competitive	   transplantation	   setting	   compared	   to	   Sf3b1+/+	   cells.	   Of	  
note,	  Obeng	   et	   al.	   did	   not	   find	   ring	   sideroblasts	   or	   circulating	   siderocytes	   in	   the	   bone	  
marrow	  consistent	  with	  other	  mouse	  models	  of	  congenital	  sideroblastic	  anemia	  (including	  
a	  conditional	  knock-­‐out	  model	  of	  Abcb7)	  (Pondarre	  et	  al.	  2007),	  potentially	  suggesting	  an	  
unknown	   difference	   between	   human	   and	   murin	   erythroid	   precursors	   with	   respect	   to	  
mitochondrial	  iron	  metabolism	  (Inoue	  et	  al.	  2016).	  	  
Moreover,	   RNA	   sequencing	   on	  myeloid	   progenitor	   cells	   sorted	   from	   3	   Sf3b1+/K700E	   and	   3	  
Sf3b1+/+	  in	  the	  study	  by	  Obeng	  et	  al.	  showed	  only	  a	  minimal	  overlap	  in	  mis-­‐spliced	  genes	  and	  
events	   between	   human	  MDS	   and	  murine	   samples.	   For	   instance,	  Abcb7	   cryptic	   splice	   site	  
was	  not	  seen	  in	  Sf3b1+/K700E	  mice	  because	  of	  the	  distinct	  intronic	  sequence	  at	  this	  region	  of	  
Abcb7.	   In	   addition,	   authors	   identified	   that	   loss	   of	   Tet2,	   which	   plays	   a	   key	   role	   in	   DNA	  
demethylation,	   in	   combination	   with	   Sf3b1+/K700E	   aggravated	   the	   macrocytic	   anemia	   and	  
impaired	   terminal	   maturation	   and	   accelerated	   the	   expansion	   of	   LT-­‐HSC,	   erythroid	   and	  
megakaryocytes	  dysplasia.	   The	   combination	  of	  Tet2	   loss	  and	  Sf3b1K700E	  was	   sufficient	   to	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rescue	  the	  competitive	  repopulation	  disadvantage	  induced	  by	  Sf3b1K700E	  alone,	  offering	  an	  
explanation	   to	   why	   the	   mutations	   in	   both	   of	   these	   genes	   are	   well-­‐tolerated	   in	   MDS	  
patients.	   Also,	   bone	  marrow	   progenitor	   cells	   expressing	   Sf3b1K700E	   showed	   an	   increased	  
sensitivity	  to	  the	  spliceosome	  modulator	  E7107	  compared	  to	  Sf3b1	  wild-­‐type.	  
Sf3b1K700E	   knock-­‐in	   mouse	   model	   from	   Mupo	   et	   al.	   presented	   progressive	   normocytic	  
anemia	  compared	  to	  wild-­‐type,	  no	  significant	  dysplasia	  and	  no	  ring	  sideroblasts,	  despite	  of	  a	  
moderate	   overall	   increase	   in	   iron	   deposits.	   Interestingly,	   Sf3b1K700E	   animals	   showed	   no	  
differences	  in	  the	  early	  erythroid	  cells,	  but	  a	  relative	  decrease	  of	  the	  more	  mature	  erythroid	  
cells	  and	  a	  decrease	  in	  HSC	  in	  mutant	  mice	  with	  no	  change	  in	  the	  size	  of	  LMPP,	  GMP,	  CMP	  
and	  MEP	  progenitors	  compartments	  compared	  to	  wild-­‐type	  mice.	  
Similarly	  to	  Obeng	  et	  al,	  Mupo	  et	  al.	  looked	  at	  the	  pattern	  of	  aberrant	  splicing	  promoted	  by	  
SF3B1K700E,	  and	   found	  that	  mutant	  animals	  have	  an	   increased	  use	  of	  cryptic	  3’	   splice	  sites	  
(SS)	   throughout	   their	   genome,	   similarly	   as	   in	   human	   cancers	   carrying	   SF3B1	   mutations.	  
Although	  the	  splicing	  defects	  observed	  in	  SF3B1K700E	  closely	  mimicked	  those	  of	  human	  MDS,	  
the	  murine	  orthologues	  of	  genes	  associated	  with	  ring	  sideroblasts	  in	  human	  MDS,	  including	  
Abcb7	   and	  Tmem14c,	  were	   not	  mis-­‐spliced	   as	   a	   result	   of	   the	   relatively	   poor	   interspecies	  
conservation	  of	  intronic	  sequences	  able	  to	  function	  as	  aberrant	  splice	  sites.	  Overall,	  the	  mild	  
phenotype	  observed	  by	  the	  authors	  in	  comparison	  to	  Sf3b1	  mutant	  human	  MDS	  has	  been	  
explained	  as	   the	  requirement	   for	  additional	  mutations	   to	  develop	  MDS	  and	  that	  different	  
phenotypic	   effects	   (i.e.	   anemia,	   ring	   sideroblasts,	   clonal	   expansion)	   of	   splicing	  mutations	  
may	  have	  distinct	  molecular	  causes	  (Mupo	  et	  al.	  2016).	  
1.4.6.2 Effects	  of	  SF3B1	  mutations	  on	  splicing	  	  
	  
In	   addition	   to	   experimental	   evidences	   in	  mice,	   transcriptome	   sequencing	   of	  MDS-­‐RS	   BM	  
MNC	   (Visconte	   et	  al.	  2015)	  and	  CD34+	   cells	   (Dolatshad	   et	  al.	  2015,	  Dolatshad	   et	  al.	  2016)	  
allowed	  the	  study	  of	  normal	  bone	  marrow,	  SF3B1	  mutated	  and	  WT	  patients,	  in	  some	  case	  
from	   different	  WHO	   subgroups,	   and	   to	   identify	   mis-­‐spliced	   events	   functionally	   linked	   to	  
MDS	   pathogenesis	   and	   downstream	   targets	   of	   SF3B1	  mutations.	  SF3B1	  mutated	   RARS/-­‐T	  
showed	   more	   abundant	   iron	   deposits	   in	   the	   mitochondria	   that	   unexpectedly,	   did	   not	  
correlate	  with	  increased	  reactive	  oxygen	  species	  (ROS)	  or	  DNA	  damage;	  instead,	  the	  distinct	  
iron	   distribution	   was	   attributed	   to	   intron	   retention	   event	   in	   the	   splicing	   pattern	   of	  
SLC25A37,	   a	   crucial	   importer	   of	   Fe2+	   into	   the	   mitochondria	   (Visconte	   et	   al.	   2015).	   Also,	  
disruption	  of	  SF3B1	   resulted	   in	  differential	  exon	  usage	  of	  genes	  known	  to	  be	   involved	   in	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MDS	   (TP53	   and	   EZH1),	   erythroid	   genes	   (ALAD,	   UROD	   and	   EPB42)	   and	   genes	   associated	  
with	   cell	   cycle	   (AURKB	   and	   CRNDE)	   and	   RNA	   processing	   (RBM5,	   RBM25,	   PRPF40A	   and	  
HNRNPD)	   when	   comparing	   uncultured	   BM	   CD34+	   cells	   of	   SF3B1	   mutated	   and	   those	   of	  
healthy	   controls	   (Dolatshad	   et	   al.	   2015).	   In	   the	   same	   study,	   altered	   splicing	   of	   genes	  
involved	   in	   MDS	   pathophysiology	   (CBL,	   ASXL1	   and	   DNMT3A),	   mitochondrial	   function	  
(ALAS2,	   NDUFAF6),	   erythroid	   differentiation	   (NFE2L2,	   PPOX,	   HMBS)	   was	   reported	   when	  
comparing	  SF3B1	  mutated	  and	  WT	  cases	   (these	   last	   all	   RCMD	  patients).	  Differential	   exon	  
usage	  was	  also	  detected	   in	  genes	   (i.e.	  NUMA1,	  SMAD4,	  BRIC2	  etc.)	   regulated	  by	  the	  DNA	  
damage-­‐induced	  mRNA	  splicing	  complex	  composed	  by	  SF3B1-­‐BRCA1	  and	  BCLAF1,	  implying	  a	  
role	  of	  SF3B1	  in	  the	  maintenance	  of	  genomic	  stability	  (Savage	  et	  al.	  2014). Notably,	  the	  lack	  
of	   MDS-­‐RS	   SF3B1	   wild	   type	   patients	   without	   other	   MDS	   co-­‐recurrent	   mutations,	   made	  
genome	  editing	   for	   functional	   studies	  and	   transcriptome	  on	  genome	  edited	  primary	  cells,	  
highly	   relevant	   to	   highlight	   the	   global	   mechanisms	   through	   which	   SF3B1	   mutations	  
contribute	   to	   changes	   in	   the	   splicing	   process.	   Recently,	   results	   from	   RNA	   sequencing	   in	  
human	  SF3B1	  mutated	  cells	  (Darman	  et	  al.	  2015,	  Shiozawa	  et	  al.	  2015)	  have	  demonstrated	  
that	  most	  of	  the	  aberrant	  splicing	  events	  selectively	  observed	  in	  SF3B1	  mutated	  samples	  
are	  caused	  by	  misrecognition	  of	  the	  3’splice	  sites	  (SS),	  consistent	  with	  the	  function	  of	  the	  
wild	  type	  protein	  and	  mostly	  by	  utilizing	  a	  cryptic	  AG	  sequence	  and	  resulting	  in	  frameshift	  
mutations	  and	  subsequent	  transcripts	  degradation	  by	  the	  NMD	  pathway	  (Figure	  9	  adapted	  
from	   (Malcovati	   et	   al.	   2016).	   Furthermore,	   treatment	   of	   cultured	   SF3B1	   mutant	   MDS	  
erythroblasts	  and	  CRISPR/Cas9-­‐generated	  SF3B1	  mutant	  cell	   line	  with	  the	  NMD	  inhibitor	  
cycloheximide,	  showed	  that	  the	  aberrantly	  spliced	  ABCB7	  transcripts	  is	  targeted	  by	  NMD	  
pathway	   (Dolatshad	   et	   al.	   2016),	   possibly	   explaining	   the	   increased	   mitochondrial	   iron	  
accumulation	  found	  in	  MDS	  patients	  with	  RS.	  	  
Additionally,	   computational	   analysis	   suggested	   that	   SF3B1	  mutations	   cause	   a	   change	   in	  
the	   size	   of	   the	   sterically	   protected	   region	  downstream	  of	   the	  branch	  point	  without	   any	  
altered	  BP	  recognition	  allowing	  the	  utilization	  of	  the	  cryptic	  AG	  sequence	  (DeBoever	  et	  al.	  
2015).	  It	  was	  also	  hypothesized	  that	  SF3B1	  mutations	  could	  alter	  interaction	  with	  U2AF2,	  
affecting	  the	  ability	  to	  recognize	  the	  canonical	  3’SS	  and	  leading	  to	  cryptic	  3’SS	  selection.	  In	  
contrast,	  Darman	  et	  al,	  demonstrated	  that	   the	  short	  and	  weak	  Py	  tract	  upstream	  of	   the	  
cryptic	  AG	  is	  insufficient	  for	  the	  recruitment	  of	  the	  U2AF2	  complex	  and	  that	  the	  integrity	  
of	   the	   canonical	   3’SS,	   and	   therefore	   interaction	   with	   U2AF2	   is	   required	   to	   observe	  
aberrant	  splicing	  as	  well.	  Also,	  they	  showed	  that	  SF3B1	  mutant	  U2	  complex	  utilizes	  a	  BP	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that	   is	  different	  from	  the	  one	  used	  by	  the	  WT	  U2-­‐complex.	  However,	  despite	  the	  recent	  
progress,	  the	  understanding	  of	  how	  mutations	  in	  SF3B1	  result	  in	  altered	  3’SS	  usage	  as	  well	  
as,	  the	  understanding	  of	  the	  normal	  function	  of	  SF3B1	  HEAT	  domains,	  where	  the	  majority	  
of	  the	  mutations	  are	  located,	  is	  still	  incomplete.	  
In	   parallel,	   other	   studies	   identified	   novel	   roles	   for	   SF3B1	   in	   binding	   to	   chromatin	   or	  
chromatin-­‐modifying	  proteins,	   for	   instance	  SF3B1	  binds	   to	  nucleosomes	  on	  exonic	  DNA,	  
independently	   of	   RNA,	   and	   the	   association	   of	   SF3B1	   with	   nucleosomes	   facilitates	   the	  
splicing	  recognition	  of	  exons	   (Kfir	  et	  al.	  2015).	  Therefore,	  disruption	  of	  SF3B1	  binding	  to	  
such	   nucleosomes	   affects	   splicing	   of	   these	   exons	   similarly	   to	   SF3B1	   knock-­‐down.	   In	   a	  
similar	   way,	   SF3B1	   and	   Polycomb	   repressive	   complex	   1	   (PRC1)	   component	   interaction	  
(Isono	  et	  al.	  2005)	  was	  shown	  to	  be	  required	  to	  repress	  Hox	  genes,	  transcription	  factors	  















Figure	  9	  RNA	  splicing	  in	  wild-­‐type	  and	  mutant	  SF3B1	  cells.	  On	  the	  left,	  SF3B1,	  core	  component	  of	  
the	  U2	  snRNP,	  is	  responsible	  of	  the	  3’SS	  recognition.	  U2	  snRNP	  is	  directed	  to	  the	  3’SS	  by	  short	  pre-­‐
mRNA	   sequences,	   including	   the	   branch	   point	   (BP)	   a	   sequence	  motif	   upstream	   the	   3’SS,	   the	   Py	  
tract	   and	   the	  AG	  dinucleotide	   at	   the	   intron-­‐exon	   junction.	  On	   the	   right	   panel,	  SF3B1	  mutations	  
result	   in	   misrecognition	   of	   3’SS,	   by	   utilizing	   a	   cryptic	   AG	   sequence.	   Based	   on	   the	   position	   of	  
premature	   termination	   codons,	   aberrant	  mRNA	   transcripts	   that	   contain	   premature	   stop	   codons	  
are	   then	   subjected	   to	   degradation	  by	   NMD	  pathway.	  Figure	   reprinted	  with	   permission	   from	   the	  
publisher	  	  (Malcovati	  et	  al.	  2016).	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1.4.6.3 Gene	  expression	  profile	  in	  SF3B1	  mutated	  cells	  	  	  
 
Gene	  expression	  profile	  offers	  an	  image	  of	  the	  transcriptional	  activity	  of	  genes	  at	  a	  specific	  
time	  point.	  For	  a	  decade,	  it	  has	  provided	  a	  powerful	  tool	  to	  identify	  common	  downstream	  
targets,	  predictors	  of	  response	  and	  prognostic	  markers	  in	  spite	  of	  the	  clinical	  heterogeneity	  
of	  MDS	  patients.	  An	  early	  GE	  study	  on	  RARS	  and	  NBM	  CD34+	  cells	  at	  day	  0	  and	  at	  day	  7	  of	  
erythroid	  differentiation	  reported	  a	  marked	  down-­‐regulation	  of	  several	  pathways	  including	  
apoptosis,	   DNA	   damage	   repair,	   mitochondrial	   function	   and	   the	   JAK/Stat	   pathway,	   a	  
mediator	  of	  cellular	   responses	  to	  growth	  factors	   (Nikpour	  et	  al.	  2010).	   In	   the	  same	  study,	  
effects	  of	  G-­‐CSF	  on	  gene	  expression	   to	   further	  understand	   its	   anti-­‐apoptotic	   role	   in	  RARS	  
erythropoiesis	   showed	   that	   the	   mitochondrial	   pathway	   including	   mitofusin	   2	   (MFN2),	  
involved	   in	   mitochondrial	   membrane	   integrity	   (Sugioka	   et	   al.	   2004),	   was	   significantly	  
modified	  by	  G-­‐CSF,	  and	  several	  heat	  shock	  protein	  genes	  were	  up-­‐regulated,	  as	  evidence	  of	  
anti-­‐apoptotic	   protection	   of	   erythropoiesis.	   By	   contrast,	   G-­‐CSF	   had	   no	   effect	   on	   iron-­‐
transport	  (i.e.	  ABCB7),	  erythropoiesis-­‐associated	  genes	  or	  the	  expression	  level	  of	  MAP3K7,	  a	  
negative	   regulator	  of	   apoptosis	   and	  down-­‐regulated	   in	  RARS	  erythroblasts	   (Nikpour	   et	   al.	  
2010).	   A	   key	   finding	   of	   the	   report	   from	  Pellagatti	   et	   al.	  was	   the	   up-­‐regulation	   of	   several	  
interferon-­‐induced	   genes	   (IRF2,	   IRF6,	   IRF2BP2,	   TOR1AIP2,	   IFNA17,	  AEN	   and	   ISG20L2)	   that	  
may	   be	   responsible	   for	   enhancement	   of	   apoptosis	   in	   erythroid	   progenitors,	   hence	   in	  
ineffective	  erythropoiesis	  of	  MDS-­‐RS	  (Pellagatti	  et	  al.	  2006).	  
Gene	   Set	   Enrichment	   Analysis	   (GSEA)	   of	   SF3B1	   mutated	   samples	   and	   in	   SF3B1	   mutant	  
(RARS	  and	  RCMD-­‐RS)	  versus	  wild	  type	  and	  control	  (RCMD)	  showed	  under-­‐expressed	  mRNA	  
profiles	   with	   emphasis	   on	   mitochondrial	   pathways	   (Papaemmanuil	   et	   al.	   2011)	   and	   up-­‐
regulated	  gene	  sets	  related	  to	  cell	  cycle	  checkpoints	  and	  mRNA	  splicing	  (Dolatshad	  et	  al.	  
2015).	   While	   the	   comparison	   of	   SF3B1	   mutant	   with	   healthy	   control	   highlighted	   down-­‐
regulated	   gene	   sets	   related	   to	   cell	   differentiation	   and	   apoptosis	   (Dolatshad	   et	  al.	   2015).	  
Although	   most	   cells,	   including	   normal	   erythroid	   cells,	   express	   extremely	   low	   levels	   of	  
mitochondrial	   ferritin	   (FTMT),	   this	   intron-­‐less	   gene	   is	   highly	   expressed	   in	   erythroblast.	  
Overexpression	   of	   FTMT	   in	   RARS	   erythroblasts	   occurs	   at	   a	   very	   early	   stage	   of	   eryhtroid	  
differentiation	  (Tehranchi	  et	  al.	  2005b),	  suggesting	  that	   it	  might	  be	  a	  cause	  rather	  than	  a	  
consequence	  of	  mitochondrial	  iron	  overload.	  Differential	  gene	  expression	  analysis	  of	  SF3B1	  
mutant	  versus	  wild	  type	  and	  controls	  highlighted	  genes	  linked	  to	  MDS-­‐RS	  pathogenesis	  such	  
as,	   ALAS2	   (up-­‐regulated)	   and	   ABCB7	   (down-­‐regulated)	   and	   also	   an	   up-­‐regulation	   of	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SLC25A37,	  encoding	  a	  mitochondrial	   iron	  importer	  and	  GLRX5,	  essential	  for	  the	  iron-­‐sulfur	  
cluster	  biosynthesis	  (Ye	  et	  al.	  2010).	  Finally,	  MDS-­‐RS	  progenitors	  up-­‐regulate	  several	  genes	  
involved	  in	  the	  hemoglobin	  pathway	  (i.e.	  HBQ1,	  HBA2,	  HBA1,	  HBB)	  compared	  to	  healthy	  
controls	   (Dolatshad	   et	   al.	   2015).	   The	   cause	   of	   this	   up-­‐regulation	   is	   not	   entirely	   clear.	  
However,	   corresponding	   studies	   in	   NBM	   CD34+	   cells	   reported	   that	   the	   process	   of	  
differentiation-­‐associated	  with	  hemoglobin	  accumulation	  occurred	  first	  at	  day	  6	  followed	  
by	  a	  rapid	  raise	  in	  the	  ratio	  between	  fetal	  and	  adult	  hemoglobin	  production	  between	  day	  
7	   and	   9	   during	   the	   transition	   from	   pro	   to	   basophilic	   erythroblasts	   (Wojda	   et	   al.	   2002).	  
Therefore	   the	   early	   up-­‐regulation	   of	   these	   genes	   may	   indicate	   a	   compromised	  

















2 AIM	  OF	  THE	  THESIS	  
	  
The	   overall	   aim	   of	   this	   thesis	   was	   to	   investigate	   the	   genotype-­‐phenotype	   relations	   in	  
patients	  with	  myelodysplastic	  syndromes	  and	  ring	  sideroblasts.	  	  
Specific	  aims	  were:	  
	  
! STUDY	  I	  
Test	   the	  hypothesis	   that	  ABCB7	   is	   a	   key	  mediator	  of	   ineffective	  erythropoiesis	   in	  MDS-­‐RS	  
patients.	  	  
	  
! STUDY	  II	  
Identify	  potential	  downstream	  targets	  of	  SF3B1	  mutations	  and	  understand	  how	  these	  affect	  
RNA	  splicing	  and	  gene	  expression	  profile	  of	  MDS-­‐RS	  patients.	  	  
	  
! STUDY	  III	  
Understand	  the	  mechanistic	  effects	  of	  SF3B1	  mutation	  in	  MDS-­‐RS	  pathogenesis	  and	  explore	  
if	  the	  mutation	  confers	  a	  loss-­‐of-­‐function	  with	  regard	  to	  gene	  expression	  and	  splicing	  of	  key	  
genes	  in	  MDS-­‐RS.	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3 METHODOLOGICAL	  APPROACHES	  	  
The	   laboratory	   techniques	  used	   in	   this	   thesis	  are	  described	   in	  detail	   in	   study	   I-­‐III.	  Hereby,	  
only	  principal	  methods	  and	  their	  potential	  limitations	  are	  listed	  and	  commented.	  
3.1 CD34+	  CELLS	  ISOLATION	  AND	  ERYTHROBLAST	  CULTURE	  	  
CD34+	   cells	  were	   isolated	   from	   the	  BM	   samples	  of	  MDS-­‐RS	  patients	   and	  healthy	   controls	  
using	   magnetic-­‐activated	   cell	   sorting	   (MACS)	   columns	   according	   to	   the	   manufacturer’s	  
instructions.	  Following	  positive	  selection	  for	  CD34,	  cells	  (0.1	  ×	  106/mL)	  were	  cultured	  for	  14	  
days	   in	   Iscoves	   medium	   supplemented	   with	   15%	   BIT9500	   serum	   substitute	   (containing	  
bovine	   serum	   albumin,	   bovine	   pancreatic	   insulin	   and	   iron/saturated	   human	   transferrin),	  
recombinant	  human	   interleukin-­‐3	   (rh-­‐IL-­‐3,	  10	  ng/mL),	   rh-­‐IL-­‐6	   (10	  ng/mL)	  and	  rh–stem	  cell	  
factor	   (rh-­‐SCF,	   25	   ng/mL).	   The	   medium	   was	   replenished	   every	   second	   day	   with	   the	  
aforementioned	   cytokines	   to	   maintain	   the	   cultures	   at	   the	   same	   cell	   concentration.	   EPO	  
(2	  U/mL)	   was	   added	   to	   the	   medium	   in	   the	   second	   week,	   beginning	   at	   day	   7,	   and	   was	  
replenished	   at	   days	   9	   and	   11	   only	   to	   the	   amount	   of	  media	   added	   to	   keep	   the	   same	   cell	  
concentration.	  
This	  cell	  culture	  system	  is	  a	  useful	  model	  for	  studies	  of	  early	  erythroid	  maturation	  as	  well	  as	  
maturation	   defects	   in	   MDS-­‐RS.	   Indeed,	   it	   allows	   for	   ample	   proliferation	   of	   intermediate	  
erythroblasts	  in	  which	  it	  is	  possible	  to	  detect	  aberrant	  mitochondrial	  ferritin	  accumulation	  in	  
MDS-­‐RS	  cells,	  but	  it	  does	  not	  produce	  mature	  red	  blood	  cells	  or	  morphologically	  typical	  ring	  
sideroblasts.	  	  
3.2 COLONY	  FORMING	  UNIT	  ASSAY	  	  
The	   first	   CFU	   assay	  was	   published	   in	   1966	   (Bradley	   et	   al.	   1966,	   Pluznik	   et	   al.	   1966).	   This	  
assay	   estimates	   the	   frequencies	   of	   multi-­‐potential	   and	   lineage-­‐committed	   hematopoietic	  
progenitors	  cells	  (HPCs)	  in	  the	  BM,	  PB	  and	  other	  hematopoietic	  tissues.	  	  A	  colony	  is	  defined	  
to	  consist	  of	  at	   least	  50	  cells.	  The	  primary	  use	  of	  this	  assay	  is	  to	  detect	  the	  differentiation	  
potential	   of	   hematopoietic	   progenitors	   cells,	   therefore	   it	   can	   be	   defined	   as	   a	   qualitative	  
proliferation	  assay	  based	  on	  number	  and	  morphology	  of	  colonies.	  
In	   study	   I,	   lentiviral-­‐transduced	   CD34+	   cells	   from	   healthy	   controls	   were	   plated	   in	   a	  
concentration	  of	  500	  cells/plate	  in	  methylcellulose	  medium	  (H4434,	  StemCell	  Technologies)	  
on	  polystyrene	  35	  mm	  petri	  dishes	  and	  cultured	  according	  to	  manufacturer’s	  guidelines.	  The	  
cells	  were	  incubated	  at	  37oC	  and	  5%	  CO2	  for	  14	  days,	  after	  which	  the	  number	  and	  type	  of	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colonies	  was	  determined	  by	  manual	  counting	  as	  per	  established	  protocols	  (Goh	  et	  al.	  2005).	  
Burst	   forming	   unit-­‐erythroid	   (BFU-­‐Es),	   colony	   forming	   unit-­‐erythroid	   (CFU-­‐Es),	   colony	  
forming	   unit-­‐granulocyte-­‐macrophage	   (CFU-­‐GMs)	   and	   colony	   forming	   unit-­‐granulocyte-­‐
erythrocyte-­‐monocyte-­‐macrophage	   (CFU-­‐GEMMs)	   were	   scored	   according	   to	   color,	  
morphology	  and	  number	  of	  cells	  with	  an	  inverted	  or	  a	  fluorescence	  microscope,	  if	  cells	  were	  
carrying	  a	  fluorescent	  reporter.	  Three	  replicates	  were	  counted	  for	  each	  sample.	  CFU	  assay	  
offers	  the	  possibility	  of	  re-­‐isolating	  cells	  from	  the	  methylcellulose-­‐based	  medium	  by	  ‘picking’	  
individual	  colonies	  and	  use	  them	  for	  further	  experiments	  (i.e.	  mutational	  analysis).	  	  
3.3 Q-­‐PCR	  	  
Quantitative	  real	  time	  PCR	  was	  used	  to:	  i)	  measure	  mRNA	  levels	  of	  selected	  genes	  (Study	  I-­‐
III),	   ii)	  validate	  gene	  expression	  data	  from	  RNA	  sequencing	  (study	  II),	   iii)	  assess	  exon	  usage	  
(study	  I	  and	  III)	  and	  finally,	  iv)	  monitor	  the	  efficiency	  of	  gene	  knock-­‐out	  (study	  I	  and	  III).	  Both	  
Sybr	   green	   and	   Taqman	   probes	   were	   used	   to	   address	   the	   aforementioned	   purposes.	   To	  
normalize	  the	  differences	  in	  cDNA	  input,	  data	  were	  normalized	  versus	  the	  expression	  of	  the	  
following	  housekeeping	  genes:	  GAPDH,	  ACTIN	  and	  HPRT.	  Fold	  change	  was	  calculated	  using	  
the	   comparative	   Ct	   method	   described	   by	   Livak	   and	   Schmittgen (Livak	   et	   al.	   2001,	  
Schmittgen	  et	  al.	  2008). Overall,	  qPCR	  is	  highly	  reproducible	  but	  is	  influenced	  by	  the	  method	  
used	  for	  nucleic	  acids	  extraction.	  Hence,	  in	  order	  to	  compare	  gene/transcript	  numbers	  from	  
different	  samples,	  it	  must	  be	  ensured	  that	  the	  same	  extraction	  procedure	  is	  used	  for	  each	  
sample.	  Also,	  the	  target	  specificity	  of	  the	  qPCR	  assay	  is	  determined	  by	  the	  choice	  of	  probes	  
and	  the	  design	  of	  the	  primers,	  which	  has	  to	  satisfy	  certain	  criteria	  such	  as	  the	   length	  (90-­‐
150	  bp)	  or	  the	  GC	  content	  (20-­‐80%).	  Finally,	  due	  to	  the	  high	  sensitivity	  of	  the	  fluorescence-­‐
based	  qPCR	  method,	  it	   is	   important	  that	  RNA	  templates	  are	  free	  from	  contaminating	  DNA	  
that	  could	  interfere	  with	  the	  final	  amplification	  signal.	  This	  feature	  is	  particularly	  important	  
when	  quantifying	  intron-­‐less	  genes,	  such	  as	  mitochondrial	  ferritin.	  Importantly,	  sensitivity	  is	  
limited	   by	   the	   fact	   that	   qPCR	   measures	   only	   a	   part	   of	   the	   transcript	   (i.e.	   the	   part	  
corresponding	  to	  the	  primer	  or	  the	  probe	  location),	  but	  not	  an	  entire	  isoform.	  Therefore,	  in	  
case	  of	  RNA	  sequencing	  splicing	  validation	  data,	  it	  is	  important	  to	  identify	  the	  specific	  mis-­‐
spliced	  region	  of	  a	  transcript	  isoform	  before	  designing	  the	  assay.	  
3.4 TAQMAN	  LOW	  DENSITY	  ARRAY	  
Low	  Density	  Array	   is	  a	  q-­‐PCR	  based	  method	   introduced	  by	  Applied	  Biosystems.	  Taqman®	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LDA	  is	  a	  modified	  method	  of	  real-­‐time	  TaqMan®	  PCR	  that	  uses	  micro	  plates	  based	  on	  micro-­‐
fluidic	  systems.	  The	  advantages	  of	  this	  technology	  include	  the	  possibility	  of	  simultaneous	  
quantification	  of	  a	  large	  numbers	  of	  target	  genes	  in	  a	  single	  sample	  retaining	  the	  sensitivity	  
of	  a	  Taqman	  qPCR.	  	  
In	  study	  II,	  the	  gene	  expression	  profile	  of	  BM	  CD34+	  cells	  from	  7	  RARS	  and	  4	  NBM	  samples	  
at	  day	  0	  and	  4	  of	  erythroid	  differentiation	  was	  investigated	  using	  this	  technology.	  Samples	  
were	  run	   in	   triplicate.	  Each	  TLDA	  card	  allowed	  simultaneous	  quantification	  of	  61	   targets	  
and	   3	   housekeeping	   genes	   per	   sample.	   Loading	   and	   setting	   up	   the	   LDA	   cards	   is	  
straightforward,	  with	  no	  needs	   for	   robotic	   liquid	  handling.	  Previous	  studies	  demonstrate	  
that	  LDA	  can	  accurately	  detect	  2-­‐fold	  changes	  in	  target	  copy	  number,	  at	  both	  low	  Cts	  (high	  
expression)	  and	  high	  Cts	  (low	  expression),	  within	  the	  approximate	  range	  of	  1	  ×	  102	  –	  1	  ×	  106	  
copies	  (Goulter	  et	  al.	  2006).	  However,	  other	  studies	  sustain	  that	  reproducibility	  decreased	  
in	  low	  copy	  genes.	  Hence,	  caution	  is	  recommended	  when	  analyzing	  LDA	  results	  of	  those	  low	  
copy	   genes	   (Lu	   et	   al.	   2008).	   In	   our	   hands,	   TLDA	   was	   a	   sensitive	   and	   high-­‐throughput	  
approach	  to	  analyze	  changes	  in	  gene	  expression	  during	  erythroid	  differentiation.	  However,	  
RNA	   extraction	   methods	   and	   high	   quality	   RNA	   are	   absolutely	   necessary	   and	   RNA	   input	  
requirements	  were	  significantly	  high	  considering	  the	  low	  amount	  of	  RNA	  in	  CD34+	  cells	  from	  
RARS	  and	  NBM	  samples	  (Hofmann	  et	  al.	  2002). 	  
3.5 PYROSEQUENCING	  
Pyrosequencing	   was	   applied	   to	   follow	   the	   fate	   of	   the	   SF3B1	   clone	   during	   erythroid	  
differentiation	  (study	  I).	  DNA	  from	  cultured	  BM	  CD34+,	  freshly	  isolated	  BM	  MNC	  and	  GPA+	  of	  
RARS	  patients	  was	  used	  with	  DNA	  from	  NBM,	  as	  wild	  type	  control,	  while	  cDNA	  was	  used	  to	  
assess	   allele	   burden	   in	   reticulocytes.	   Mutation-­‐specific	   assays	   were	   designed	   using	  
PyroMark	   assay	   design	   software	   and	   performed	   according	   to	   the	   PyroMark	   Q24	   user	  
manual	  (Qiagen).	  PCR	  reactions	  and	  mutation	  analysis	  by	  pyrosequencing	  were	  performed	  
according	  to	  procedures	  and	  reagents	  provided	  by	  manufacturer.	  Pyrosequencing	  involves	  
several	   steps:	   i)	   a	   sequencing	   primer	   is	   added	   to	   a	   single	   strand	   PCR	   amplicon.	   ii)	   the	  
hybridized	   primer	   and	   single-­‐stranded	   template	   are	   incubated	   with	   the	   enzymes	   DNA	  
polymerase,	  ATP	  sulfurylase,	  luciferase,	  and	  apyrase,	  as	  well	  as	  the	  substrates	  adenosine	  5'	  
phosphosulfate	   (APS)	  and	   luciferin.	   iii)	  dNTPs	  are	  added	   to	   the	   reaction	  and	  every	   time	  a	  
dNTP	  is	  incorporated	  in	  the	  strand,	  a	  pyrophosphate	  (Ppi)	  is	  released.	  iv)	  the	  ATPsulfurylase	  
converts	  PPi	  to	  ATP;	  ATP	  mediates	  conversion	  of	  luciferin	  into	  oxyluciferin	  that	  generates	  a	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light	   signal.	   The	   height	   of	   each	   peak	   (light	   signal)	   is	   proportional	   to	   the	   number	   of	  
nucleotides	  incorporated	  while	  apyrase	  degrades	  all	  the	  unincorporated	  nucleotides.	  	  
Overall,	   pyrosequencing	   is	   a	   useful	   method	   to	   quantify	   mutated	   allele	   burden	   of	   target	  
genes	  (i.e.	  SF3B1)	  and	  it	  can	  be	  used	  as	  validation	  method	  after	  targeted	  gene	  sequencing.	  
In	  the	  mutational	  analysis,	  we	  set	  as	  thresholds,	  mutation	  read	  above	  25%	  as	  positive	  and	  
read	  below	  5%	  as	  negative.	  Of	  note,	  the	  sensitivity	  of	  this	  method	  varies	  depending	  on	  cell	  
type,	  for	  instance	  pyrosequencing	  on	  colonies	  picked	  from	  methylcellulose	  may	  encounter	  
risk	  of	  contamination	  from	  other	  colonies	  or	  negative	  measurements	  due	  to	  scarce	  amount	  
and	  low	  quality	  of	  the	  DNA	  isolated	  from	  the	  colonies.	  Today	  more	  sensitive	  methods	  (i.e.	  
droplet	  digital	  PCR)	  are	  available	  to	  address	  similar	  research	  questions,	  but	  at	   the	  time	  of	  
our	  studies,	  we	  employed	  well-­‐established	  and	  appropriate	  methods.	  	  
3.6 RNA	  SEQUENCING	  	  
Spliceosome	   mutations	   are	   expected	   to	   exert	   their	   effects	   through	   alterations	   in	   RNA	  
expression	  and	  splicing,	  making	  the	  study	  of	  the	  MDS	  transcriptome	  of	  critical	  importance.	  
The	   type	   of	   information	   that	   can	   be	   gained	   from	   RNA	   sequencing	   include	   “annotated”	  
information	   such	   as	   expressed	   transcripts,	   exon/intron	   boundaries,	   transcriptional	   start	  
sites	  (TSS),	  and	  poly-­‐A	  sites;	  as	  well	  as	  quantitative	  data	  such	  as,	  differences	  in	  expression,	  
alternative	   splicing,	  alternative	  TSS,	  and	  alternative	  polyadenylation	  between	   two	  group	  
of	  samples	  (Wang	  et	  al.	  2009).	  RNA	  sequencing	  involves	  RNA	  extraction,	  cDNA	  synthesis,	  
fragmentation	   and	   library	   synthesis.	   The	   library	   is	   then	   sequenced	   using	   short-­‐read	  
sequencing	  which	  produces	  millions	  of	  short	  sequence	  reads	  that	  correspond	  to	  individual	  
cDNA	   fragments.	   The	   precision	   of	   the	   RNA	   sequencing	   gene	   quantification	   is	   directly	  
dependent	  on	  the	  number	  of	  reads	  that	  are	  mapped	  to	  transcripts.	  The	  coverage	  of	   the	  
transcriptome	  affects	  the	  accuracy	  of	  transcripts	  abundance	  estimation	  and	  the	  sensitivity	  
of	  transcripts	  detection,	  which	  are	  critical	  features	  of	  all	  gene	  expression	  studies.	  	  
In	   study	   II,	   RNA	   sequencing	   was	   used	   for	   transcriptome	   profiling	   as	   well	   as	   for	   the	  
identification	  of	  alternative	  splicing	  events.	  Total	  RNA	  from	  BM	  CD34+	  cells	  of	  3	  MDS-­‐RS	  
and	  3	  NBM	  samples	  during	  early	  erythroid	  differentiation	  was	  depleted	  of	  ribosomal	  RNA	  
and	   strand-­‐specific	   libraries	   were	   constructed	   using	   Sequencing	   by	   Oligo	   Ligation	  
Detection	   (SOLiD™)	   system.	   Ribosomal	   depletion,	   in	   contrast	   to	   PolyA	   enrichment,	  
preserves	   non-­‐polyadenylated	   RNAs	   allowing	   the	   investigation	   of	   immature	  mRNAs	   and	  
non-­‐polyadenylated	  non-­‐coding	  RNAs	  (ncRNAs).	  Due	  to	  the	  very	  labile	  nature	  of	  RNA,	  we	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extracted	  RNA	  immediately	  after	  the	  CD34+	  enrichment	  to	  assure	  high	  quality	  and	  a	  good	  
yield.	  Small	  amounts	  of	  the	  RNA	  samples	  were	  used	  to	  assess	  RNA	  integrity	  before	  starting	  
library	   synthesis.	   Libraries	   were	   sequenced	   on	   the	   SOLiD	   5500	   Wildfire	   system.	   The	  
sequencing	   by	   ligation	   approach	   used	   in	   SOLiD	   involves	   hybridization	   and	   ligation	   of	  
primed	   template	   and	   fluorescently	   labeled	   anchor-­‐probe	   with	   known	   base(s).	   In	   each	  
cycle,	   the	   emitted	   fluorescence	   of	   ligated	   probe	   is	   captured	   for	   imaging	   the	   template.	  
Unlike	   other	   sequencing	   platforms,	   SOLiD	   utilizes	   two-­‐base-­‐encoding	   probes,	   in	   which	  
each	   ligation	   signal	   represents	   two	  bases	  of	  nucleotides,	  defined	  as	   color-­‐space	   (Mardis	  
2008,	  Metzker	  2010).	  
The	  sequencing	  performed	  generated	  a	  read	   length	  of	  75bp	  bases	  that	  were	  mapped	  to	  
the	   human	   genome	   hg19	   and	   assembled	   into	   transcripts	   and	   differential	   expression	  
estimation,	   exon	   usage	   and	   relative	   abundance	   (fragments	   per	   kilobase	   of	   exon	   per	  
million	  of	  fragments	  mapped,	  FPKM)	  was	  calculated.	  Genes	  were	  considered	  as	  expressed	  
if	  FPKM>1.	  
In	   conclusion,	   RNA	   sequencing	   usually	   requires	   complex	   analysis	   including	   filtering	   of	  
sequencing	   reads,	   assembling	   reads	   into	   transcripts	   or	   aligning	   them	   to	   reference	  
sequences,	   annotating	   the	   putative	   transcripts,	   quantifying	   the	   number	   of	   reads	   per	  
transcript,	   and	   performing	   a	   statistical	   comparison	   of	   transcript	   abundance	   across	  
samples.	   RNA	   sequencing	   studies	   based	   on	   clear	   and	   explicit	   hypothesis	   should	   be	  
preferred	   and	   pursued	   over	   hypothesis-­‐free	   studies	   that	   focus	   on	   finding	   significant	  
correlations	  in	  very	  large	  data	  sets.	  This	  is	  especially	  true	  in	  the	  prospective	  of	  subsequent	  
functional	  data	  validation	  required	  after	  sequencing.	  
3.7 LENTIVIRAL	  TRANSDUCTION	  	  
In	   study	   I	  and	   III	   lentiviral	  vectors	  were	  used	   to	   transduce	  both	  human	  K562	  cell	   line	  and	  
human	  bone	  marrow	  progenitors	  cells.	  Our	  plasmids	  were	  2nd	  generation	  lentiviral	  systems	  
both	  constitutive	  (i.e.	  pLKO.1	  and	  Lenti	  V2-­‐GFP)	  and	  inducible	  plasmids	  and	  they	  were	  used	  
in	  knock	  –out	  and	  over-­‐expressing	  experiments,	  respectively.	  	  
For	   decades,	   these	   vectors	   have	   been	   largely	   employed	   in	   gene	   therapy	   and	   functional	  
studies	   for	   their	   ability	   to	   integrate	   into	   dividing	   but	   also,	   quiescent	   cells	   (Naldini	   et	   al.	  
1996b)	  such	  as	  HSC.	  The	  advantageous	  feature	  of	  lentiviral	  vectors	  is	  the	  ability	  to	  mediate	  
transduction	   and	   stable	   expression	   both	   in	   vivo	   and	   in	   vitro	   (Naldini	   et	   al.	   1996a).	   This	  
feature	  makes	  these	  vectors	  a	  good	  model	  for	  instance	  for	  long-­‐term	  differentiation	  assays,	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often	   crucial	   in	   disorders	   characterized	   by	   ineffective	   hematopoiesis,	   such	   as	   MDS.	   The	  
efficiency	   of	   transgene	   expression	   is	   also	   depending	   on	   the	   type	   of	   promoter	  driving	   the	  
expression.	  It	  has	  been	  reported	  that	  vectors	  containing	  the	  EF1α	  and	  to	  lesser	  extent,	  the	  
PGK	  promoter,	  govern	  high-­‐level	  gene	  expression	  in	  hematopoietic	  progenitors	  (Salmon	  et	  
al.	  2000).	  Also,	  when	  the	  viral	  vector	  enters	   the	  cell,	   it	   integrates	   into	   the	  genome	  and	   is	  
passed	  on	  to	  the	  progeny	  of	  the	  cells.	  However,	  the	  site	  of	  integration	  is	  random	  and	  it	  may	  
disturb	  the	  function	  of	  other	  genes	  and/or	  lead	  to	  the	  activation	  of	  oncogenes	  (Cattoglio	  et	  
al.	   2007).	   Interestingly,	   while	   retroviral	   vectors	   integrate	   preferably	   near	   transcriptional	  
start	   sites,	   lentiviral	   vectors	   show	   a	   potentially	   safer	   integration	   profile	   in	   terms	   of	  
probability	  of	  oncogene	  activation	  (Modlich	  et	  al.	  2009).	  	  
Notably	  unlike	  cell	  lines,	  CD34+	  cells	  tend	  to	  be	  less	  susceptible	  to	  manipulation	  and	  require	  
a	   high	   concentration	   of	   virus	   inoculum	   thereby	   demanding	   time-­‐consuming	   virus	   stock	  
preparation	  where	  batch	  variation	  can	  occur.	  	  
3.8 SHORT	  HAIRPIN	  RNA	  
In	   study	   I	   we	   used	   shRNAs	   to	   knock-­‐down	   ABCB7	   in	   human	   bone	   marrow	   progenitors.	  
shRNAs	  require	  the	  use	  of	  an	  expression	  vector,	  therefore	  they	  were	  cloned	  into	  a	  pLKO.1	  
vector	   carrying	   GFP	   as	   reporter.	   Flow	   cytometry	   was	   used	   to	   separate	   cells	   expressing	  
fluorescence	  thereby	  assessing	  transduction	  efficiency.	  When	  the	  vector	  has	  integrated	  into	  
the	  host	  genome,	   the	   shRNA	   is	   transcribed	   in	   the	  nucleus	  by	  polymerase	   III.	   The	  product	  
mimics	   the	  pri-­‐microRNA	   (pri-­‐miRNA)	   and	   is	   processed	  by	  Drosha.	   Exportin	  5	   exports	   the	  
resulting	  pre-­‐shRNA	  from	  the	  nucleus.	  This	  product	  is	  then	  processed	  by	  Dicer	  and	  loaded	  
into	  the	  RNA-­‐induced	  silencing	  complex	  (RISC).	  The	  sense	  strand	  is	  degraded.	  The	  antisense	  
(guide)	   strand	   directs	   RISC	   to	  mRNA	   that	   has	   a	   complementary	   sequence.	   In	   the	   case	   of	  
perfect	  complementarity,	  RISC	  cleaves	  the	  mRNA.	  In	  the	  case	  of	  imperfect	  complementarity,	  
RISC	  represses	  translation	  of	  the	  mRNA.	   In	  both	  of	  these	  cases,	  the	  shRNA	  leads	  to	  target	  
gene	  silencing.	  	  
Since	  our	  shRNAs	  vectors	  carried	  a	  fluorescent	  marker,	  we	  could	  measure	  the	  knock-­‐down	  
efficiency	  over	  time	  by	  quantifying	  the	  target	  mRNA	  in	  sorted	  GFP+	  cells	  by	  qPCR	  without	  the	  
need	  of	  a	  clonal	   isolation.	  Although	  shRNAs	  have	  been	  the	  most	  common	  tool	  for	   loss-­‐of-­‐
function	   studies,	   the	   transduction	   efficiency	   can	   be	   very	   different	   between	   various	   cell-­‐
types,	  and	  for	  some	  gene	  target	   there	   is	  no	  effective	  shRNA.	  Also,	   in	  some	  circumstances	  
shRNAs	   can	   trigger	   non-­‐specific	   effects	   and/or	   sequence-­‐specific	   off-­‐target	   effects	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(Barrangou	  et	  al.	  2015).	  These	  off-­‐target	  effects	  are	  very	  difficult	  to	  monitor,	  thereby	  forcing	  
the	   researcher	   to	   adopt	   several	   shRNA	   constructs	   per	   gene	   and	   to	   pursue	   “rescue	  
experiments”.	   In	   such	   experiment,	   knock-­‐down	   of	   the	   endogenous	   gene	   of	   interest	   is	  
phenotypically	  rescued	  by	  induced	  expression	  of	  the	  modified	  gene,	  that	  is	  not	  targeted	  by	  
the	  knock-­‐down	  construct.	  
3.9 CRISPR/CAS9	  GENOME	  EDITING	  
One	   of	   the	   aims	   in	   study	   III	   was	   to	   understand	   if	   the	   phenotype	   observed	   in	   MDS-­‐RS	  
patients	  was	   the	   result	   of	   a	   loss-­‐of-­‐function	  mutation.	   Therefore,	  we	   designed	   knock-­‐out	  
experiments	  using	  CRISPR/Cas9	  technology	  for	  its	  high	  efficiency,	  low	  off-­‐target	  effects	  and	  
for	   its	   possibility	   to	   introduce	   K700E	   allowing	   for	   studies	   of	   the	   effects	   of	   this	  mutation.	  
Study	  III	  is	  in	  manuscript	  form	  and	  some	  experiments	  are	  ongoing.	  	  
The	   Clustered	   Regularly	   Interspaced	   Short	   Palindromic	   Repeats	   (CRISPR)	   is	   a	   bacterial	  
immune	   system	   that	   has	   been	  modified	   for	   genome	   engineering.	   CRISPR	   consists	   of	   two	  
components:	   a	   “guide”	   RNA	   (gRNA)	   and	   a	   non-­‐specific	   CRISPR-­‐associated	   endonuclease	  
(Cas9).	  The	  gRNA	  is	  a	  short	  synthetic	  RNA	  composed	  of	  a	  targeting	  and	  a	  scaffold	  sequence	  
(derived	  from	  endogenous	  bacterial	  crRNA	  and	  tracRNA)	  necessary	  for	  Cas9-­‐binding	  and	  a	  
user-­‐defined	   20	   nucleotide	   sequence	   which	   defines	   the	   genomic	   target	   to	   be	   modified	  
(target	   sequence).	  The	   sequence	  has	   to	  be	  unique	   compared	   to	   the	   rest	  of	   the	   genome	  
and	   the	   target	   sequence	  must	   precede	   a	   5’-­‐NGG	   sequence	   called	   Protospacer	   Adjacent	  
Motif	  (PAM).	  The	  PAM	  sequence	  is	  necessary	  for	  target	  binding	  and	  the	  exact	  sequence	  is	  
dependent	  upon	  the	  species	  of	  Cas9	   (Figure	  10A)	   (Ran	  et	  al.	  2013).	  Once	  expressed,	  the	  
Cas9	  protein	  and	  the	  gRNA	  form	  a	  riboprotein	  complex,	  Cas9	  undergoes	  a	  conformational	  
change	   upon	   gRNA	   binding	   that	   shifts	   the	   molecule	   from	   an	   inactive,	   non-­‐DNA	   binding	  
conformation,	   into	  an	  active	  DNA-­‐binding	  conformation.	  The	  Cas9-­‐gRNA	  complex	  will	  bind	  
any	  genomic	  sequence	  with	  a	  PAM,	  but	  the	  extent	  to	  which	  the	  gRNA	  spacer	  matches	  the	  
target	   DNA	   determines	   whether	   Cas9	   will	   cut.	   Once	   the	   Cas9-­‐gRNA	   complex	   binds	   a	  
putative	  DNA	  target,	  a	  “seed”	  sequence	  at	  the	  3ʹ′	  end	  of	  the	  gRNA	  targeting	  sequence	  begins	  
to	  anneal	  to	  the	  target	  DNA	  (Larson	  et	  al.	  2013).	  Cas9	  will	  only	  cleave	  the	  target	  if	  sufficient	  
homology	  exists	  between	  the	  gRNA	  spacer	  and	  target	  sequences.	  Cas9	  undergoes	  a	  second	  
conformational	  change	  upon	  target	  binding	  that	  positions	  the	  nuclease	  domains	  to	  cleave	  
opposite	   strands	  of	   the	   target	  DNA.	  The	  Cas9-­‐mediated	  DNA	  cleavage	   results	   in	  a	  double	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strand	  break	  (DSB)	  within	  the	  target	  DNA,	  3-­‐4	  nucleotides	  upstream	  of	  the	  PAM	  sequence	  




The	  DSB	  is	  then	  repaired	  by	  one	  of	  two	  repair	  pathways:	  the	  Non-­‐Homologous	  End	  Joining	  
(NHEJ)	   pathway	   and	   the	   Homology	   Directed	   Repair	   (HDR)	   pathway.	   The	   NHEJ	   repair	  
pathway	   is	   very	   efficient	   but	   error-­‐prone.	   It	   generates	   small	   indels	   in	   the	   target	   DNA	   or	  
frameshift	   mutations	   leading	   to	   premature	   stop	   codons	   within	   the	   open	   reading	   frame	  
Figure	  10 A	  The	  Cas9	  nuclease	  (in	  yellow)	  is	  targeted	  to	  genomic	  DNA	  by	  a	  gRNA	  sequence	  (blue)	  and	  
a	   scaffold	   (red).	   The	   guide	   sequence	   pairs	  with	   the	   DNA	   target	   (blue	   bar	   on	   top	   strand),	   directly	  
upstream	  of	  a	  required	  5ʹ′-­‐NGG	  motif	  (PAM;	  pink).	  Cas9	  mediates	  a	  DSB	  3	  bp	  upstream	  of	  the	  PAM	  
(red	   triangle).	  B Schematic	   representation	  of	   the HDR	  and	  NHEJ	   repair	   pathways. Figures	  adapted	  
with	  the	  permission	  from	  the	  publisher	  (Ran	  et	  al.	  2013).	  
A
B
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(ORF)	  of	  the	  targeted	  gene.	  Ideally,	  the	  end	  result	  is	  a	  loss-­‐of-­‐function	  mutation	  within	  the	  
targeted	  gene;	  but	  the	  efficacy	  of	  the	  knock-­‐out	  phenotype	  is	  ultimately	  determined	  by	  the	  
amount	  of	  residual	  gene	  function,	  that	  is	  why	  it	  is	  important	  to	  evaluate	  for	  example	  the	  KO	  
efficiency	  at	  protein	  level.	  	  
By	   contrast,	   the	   HDR	   pathway	   can	   be	   used	   to	   generate	   specific	   nucleotide	   changes,	   for	  
example	  to	  introduce	  a	  point	  mutation	  such	  as	  K700E	  in	  SF3B1.	  This	  pathway	  is	  less	  efficient	  
but	  more	  precise.	  However,	  to	   induce	  HDR,	  a	  DNA	  repair	  template	  containing	  the	  desired	  
sequence	   must	   be	   delivered	   into	   the	   cells	   along	   with	   the	   gRNA	   and	   Cas9.	   The	   repair	  
template	   must	   contain	   the	   desired	   edit	   as	   well	   as	   additional	   homologous	   sequence	  
upstream	   and	   downstream	   of	   the	   target.	   It	   can	   be	   a	   single	   or	   a	   double-­‐stranded	  
oligonucleotide,	  or	  a	  double-­‐stranded	  DNA	  plasmid	  depending	  on	   the	  specific	  application.	  
Importantly,	  the	  template	  must	  lack	  the	  PAM	  sequence	  that	  is	  present	  in	  the	  genomic	  DNA	  
to	   avoid	   a	  possible	   cleavage	  mediated	  by	  Cas9.	   Therefore,	   it	   is	  wise	   to	   introduce	   a	   silent	  
mutation	   in	   the	   repair	   template,	   so	   that	   the	   PAM	   is	   no	   longer	   present.	   However,	   the	  
efficiency	  of	  HDR	  in	  CD34+	  cells	  has	  been	  reported	  to	  be	  low	  (<10%)	  (Genovese	  et	  al.	  2014)	  
due	   to	   the	   fact	   that	   human	   progenitor	   cells	   poorly	   tolerate	   Cas9	   and	   generally,	   the	  
introduction	  of	  vectors	  or	  oligonucleotides	  by	  nucleofection.	  Also,	  whereas	  the	  efficiency	  of	  
Cas9	   cleavage	   is	   relatively	   high	   and	   that	   of	   HDR	   is	   relatively	   low,	   a	   portion	   of	   the	   Cas9-­‐
induced	   DSBs	   will	   be	   repaired	   via	   NHEJ,	   meaning	   that	   the	   resulting	   cells	   population	   will	  
contain	   a	   combination	   of	   wild-­‐type	   alleles,	   NHEJ-­‐repaired	   alleles,	   and/or	   the	   HDR-­‐edited	  
allele.	   Thus,	   considering	   the	   fact	   that	  we	   study	  differentiating	   cells	   and	   that	   CRISPR/Cas9	  
modifies	  gene	  (via	  knock-­‐out	  or	  knock-­‐in)	  at	  DNA	  genomic	  level	  and	  with	  sometime	  very	  low	  
efficiency	  rate,	  it	  is	  crucial	  to	  confirm	  the	  presence	  of	  the	  desired	  edits	  experimentally	  (i.e.	  
by	  sequencing	  technologies	  or	  ddPCR	  or	  western	  blot),	  to	  distinguish	  NHEJ	  and	  HRD	  events	  
and	  to	  isolate	  clones	  (both	  homozygous	  and	  heterozygous)	  containing	  the	  desired	  changes.	  
However,	  generating	  clones	  may	  be	  difficult	  especially	  in	  primary	  cells	  (i.e.	  CD34+	  cells)	  if	  the	  
gene	   of	   interest	   is	   crucial	   for	   cell	   proliferation	   or	   survival,	   thereby	  making	   the	   knock-­‐out	  
efficiency	   validation	   very	   challenging.	   In	   conclusion,	   while	   CRISPR/Cas9	   allows	   the	  
generation	  of	  a	  full	  knock-­‐out,	  (i.e.	  the	  complete	  loss	  of	  function),	  shRNAs	  reduce	  the	  gene	  




4 RESULTS	  AND	  DISCUSSIONS	  
4.1 STUDY	  I	  
In	  study	  I,	  in	  order	  to	  investigate	  whether	  ABCB7	  is	  an	  important	  mediator	  of	  the	  aberrant	  
iron	  accumulation	  and	  ineffective	  erythropoiesis	  in	  MDS-­‐RS,	  we	  modulated	  its	  expression	  in	  
human	   bone	   marrow	   progenitors	   cells.	   First,	   down-­‐regulation	   of	   ABCB7	   in	   normal	  
progenitors	  by	  shRNAs	  fused	  with	  GFP	  significantly	  reduced	  erythroid	  colony	  growth	  and	  to	  
a	   lesser	   extent	  myeloid	   colony	   formation	   (N=3)	   (Figure	   1A,	   study	   I).	  ABCB7	   silenced	   cells	  
were	  cultured	  for	  14	  days	  in	  our	  well-­‐established	  erythroblast	  culture	  system	  (Tehranchi	  et	  
al.	  2003,	  Pellagatti	  et	  al.	  2007).	  While	  no	  significant	  effects	  on	  cell	  survival	  were	  observed	  
during	  the	  first	  7	  days,	  the	  percentage	  of	  silenced	  ABCB7	  GFP+	  cells	  dropped	  drastically	  at	  
day	   14	   compared	   to	   approximately	   8-­‐10%	   in	   the	   scramble	   controls	   (Figure	   1B,	   study	   I).	  
During	   the	   14	   days	   of	   culture,	   cells	   expressing	   the	   early	   erythroid	   CD36	  marker	   did	   not	  
decrease,	  but	  showed	  a	  decrease	  of	  GPA+	  suggesting	  that	  ABCB7	  may	  affect	  more	  the	  later	  
stages	  of	  erythroid	  maturation	  (Figure	  1C-­‐D,	  study	  I).	  
Next,	  we	  explored	  potential	  changes	  in	  gene	  expression	  in	  CD34+	  GFP+	  sorted	  ABCB7	  down-­‐
regulated	   cells	   during	   differentiation.	   After	   3	   days	   of	   culture,	   we	   could	   observe	   a	   2-­‐fold	  
increase	  of	  mitochondrial	   ferritin	   (FTMT).	  At	  day	  7	   the	  ALAS2	   expression	  was	   significantly	  
decreased,	   indicating	   a	   reduced	   heme	   synthesis	   at	   this	   time	   point.	   Furthermore,	   we	  
observed	   a	   reduction	   of	   FOXO3A,	   involved	   in	   the	   protection	   from	   oxidative	   stress,	   and	  
MAP3K7,	  a	  negative	  regulator	  of	  apoptosis	  were	  also	  reduced	  upon	  ABCB7	  down-­‐regulation	  
(Figure	  1E,	  study	  I).	  
Vice	   versa,	   over-­‐expression	   of	  ABCB7	   using	   a	   constitutive	   vector	   expressing	   YFP	   rescued	  
erythroid	  maturation	  and	  restored	  colony	  growth	  of	  these	  cells.	  CD34+	  cells	  from	  4	  MDS-­‐RS	  
patients	  over-­‐expressing	  ABCB7	  showed	  enhanced	  erythroid	  colony	  growth,	  in	  particular	  of	  
the	  BFU-­‐E	  colonies,	  compared	  to	  cells	  transduced	  with	  the	  empty	  vector	  (Figure	  2A-­‐B,	  study	  
I).	   Importantly,	  ABCB7	   forced	   expression	   decreased	   the	  mRNA	   level	   of	   FTMT,	   suggesting	  
that	  ABCB7	  may	  have	  a	  role	  in	  the	  aberrant	  mitochondrial	  iron	  accumulation	  (Figure	  2C-­‐D,	  
study	  I).	  	  
RNA	  samples	  from	  5	  SF3B1	  mutated	  MDS-­‐RS	  patients	  and	  3	  healthy	  controls	  were	  obtained	  
at	  day	  7	  and	  day	  14	  of	  in	  vitro	  erythroid	  differentiation	  and	  used	  to	  investigate	  a	  potential	  
differential	  exon	  usage	  previously	  detected	  in	  a	  pilot	  RNA	  sequencing	  experiment.	  The	  latter	  
analysis	   highlighted	   an	   altered	   usage	   between	   exons	   8	   and	   9.	   Primers	  were	   designed	   to	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specifically	   quantify	   different	   regions	   of	   ABCB7	   mRNA	   transcript.	   Exon	   usage	   was	   more	  
heterogeneous	  within	  the	  MDS-­‐RS	  population	  compared	  to	  the	  healthy	  controls.	  In	  spite	  of	  
a	   profound	   down-­‐regulation	   in	   all	   investigated	   regions	   at	   both	   time	   points	   (Figure	   3A-­‐B,	  
study	  I),	  it	  was	  difficult	  to	  detect	  a	  strong	  effect	  on	  this	  specific	  exonic	  region	  7J8-­‐9	  (Figure	  
3E,	  study	  I).	  Furthermore,	  transient	  siRNA-­‐mediated	  down-­‐regulation	  of	  SF3B1	  in	  K562	  cells	  
resulted	  in	  reduced	  expression	  of	  ABCB7,	  a	  reduction	  that	  was	  even	  more	  pronounced	  when	  
cells	  were	  treated	  with	  hemin	  to	  induce	  erythroid	  differentiation	  (Figure	  4,	  study	  I).	  
To	   summarize,	   in	   study	   I	  we	   examined	   the	   role	   of	  ABCB7,	   an	  ATP-­‐binding	   cassette	   (ABC)	  
transporter	  located	  at	  the	  inner	  membrane	  of	  the	  mitochondria.	  Missense	  mutations	  in	  this	  
gene	   lead	   to	   X-­‐linked	   sideroblastic	   anemia	   and	   ataxia	   (XLSA/A)	   (Allikmets	   et	   al.	   1999).	  
Notably,	  the	  existence	  of	  an	  inherited	  disorder	  XLSA/A	  caused	  by	  mutations	  in	  ABCB7	  is	  very	  
revealing	  of	  the	  probable	  consequences	  of	  reduced	  expression	  of	  the	  same	  gene	  in	  acquired	  
disorders.	  Direct	   sequencing	  of	  ABCB7,	   including	   the	  promoter	   region,	  was	  performed	  on	  
DNA	  from	  13	  RARS	  patients	  and	  did	  not	  show	  any	  mutations,	  nor	  significant	  differences	  in	  
the	   methylation	   status	   of	   ABCB7	   promoter	   region	   of	   RARS	   patients	   compared	   to	   NBM	  
(Nikpour	   et	   al.	   2010).	   Previous	   studies	   performing	  ABCB7	   silencing	   and	   conditional	   gene	  
targeting	   in	   mice	   resulted	   in	   siderocytosis	   without	   ring	   sideroblasts	   formation	   and	  
highlighted	   the	   importance	   of	   ABCB7	   in	   hematopoiesis	   and	   cytosolic	   iron-­‐sulfur	   cluster	  
biogenesis	  (Pondarre	  et	  al.	  2006,	  Pondarre	  et	  al.	  2007).	  Additionally,	  silencing	  of	  ABCB7	   in	  
HeLa	   cells	   resulted	   in	   an	   iron-­‐deficient	   phenotype	   with	   mitochondrial	   iron	   accumulation	  
(Cavadini	  et	  al.	  2007).	  	  
At	  the	  time	  when	  study	  I	  was	  designed,	  ABCB7	  had	  been	  reported	  to	  be	  significantly	  down-­‐
regulated	  in	  MDS-­‐RS	  patients	  in	  comparison	  with	  healthy	  controls	  and	  other	  MDS	  subtypes	  
(i.e.	   RA	   and	   RAEB)	   (Boultwood	   et	   al.	   2008).	   Furthermore,	   we	   observed	   that	   ABCB7	  
expression	   levels	   decreased	   during	   differentiation	   of	   MDS-­‐RS	   cultured	   erythroblasts,	   in	  
contrast	   to	   a	   continuous	   increase	   during	   normal	   erythroid	   differentiation	   (Nikpour	   et	   al.	  
2010),	   raising	  the	  hypothesis	   that	   low	  ABCB7	   levels	  would	  reflect	  abnormal	  mitochondrial	  
iron	  homeostasis.	   Intriguingly,	  ABCB7	  expression	  increased	  in	  normal	  erythroblast	  cultures	  
in	  parallel	  with	  hemoglobinization,	  in	  contrast	  to	  the	  gradual	  decrease	  of	  ABCB7	  expression	  
from	  day	  0	  to	  day	  14	  in	  MDS-­‐RS,	  thereby	  supporting	  a	  critical	  role	  of	  ABCB7	  in	  aberrant	  iron	  
accumulation.	   Interestingly,	   although	   a	   functional	   relation	   between	   ABCB7	   and	   RS	  
formation	   has	   not	   been	   established	   in	   MDS-­‐RS,	   ABCB7	   expression	   level	   is	   inversely	  
correlated	  with	  the	  percentage	  of	  marrow	  ring	  sideroblasts	  (Boultwood	  et	  al.	  2008).	  As	  the	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erythroblast	  culture	  model	  does	  not	  produce	  ring	  sideroblasts,	  we	  used	  the	  expression	  of	  
FTMT	  as	  surrogate	  marker	  for	  aberrant	  iron	  accumulation,	  which	  accumulates	  during	  early	  
erythroid	  differentiation	  of	  RARS	  progenitors	  (Tehranchi	  et	  al.	  2003,	  Tehranchi	  et	  al.	  2005b). 
Specifically,	  FTMT	   gene	  and	  protein	  expression	   increased	  after	  ABCB7	   silencing	   in	  normal	  
progenitors	   during	   erythroid	   differentiation.	   ABCB7	   down-­‐regulation	   and	   FTMT	   over-­‐
expression	  both	  lead	  to	  increased	  RNA-­‐binding	  activity	  of	  iron	  regulatory	  proteins	  (IRPs)	  and	  
consequently	  an	  increase	  in	  cellular	  iron	  uptake	  from	  transferrin	  (Nie	  et	  al.	  2005,	  Cavadini	  et	  
al.	  2007),	  which	  mainly	  incorporates	  into	  FTMT.	  The	  avidity	  of	  FTMT	  for	  iron	  is	  stronger	  than	  
that	  of	  its	  cytosolic	  counterpart	  (Nie	  et	  al.	  2005).	  Hence,	  FTMT	  over-­‐expression	  may	  lead	  to	  
the	  functional	   iron	  deficiency	  in	  RARS	  erythrocytes,	  evident	  by	  the	  finding	  of	  hypochromic	  
erythrocytes	   in	   RARS	   (Ljung	   et	   al.	   2004).	  Moreover,	   FTMT	   expression	   decreased	   in	   RARS	  
samples	   with	   forced	   expression	   of	   ABCB7,	   in	   spite	   of	   relatively	   moderate	   transduction	  
frequencies. 	  
Silencing	  of	  ABCB7	  in	  NBM	  cells	  inhibited	  erythropoiesis	  more	  than	  myelopoiesis,	  indicating	  
that	  the	  ABCB7	  protein	  may	  be	  more	  important	  for	  differentiation	  of	  the	  erythroid	  lineage	  
than	   the	   myeloid	   lineage.	   Interestingly,	   this	   finding	   corroborates	   with	   a	   recent	   study	  
showing	   that	  mitochondrial	   damage	   impairs	   elimination	  of	  mitochondria	  during	  erythroid	  
differentiation	  leading	  to	  enhanced	  erythrocyte	  destruction	  (Ahlqvist	  et	  al.	  2015).	  
In	   particular,	  ABCB7	   down-­‐regulation	   impaired	   late	   erythroid	   differentiation	   and	   survival,	  
while	  earlier	  and	  intermediate	  stages	  were	  unaffected.	  This	  pattern	  corresponds	  well	  to	  the	  
MDS-­‐RS	  morphology,	  which	  is	  dominated	  by	  intermediate	  and	  late	  dysplastic	  erythroblasts.	  
Thus,	  it	  is	  possible	  that	  reduced	  ABCB7	  levels	  results	  in	  marked	  cellular	  phenotypic	  changes	  
first	  when	  iron	  turnover	  or	  heme	  synthesis	  increases	  above	  a	  critical	  threshold.	  Our	  finding	  
of	  a	  strong	  association	  between	  MDS-­‐RS	  and	  low	  gene	  expression	  levels	  of	  ABCB7	  and	  the	  
fact	  that	  over-­‐expression	  of	  ABCB7	  restored	  erythropoiesis	  and survival	  of	  RARS	  progenitors	  
while	  decreasing	  the	  expression	  of	  aberrant	  mitochondrial	   ferritin,	  raises	  the	  possibility	  of	  
therapeutic	  approaches	  for	  MDS-­‐RS	  for	  instance	  by	  using	  drugs	  or	  genetics	  approaches	  (i.e.	  
in	  vitro	  transcribed	  mRNAs)	  to	  boost	  the	  expression	  of	  ABCB7.	  	  
Importantly,	   studies	   from	  Papaemmanuil	   and	  Yoshida	   et	   al.	   reported	   high	   frequencies	   of	  
mutations	  in	  SF3B1	  in	  MDS-­‐RS	  patients	  and	  encouraged	  us	  to	  explore	  a	  potential	  association	  
between	   SF3B1	   gene	   mutation	   and	   ABCB7	   down-­‐regulation	   in	   RARS.	   Transient	   siRNA-­‐
mediated	   down-­‐regulation	   of	   SF3B1	   during	   erythroid	   differentiation	   resulted	   in	   reduced	  
expression	  of	  ABCB7,	  suggesting	  a	  possible	  link	  between	  the	  two	  genes.	  Finally,	  we	  reported	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altered	  usage	  of	  ABCB7	  exons	  as	  a	  possible	  explanation	  of	  the	  reduced	  ABCB7	  expression	  in	  
MDS-­‐RS,	  which	  might	  have	  been	  secondary	  to	  the	  altered	  SF3B1	  function	  due	  to	  mutation.	  
Whether	  this	  relationship	  plays	  a	  role	  in	  RARS	  pathogenesis	  was	  not	  clear	  at	  the	  time	  of	  this	  
publication	  but	  was	   later	  confirmed	  by	  other	  studies	   (Darman	  et	  al.	  2015,	  Shiozawa	  et	  al.	  
2015).	  
4.2 STUDY	  II	  	  
In	  study	  II	  RNA	  sequencing	  comparing	  MDS-­‐RS	  SF3B1	  mutated	  and	  NBM	  CD34+	  cells	  during	  
early	   erythroid	   differentiation	   (day	   0	   and	   4)	   showed	   marked	   dissimilarities	   in	   gene	  
expression,	  pathways	  and	   splicing.	   In	  particular,	   several	  of	   the	   top	  20	  up-­‐regulated	  genes	  
(such	  as	  HBM,	  HBA2,	  HBA1,	  ALAS2)	  in	  MDS-­‐RS	  were	  involved	  in	  the	  heme	  and	  hemoglobin	  
biosynthesis	  (Table	  I,	  study	  II).	  The	  μ-­‐globin	  (HBM)	  gene	  was	  the	  most	  up-­‐regulated	  among	  
the	   genes	   involved	   in	   the	   hemoglobin	   pathway.	   HBM	   was	   initially	   identified	   as	   a	  
pseudogene	  and	  later	  detected	  particularly	  abundant	  in	  cord	  blood	  reticulocytes	  (Goh	  et	  al.	  
2005).	   HBA1	   and	   HBA2	   encode	   the	   α-­‐globin	   protein	   and	   mutations	   in	   these	   genes	   are	  
generally	  the	  most	  common	  cause	  of	  α-­‐talassemia	  (Hardison	  et	  al.	  2002).	  Of	  note,	  HBA2	  was	  
reported	  down-­‐regulated	  in	  differentiating	  erythroblasts	  of	  MDS	  patients	  with	  del(5q)	  after	  
treatment	  with	  lenalidomide	  (Pellagatti	  et	  al.	  2007).	  Among	  the	  most	  up-­‐regulated	  genes	  in	  
MDS-­‐RS,	   we	   reported	   also	   ALAS2,	   a	   gene	   known	   for	   its	   fundamental	   role	   in	   the	   heme	  
synthesis	  and	  expressed	  exclusively	   in	  erythroid	  cells.	  The	  gene	  expression	   levels	  of	  HBM,	  
HBA2,	   HBA1,	   ALAS2	   were	   similar	   in	   SF3B1	   mutated	   (n=6)	   and	   wild-­‐type	   (n=2)	   patients.	  
However,	  transcriptome	  data	  from	  Dolatshad	  et	  al.	   (Dolatshad	  et	  al.	  2015)	  reported	  these	  
genes	  to	  be	  differentially	  expressed	  between	  SF3B1	  mutated	  and	  wild-­‐type	  patients.	  	  
The	  expression	  of	  several	  de-­‐regulated	  genes	   (TIMD4,	  ALAS2,	  CD5L,	  LYVE1,	  CXCL18,	  MSR1	  
and	  CXCL12)	   detected	   by	   RNA	   sequencing	  was	   confirmed	   by	   TLDA	   analysis	   (Figure	   4C-­‐D,	  
study	  II).	  Out	  of	  61	  genes	  selected	  for	  TLDA,	  20	  genes	  at	  day	  0	  and	  17	  genes	  at	  day	  4	  were	  
differentially	   expressed	   between	  MDS-­‐RS	   and	   NBM.	   Interestingly,	   several	   of	   these	   genes	  
(ABCB7,	   ALAS2,	   APOE,	   HBB,	   MFN2,	   SEPP1)	   have	   been	   shown	   to	   be	   involved	   in	   defense	  
against	  oxidative	  stress	  suggesting	  that	  MDS-­‐RS	  progenitors	  are	  challenged	  by	  ROS	  during	  
early	  differentiation	  (Miyata	  et	  al.	  1996,	  Saito	  et	  al.	  1999,	  Shen	  et	  al.	  2007,	  Liesa	  et	  al.	  2012,	  
Bayeva	  et	  al.	  2013)	  (Supplementary	  Table	  9,	  study	  II).	  This	  finding	  is	   in	   line	  with	  a	  positive	  
enrichment	  of	  the	  oxidative	  phosphorylation	  pathway,	  and	  together	  with	  a	  down-­‐regulation	  
of	  the	  ABC	  transporters	  strongly	  implies	  a	  mitochondrial	  dysfunction	  in	  MDS-­‐RS	  (Figure	  1E-­‐F,	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study	   II).	   Previous	   studies	   have	   shown	   that	   low-­‐risk	   MDS	   patients	   exhibit	   a	   significant	  
increase	   of	   oxidative	   damage	   to	   DNA,	   which	   could	   contribute	   to	   genomic	   instability	   and	  
disease	  progression	  (Ghoti	  et	  al.	  2007,	  Novotna	  et	  al.	  2009).	  
In	   addition,	   the	   up-­‐regulation	   of	   genes	   involved	   in	   the	   heme	   biosynthesis	   pathway	   may	  
indicate	   a	   compromised	   hemoglobinization	   and	   an	   impaired	   ability	   of	   mitochondrial	  
pathways	  to	  use	  iron,	  leading	  to	  the	  increased	  mitochondrial	  iron	  accumulation	  observed	  in	  
MDS	  patients	  with	   ring	  sideroblasts.	  Although	  the	  altered	  expression	  of	   these	  genes	   is	  an	  
intriguing	   finding	   in	  MDS-­‐RS	  patients,	  mutations	   found	   in	   congenital	   sideroblastic	   anemia	  
(i.e.	  ALAS2	  mutations)	  have	  not	  been	  described	  in	  MDS.	  	  
The	  fact	  that	  splicing	  and	  gene	  expression	  patterns	  undergo	  major	  changes	  during	  normal	  
differentiation	   (An	   et	   al.	   2014,	   Cheng	   et	   al.	   2014,	   Pimentel	   et	   al.	   2016),	   made	   this	  
longitudinal	   study	   during	   erythroid	   maturation	   highly	   relevant.	   We	   employed	   RNA	  
sequencing	   to	   identify	   mis-­‐spliced	   events	   functionally	   linked	   to	   MDS-­‐RS	   disease	  
pathogenesis	   in	   its	  earliest	  stages.	   In	  particular,	  18	  genes	  were	  mis-­‐spliced	  at	  day	  0	  and	  2	  
genes	   (ANKHD1	   and	   TMEM14C)	   showed	   altered	   splicing	   at	   day	   4.	   Only	   TMEM14C	   was	  
differentially	   spliced	   at	   both	   time	   points	   (Supplementary	   Table	   7,	   study	   II).	   Of	   note,	   the	  
coverage	  of	  ABCB7	   for	  which	  we	  previously	   reported	  altered	  exon	  usage	  during	  erythroid	  
maturation,	  was	  suboptimal	  for	  this	  analysis.	  	  Among	  those,	  the	  function	  of	  TMEM14C	  and	  
TFCP2	  was	  closely	  related	  to	  mitochondria	  and	  in	  particular	  to	  heme	  biosynthesis	  (Yien	  et	  al.	  
2014,	   Yien	   et	   al.	   2015)	   (Figure	   3A,	   study	   II).	   Tmem14c	   encodes	   a	   mitochondrial	   inner	  
membrane	  protein	  required	  for	  the	  transport	  of	  mitochondrial	  porphyrin	  (Yien	  et	  al.	  2015).	  
Recent	  evidence	  suggests	  that	  protoporphyrin	  IX	  synthesis	  in	  Tmem14c-­‐deficient	  eryhtroid	  
cells	  was	  blocked	  causing	  an	  accumulation	  of	  porphyrin	  precursors.	  In	  these	  cells,	  the	  heme	  
synthesis	   defect	   was	   ameliorated	   with	   a	   protoporphyrin	   IX	   analogue,	   indicating	   that	  
Tmem14c	   functions	   mainly	   in	   the	   terminal	   stages	   of	   the	   heme	   synthesis	   facilitating	   the	  
import	  of	  protoporphyrinogen	   IX	   into	   the	  mitochondrial	  matrix,	   and	   is	   required	   for	  heme	  
synthesis	  and	  late	  erythropoiesis	  (Yien	  et	  al.	  2014,	  Yien	  et	  al.	  2015).	  Also,	  Tmem14c	  knock-­‐
down	  in	  zebrafish	  led	  to	  profound	  anemia	  without	  affecting	  erythroid	  lineage	  specification	  
(Nilsson	   et	   al.	   2009).	   Our	   transcriptome	   analysis	   reported	   two	   isoforms	   of	   TMEM14C:	  
TCONS15	   strongly	   up-­‐regulated	   and	   TCONS16,	   significantly	   down-­‐regulated	   in	   MDS-­‐RS	  
patients	   versus	   NBM.	   Of	   note,	   TMEM14C	   TCONS15	   was	   significantly	   down-­‐regulated	   in	  
SF3B1	  wild-­‐type	  compared	  to	  mutated	  patients	  (Figure	  3A,	  study	  II).	  On	  the	  other	  hand,	  the	  
shorter	   isoform	   TCONS16	   lacked	   14	   bases	   in	   the	   5’UTR	   within	   the	   predicted	   internal	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ribosome	   entry	   site	   (IRES)	   important	   for	   translation	   of	   specific	   mRNAs	   during	   mitosis,	  
apoptosis	   and	   hypoxia	   (Hellen	   et	   al.	   2001)	   (Figure	   3B,	   study	   II).	   Therefore,	   a	   sequence	  
change	   in	   this	   region	   could	   affect	   the	   translation	   of	   TMEM14C,	   with	   consequences	   for	  
mitochondrial	   function	   and	   haemoglobin	   synthesis	   (Yien	   et	   al.	   2015).	   Moreover,	   we	  
detected	   3	   different	   isoforms	   of	   TFCP2	   differentially	   expressed	   between	   MDS-­‐RS	   and	  
healthy	   controls	   (Figure	   3A,	   study	   II).	   TFCP2	   is	   a	   transcription	   factor	   that	   activates	   the	  
transcription	  of	  the	  α-­‐globin	  gene,	  thus	  regulating	  the	  erythroid	  gene	  expression	  (Kang	  et	  al.	  
2005).	  Among	  the	  3	  isoforms	  found,	  TCONS_0012739	  lacked	  153	  bases	  in	  the	  sixth	  exon	  of	  
the	  mRNA	  corresponding	  to	  the	  CP2	  DNA	  binding	  domain	  that	  binds	  the	  α-­‐globin	  promoter	  
(Figure	  3C,	  study	  II).	  CP2	  is	  a	  major	  factor	   in	  the	  regulation	  of	  globin	  expression	   in	  human	  
and	  mouse	  erythroid	  cells,	  and	  CP2	  binding	  to	  the	  promoter	   is	  essential	   for	  the	  enhanced	  
transcription	  of	  globin	  genes	  in	  erythroid	  differentiation	  (Chae	  et	  al.	  2003).	  We	  used	  qPCR	  to	  
measure	   the	   abundance	   of	   transcripts	   containing	   exon	   6	   and	   we	   observed	   a	   1.3	   fold-­‐
decrease	   in	  MDS-­‐RS	  versus	  NBM,	  whereas	  the	  expression	  of	  TCONS00112740	  (referred	  as	  
TCONS40	   in	   study	   II)	   showed	   the	   same	   trend	   as	   in	   the	   RNA	   Sequencing,	   however	   inter-­‐
patient	   variation	   was	   high	   and	   the	   comparison	   was	   not	   statistically	   significant.	   The	  
additional	  16	  mis-­‐spliced	  genes	  were	  related	  to	  various	  functions,	  such	  as	  DNA	  replication	  
(DUT),	  MAPK	  signalling	  pathway	  (MBIP),	  transcription	  regulation	  (ZNF518B,	  EIF2B4,	  TGFI2),	  
blood	  coagulation	   (PROCR),	   intracellular	   trafficking	  and	  energy	  metabolism	  (ACBD3,	  SNX3,	  
CYP2S1,	  NUDT7)	   (Supplementary	   Table	   7,	   study	   II).	   In	   particular,	   EIF2B4	   acts	  within	   a	   tri-­‐
subunits	  complex	  that	  includes	  EIF2α	  kinase.	  In	  normal	  erythropoiesis,	  heme	  induces	  globin	  
transcription	  and	  translation	  by	  binding	  the	  inhibitors	  BACH1	  and	  EIF2α	  kinase,	  respectively,	  
so	   as	   soon	   as	   heme	   is	   present,	   globin	   synthesis	   begins	   (Yang	   et	   al.	   2016).	   This	   inhibition	  
occurs	   when	   the	   intracellular	   concentration	   of	   heme	   declines,	   thereby	   preventing	   the	  
synthesis	  of	  globin	  peptides	  in	  excess	  of	  heme	  (Han	  et	  al.	  2001).	  	  
Next,	  we	  investigated	  whether	  SF3B1	  mutated	  progenitors	  cells	  had	  a	  growth	  disadvantage	  
compared	   to	   SF3B1	   wild-­‐type	   cells.	  MDS-­‐RS	   is	   characterized	   by	   ineffective	   erythropoiesis	  
and	  anaemia,	  but	  the	  exact	  stage	  of	  erythroid	  maturation	  at	  which	  this	  defect	  occurs	   it	   is	  
poorly	   understood	   (Hattangadi	   et	   al.	   2011).	   Previous	   investigations	   have	   described	  
apoptotic	   features	  of	  RARS	  erythroblasts	   in	  bone	  marrow	  biopsies	   as	  well	   as	   in	   erythroid	  
culture	   systems	   (Tehranchi	   et	   al.	   2003,	   Tehranchi	   et	   al.	   2005a,	   Tehranchi	   et	   al.	   2005b).	  
Interestingly,	  this	  does	  not	  translate	  into	  a	  decreased	  proportion	  of	  marrow	  erythroid	  cells,	  
but	   rather	   to	   erythroid	   expansion,	   indicating	   concomitant	   stimulation	   of	   erythroid	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proliferation	  and	  survival	   (Nikpour	  et	  al.	  2013).	  First,	  we	  measured	  SF3B1	  allele	  burden	   in	  
CD34+	  cells	  isolated	  from	  5	  MDS-­‐RS	  patients	  at	  day	  0,	  4,	  7,	  11	  and	  14	  of	  the	  erythroid	  and	  
myeloid	  differentiation	  (Figure	  4E,	  study	  II).	  Allele	  burden	  was	  stable	  over	  time	  and	  a	  similar	  
pattern	  was	  observed	   in	  patients	  with	  or	  without	   transfusion	  need,	   i.e.	   the	  production	  or	  
not	  of	  erythrocytes	  did	  not	   influence	   the	   results.	  Then,	   to	  exclude	   the	  possibility	   that	   the	  
culture	  system	  would	  have	  conferred	  a	  growth	  advantage	  of	  the	  mutated	  clone,	  we	  selected	  
GPA+	   cells	   from	   freshly	   obtained	   BM	   CD34-­‐	   cells	   of	   7	  MDS-­‐RS	   patients	   carrying	   different	  
SF3B1	   mutations.	   Allele	   burden	   in	   the	   GPA+	   fraction	   was	   similar	   to	   the	   BMCD34+	   and	  
erythroblast	  D14	  fractions	  previously	  evaluated.	  Finally,	  we	  assessed	  SF3B1	  allele	  burden	  in	  
reticulocytes	  obtained	  from	  peripheral	  blood	  of	  non-­‐transfused	  MDS-­‐RS	  patients	  with	  stable	  
anemia	  and	  a	  median	  of	  47%	  (33-­‐70)	  RS	  of	  total	  BM	  erythroblasts.	  The	  SF3B1	  allele	  burden	  
was	  1.5	   fold	   lower	   in	   reticulocytes	  compared	   to	  corresponding	   fresh	  CD34+	   cells	  and	  cells	  
cultured	  for	  14	  days,	  and	  1.4	  fold	  lower	  than	  in	  freshly	  isolated	  GPA+	  cells	  (Figure	  4F,	  study	  
II).	  These	  results	  imply	  reduced	  differentiation	  of	  SF3B1	  mutated	  erythroblasts	  at	  the	  stage	  
when	   they	   mature	   into	   erythrocytes,	   and	   indicate	   that	   SF3B1	   mutations	   do	   not	   inhibit	  
growth	   and	   maturation	   of	   marrow	   erythroblasts,	   in	   spite	   of	   the	   mitochondrial	   iron	  
accumulation.	   Conversely,	   the	   decreased	   allele	   burden	   in	   reticulocytes	   indicates	   that	   the	  
main	  threat	  to	  red	  cell	   formation	  develops	  during	  terminal	  differentiation	  to	  erythrocytes.	  
The	  fate	  of	  SF3B1	  clone	  has	  been	  also	  assessed	  in	  an	  ongoing	  study	  using	  an	  ex-­‐vivo	   long-­‐
term	  culture	  model	  able	  to	  reproduce	  self-­‐renewal	  potential	  of	  HSC	  and	  to	  generate	  ring	  
sideroblasts,	  erythroid	  islands	  and	  red	  blood	  cells.	  In	  this	  culture,	  the	  SF3B1	  mutant	  clone	  
was	  stable	  throughout	  4	  weeks	  of	  culture	  (Elvarsdóttir	  et	  al.	  2016).	  	  
To	   summarize,	   study	   II	   offers	   a	   number	   of	   potential	   targets	   affected	   by	   the	   SF3B1	  
mutations,	   and	   demonstrates	   how	   these	   targets	   may	   contribute	   to	   the	   MDS-­‐RS	  
pathogenesis.	  Mutations	  of	  SF3B1	  may,	  via	  altered	  gene	  expression	  or	  mis-­‐splicing	  of	  key	  
genes	  in	  the	  heme	  and	  hemoglobin	  synthesis,	  disturb	  mitochondrial	  iron	  handling	  in	  a	  way	  
that	  causes	  mitochondrial	   iron	  accumulation	   in	  MDS-­‐RS.	   In	  addition,	   this	   study	   indicates	  
that	   potential	   therapeutic	   targets	   such	   as	   ACE-­‐536	   or	   ACE-­‐011	   (Dussiot	   et	   al.	   2014,	  
Suragani	  et	  al.	  2014),	  targeting	  the	  late	  stages	  of	  erythropoiesis	  and	  currently	  evaluated	  in	  
clinical	   trials	  may	   be	   suitable	   to	   treat	  MDS-­‐RS	   patients.	   A	  major	   challenge	  would	   be	   to	  
establish	   if	   SF3B1	  mutations	   are	   causative	   of	   the	   development	   of	  MDS-­‐RS,	   or	   if	   they	   are	  
involved	   in	   the	  disease	  progression,	  merely	  altering	  the	  phenotype	  and	   in	  some	  cases	  co-­‐
operating	  with	  other	  mutations,	  with	  no	  effect	  on	  the	  natural	  history	  of	  the	  disease.	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4.3 STUDY	  III	  
Our	  aim	  was	   to	   investigate	   the	   impact	  of	   the	  SF3B1	   K700E	  mutation	   in	  myeloid	   cells	   and	  
explore	  if	  this	  mutation	  confers	  a	  loss-­‐of-­‐function	  in	  regards	  of	  gene	  expression	  and	  splicing	  
of	  key	  genes	   in	  MDS-­‐RS.	  From	  a	  therapeutic	  point	  of	  view	  it	   is	   important	  to	  understand	  if	  
the	   clinical	   phenotype	  derives	   from	  a	   loss	  or	   a	   gain	  of	   function	  of	   SF3B1.	   To	  date,	   SF3B1	  
heterozygous	   mouse	   models	   have	   failed	   to	   develop	   the	   human	  MDS-­‐RS	   phenotype	   and	  
knock-­‐in	  mice	  generated	  only	  a	  mild	  phenotype	  in	  terms	  of	  RS	  formation	  and	  specific	  mis-­‐
splicing	   events	   observed	   in	  MDS-­‐RS	   progenitors.	   Also,	   it	   is	   still	   unclear	   if	   SF3B1	   alone	   is	  
sufficient	  to	  initiate	  the	  disease	  in	  human	  primary	  cells.	  In	  this	  study,	  we	  used	  CRISPR/Cas9	  
technology	  to	  knock-­‐out	  SF3B1	  and	  a	  tetracycline	  inducible	  system	  to	  express	  the	  wild-­‐type	  
and	   the	   recombinant	  SF3B1	  K700E	   in	  human	  K562	  cells.	   First,	  we	   transduced	  K562	  SF3B1	  
wild-­‐type	   cells	  with	   an	   empty	   vector	   (Lentiv2-­‐GFP)	   and	  with	   Lentiv2-­‐GFP	   targeting	   either	  
exon	   1	   (Ex1-­‐intr)	   or	   exon	   2	   (Ex2)	   of	   SF3B1.	   The	   targeting	   vector	   efficiently	   knocked-­‐out	  
SF3B1	  in	  K562	  cells	  causing	  83%	  and	  49%	  protein	  reduction	  in	  Ex1-­‐intr	  and	  Ex2	  respectively	  
(Figure	   1A,	   study	   III),	   and	   98.6%	   deletion	   in	   exon	   1	   and	   68%	   in	   exon	   2	   at	   genomic	   level	  
(Figure	  1B-­‐C,	   study	   III).	  Moreover,	   the	   cutting	  efficiency	  of	   CRISPR/Cas9	  was	  evaluated	  at	  
mRNA	   level	   using	   primers	   specific	   for	   the	   predicted	   deleted	   regions	   in	   GFP+	   cells	   and	   a	  
significant	  reduction	  was	  detected	  in	  both	  exons	  (Figure	  1D-­‐E,	  study	  III).	  Then,	  by	  targeting	  
exon1-­‐intron,	   we	   generated	   two	   single	   cell-­‐derived	   heterozygous	   clones,	   EX1-­‐int	   N5	   and	  
EX1-­‐int	  N7,	  both	  carrying	  a	  frameshift	  deletion,	  while	  gRNAs	  against	  exon	  2	  produced	  two	  
clones,	   Ex2	   N15	   homozygous	   and	   Ex2	   N2	   heterozygous	   (Figure	   2A-­‐C,	   study	   III).	   Protein	  
alignment	  of	  Lentiv2-­‐GFP	  N1	  (wild-­‐type	  for	  Exon1-­‐int	  and	  Ex2)	  against	  each	  clone	  showed	  
that	  frameshift	  deletions	  induced	  by	  CRISPR/Cas9	  led	  to	  various	  amino	  acids	  substitutions	  in	  
the	  heterozygous	  clones,	  but	  not	  in	  Ex2	  N15	  where	  the	  deletion	  did	  not	  change	  the	  amino-­‐
acid	  sequence	  (Figure	  2D-­‐E,	  study	  III).	  These	  results	  were	  supported	  by	  western	  blot	  analysis	  
showing	  a	  50%	  reduction	  of	  SF3B1	  protein	  in	  all	  heterozygous	  clones	  (EX1-­‐int	  N5,	  EX1-­‐int	  N7	  
and	  Ex2	  N2)	  in	  addition	  to	  an	  almost	  complete	  loss	  of	  protein	  in	  the	  homozygous	  clone	  Ex2	  
N15	  (Figure	  2F,	  study	  III).	  Conversely,	  to	  test	  if	  SF3B1	  K700E	  mutation	  may	  induce	  an	  MDS-­‐
like	  molecular	  phenotype	  in	  K562	  cells,	  we	  cloned	  SF3B1	  WT	  or	  mutant	  K700E	  into	  a	  Tet-­‐on	  
inducible	   vector	   containing	  GFP.	  Upon	   transduction	  and	   treatment	  with	  doxycycline,	   cells	  
were	   sorted	   for	   high	   and	   low	  GFP	   levels,	   and	   part	   of	   the	   cells	  were	   cultured	   to	  monitor	  
possible	   toxic	   effects	   of	   the	   vector,	   which	   did	   not	   affect	   cell	   viability	   during	   14	   days	   of	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culture.	   Of	   note,	   the	   mRNA	   expression	   level	   of	   SF3B1	   recombinant	   and	   wild-­‐type	   were	  
similar	  to	  that	  of	  physiological	  levels	  (Figure	  3	  A-­‐B,	  study	  III).	  	  
To	  evaluate	  how	  K700E	  expression,	  and	  loss	  or	  reduction	  of	  the	  normal	  SF3B1	  protein	  affect	  
gene	  expression	  and	   splicing,	  we	   focused	  on	   three	  well-­‐known	  genes	   in	  MDS-­‐RS	   for	   their	  
potential	  role	  in	  the	  disease	  pathogenesis:	  ABCB7,	  ALAS2	  and	  TMEM14C.	  	  
Loss	   or	   reduction	   of	   SF3B1	   normal	   protein	   resulted	   unexpectedly	   in	   an	   MDS-­‐RS-­‐like	  
phenotype	  with	  reduced	  ABCB7	  expression	  and	  altered	  exon	  usage	  (Figure	  4B	  and	  Figure	  5E,	  
study	   III),	   increased	   levels	   of	   ALAS2	   expression	   (Figure	   4C,	   study	   III)	   and	   mis-­‐splicing	   of	  
TMEM14C	   (Figure	   5C,	   study	   III).	   Furthermore,	   loss	   of	   SF3B1	   compromised	   cell	   growth	   in	  
K562,	  but	  did	  not	  increase	  apoptosis	  suggesting	  that	  the	  reduced	  cell	  growth	  instead	  might	  
be	  due	  to	  an	  impaired	  regulation	  of	  the	  cell	  cycle	  (Figure	  6A-­‐B,	  study	  III).	  	  
Intriguingly,	   expression	   of	   K700E	   mutation	   at	   physiological	   level,	   induced	   mis-­‐splicing	   of	  
TMEM14C	   (Figure	   5B,	   study	   III),	   decrease	   ABCB7	   and	   increase	   ALAS2	   expression	   levels	  
(Figure	   4D-­‐E,	   study	   III),	   as	   observed	   in	  MDS-­‐RS	   patients	   and	   in	   knock-­‐out	   cells;	   however	  
ALAS2	   expression	   in	   the	   mutant	   samples	   was	   less	   pronounced	   compared	   to	   the	   that	   of	  
patients,	  or	  that	  detected	  in	  the	  KO	  clones.	  Importantly,	  SF3B1	  WT	  expression	  resulted	  in	  a	  
moderate	  increase	  of	  ABCB7	  as	  well	  as	  an	  unexpected	  increase	  in	  ALAS2. These	  results	  may	  
be	  explained	  by	  the	  fact	  that	  ABCB7	  has	  been	  previously	  reported	  to	  be	  mis-­‐spliced	  in	  MDS-­‐
RS	  and	  to	  be	  one	  of	  the	  targets	  of	  mutant	  SF3B1-­‐induced	  nonsense-­‐mediated	  decay	  (NMD	  
pathway)	   (Darman	   et	   al.	   2015).	   Conversely,	  ALAS2	  was	   characterized	   by	   differential	   exon	  
usage	   (Dolatshad	   et	   al.	   2015),	   however	   according	   to	  Darman	   et	   al.	   study	   (Darman	   et	   al.	  
2015)	  ALAS2	  was	  not	  identified	  as	  a	  target	  of	  the	  NMD	  surveillance	  system.	  According	  to	  this	  
study,	   SF3B1	   heterozygous	   mutation	   in	   MDS-­‐RS	   patients	   causes	   splicing	   events,	   half	   of	  
which	   are	   operated	   by	   normal	   SF3B1	   and	   the	   other	   half	   by	   abnormal	   SF3B1.	   Splicing	  
mediated	  by	  normal	  SF3B1	  leads	  to	  canonical	  transcripts	  and	  proteins,	  whereas	  the	  mutant	  
splicing	  factor	  mis-­‐recognizes	  the	  3’	  splice	  site	  and	  generates	  frameshift	  mutations	  resulting	  
in	   an	   unproductive	   isoform	   that	   would	   shunt	   the	   gene	   from	   the	   normally	   translated	  
pathway	   into	  the	  NMD	  pathway	  (Darman	  et	  al.	  2015).	  Therefore,	  we	  could	  speculate	  that	  
the	  haploinsufficiency	   in	  MDS-­‐RS	  SF3B1	  mutated	  patients	  may	   lead	   to	   gain-­‐of-­‐function	  at	  
stem	   cell	   level	   (i.e.	   proliferation	  of	  HSC),	   but	   loss-­‐of-­‐function	   at	   precursors	   level,	   perhaps	  
caused	  by	  ABCB7	  mis-­‐splicing	  resulting	  in	  ineffective	  erythropoiesis	  (Boultwood	  et	  al.	  2008,	  
Nikpour	  et	  al.	  2013).	  These	  observations	  may	  be	  relevant	  for	  the	  treatment	  of	  MDS-­‐RS	  as	  
recent	  studies	  have	  shown	  that	  SF3B1	  haploinsufficiency	  is	  responsible	  for	  the	  proliferative	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capacity	   of	  HCS.	   It	   also	   implies	   that	   the	  use	  of	   splicing	   factor	  modulators	  may	   selectively	  
target	   MDS-­‐RS	   cells	   with	   somatic	   mutations	   in	   SF3B1,	   as	   recently	   shown	   by	   the	   E7107	  
treatment	  of	  progenitor	  cells	  from	  Sf3b1K700E	  mice	  (Obeng	  et	  al.	  2016).	  
In	   summary,	   our	   data	   indicates	   that	   SF3B1	   mutation	   exerts	   its	   effects	   through	   a	   loss-­‐of-­‐
function.	   The	   degree	   to	   which	   the	   function	   is	   lost	   varied	   in	   the	   different	   experimental	  
systems,	  however	  both	  knock-­‐out	  and	  expression	  of	   the	  mutant	  result	   in	  gene	  expression	  
patterns	   similar	   to	   those	   observed	   in	   MDS-­‐RS	   patients. Detailed	   RNA	   sequencing	   and	  
genome	  editing	   experiments	   in	  primary	   cells	  will	   be	   essential	   to	  decipher	  whether	  SF3B1	  
mutations	  act	  though	  a	  gain	  or	  a	  loss	  of	  function.	  In	  contrast	  to	  our	  data,	  the	  fact	  that	  SF3B1	  
mutations	   cluster	   at	   hotspots,	   in	   a	  mutation	   pattern	   that	   is	   characteristic	   for	   oncogenes,	  
suggest	  a	  possible	  gain-­‐of-­‐function	  (Zhou	  et	  al.	  2015).	  Yet	  it	  remains	  to	  be	  unraveled	  what	  
functional	   role	  SF3B1	  mutations	  may	  play	   during	  oncogenesis	   and	  whether	   dys-­‐regulated	  
SF3B1	   activity	   is	   required	   for	   cancer	   maintenance.	   SF3B1	   small-­‐molecule	   inhibitors	   are	  
currently	  under	  development	  and	  have	  entered	  clinical	  trials	  (Webb	  et	  al.	  2013).	  Moreover,	  
the	  absence	  of	  frameshift	  deletions	  among	  hundreds	  of	  MDS-­‐RS	  patients,	  and	  the	  fact	  that	  
the	   observed	   mutations	   are	   less	   deleterious	   than	   expected	   on	   the	   basis	   of	   chance	  
(Papaemmanuil	   et	   al.	   2011),	  may	   imply	   that	   the	  mutant	   SF3B1	   protein	   retains	   structural	  
integrity,	  but	  with	  altered	  function	  (Malcovati	  et	  al.	  2016),	  therefore	  arguing	  for	  SF3B1	  as	  a	  
neomorphic	  mutation	   (Darman	   et	   al.	   2015).	   However,	   loss-­‐of-­‐function	   effects	   have	   been	  
described	  as	  a	  consequence	  of	  common	  point	  mutations,	   such	  as	  R882	  DNMT3A	   in	  acute	  
myeloid	  leukemia.	  This	  mutation	  acts	  as	  dominant	  negative	  against	  the	  WT	  enzyme	  causing	  
hypomethylation	  throughout	  the	  genome	  of	  these	  patients	  (Russler-­‐Germain	  et	  al.	  2014).	  	  
Future	   studies	   should	   aim	   to	   optimize	  methods	   to	   introduce	   SF3B1	   point	  mutations	   and	  
genetically	  modify	  normal	  primary	  bone	  marrow	  CD34+	  cells	  in	  order	  study	  the	  role	  of	  SF3B1	  
in	   disease	   initiation.	   Importantly,	   considering	   that	   SF3B1	   is	   shared	   by	   two	   distinct	  
spliceosome	  complexes	   (major	  and	  minor)	  owing	   to	   its	   importance	   in	   the	   removal	  of	  any	  
type	  of	   intron,	   a	  disturbance	   in	   the	   splicing	  mechanism	  by	  mutations	  may	  have	  dramatic	  
consequences	  on	   transcription	   and	  expression	  of	   thousand	  of	   gene.	   Therefore,	   it	  may	  be	  
relevant	  to	  pursue	  a	  combined	  analysis	  of	  transcriptiome	  and	  proteomics	  and	  to	  investigate	  
the	   biochemical	   properties	   of	   transcripts,	   including	   protein-­‐RNA	   interactions	   and	   domain	  
activity,	  which	  may	  have	  a	   great	   impact	  on	   translational	   efficiency	  and	  offer	   insights	   into	  
therapeutic	  opportunities	  able	  to	  modulate	  SF3B1.	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5 CONCLUDING	  REMARKS	  AND	  FUTURE	  DIRECTIONS	  
MDS-­‐RS	   is	   characterized	   by	   ineffective	   erythropoiesis,	   the	   presence	   of	   bone	  marrow	   ring	  
sideroblasts	  and	  anemia.	  Undeniably,	  MDS-­‐RS	  being	  a	  disease	  of	  the	  elderly,	  other	  factors	  
may	  have	  an	  impact	  on	  its	  development.	  At	  present,	  the	  available	  treatments	  aim	  primarily	  
to	  improve	  erythroid	  output.	  
Before	   the	   discovery	   that	   SF3B1	   splicing	   mutations	   were	   associated	   with	   MDS-­‐RS,	   the	  
general	  hypothesis	  was	  that	  X-­‐linked	  sideroblastic	  anemia	  and	  acquired	  RARS	  were	  sharing	  
the	  same	  molecular	  basis.	  Indeed,	  the	  existence	  of	  an	  inherited	  disorder	  XLSA/A	  caused	  by	  
mutations	  in	  ABCB7	  led	  us	  to	  investigate	  the	  possible	  consequences	  of	  reduced	  expression	  
of	  the	  same	  gene	  in	  acquired	  disorders,	  with	  the	  major	  aim	  of	  understanding	  the	  reason	  for	  
the	  aberrant	  iron	  accumulation	  in	  MDS-­‐RS.	  
In	  study	  I,	  we	  unraveled	  the	  role	  of	  ABCB7	  and	  reported	  evidences	  that	  this	  gene	  is	  a	  key	  
mediator	   of	   the	   MDS-­‐RS	   phenotype.	   In	   normal	   bone	   marrow	   ABCB7	   down-­‐regulation	  
reduced	   erythroid	   differentiation,	   growth	   and	   colony	   formation	   and	   resulted	   in	   a	   gene	  
expression	  pattern	  similar	  to	  that	  observed	  in	  RARS	  erythroblasts,	  and	  in	  the	  accumulation	  
of	   mitochondrial	   ferritin.	   Conversely,	   forced	   ABCB7	   expression	   restored	   erythroid	   colony	  
growth	  and	  decreased	  mitochondrial	  ferritin	  in	  MDS-­‐RS	  CD34+	  progenitor	  cells.	  In	  addition,	  
we	  suggested	  a	  relation	  between	  SF3B1	  mutation	  and	  ABCB7	  down-­‐regulation	  and	  showed	  
altered	  usage	  of	  ABCB7	  exons	  as	  a	  possible	  explanation	  of	  the	  reduced	  ABCB7	  expression	  in	  
MDS-­‐RS	  and	  a	  secondary	  effect	  to	  the	  altered	  SF3B1	  function;	  an	  hypothesis	  later	  supported	  
by	  other	  authors	  in	  a	  detailed	  RNA	  sequencing	  study	  (Darman	  et	  al.	  2015).	  	  
The	  discovery	  of	   splicing	  mutations	   in	  MDS	  has	  provoked	   the	   field	  with	  more	   challenging	  
tasks.	   These	   mutations	   occur	   in	   a	   mutually	   exclusive	   manner	   with	   one	   another	   and	   at	  
highly	  restricted	  residues.	  Interestingly,	  each	  of	  these	  mutations	  is	  associated	  with	  distinct	  
clinical	  subtypes	  and	  phenotypes	  of	  MDS	  (i.e.	  SF3B1	  mutations	  with	  the	  ring	  sideroblasts).	  
Undeniably,	  evidence	  that	  aberrant	  pre-­‐mRNA	  splicing	  contributes	  to	  the	  disease	  phenotype	  
is	   strong	   and	   it	   has	   raised	   an	   array	   of	   mechanistic,	   functional	   and	   biological	   questions.	  
However,	   understanding	   the	   functional	   role	   of	   mutations	   in	   spliceosomal	   genes	   is	   just	  
beginning.	   Most	   reports	   used	   RNA	   sequencing	   to	   study	   splicing	   throughout	   normal	  
hematopoiesis.	  One	  common	  concept	  is	  that	  each	  stage	  of	  hematopoiesis	  is	  defined	  by	  cell	  
type-­‐specific	   differential	   splicing,	   which	  may	   reflect	   into	   changes	   in	   gene	   expression	   and	  
result	   in	  altered	  function	  and/or	  stability	  of	  the	  encoded	  proteins.	  This	   idea	  inspired	  us	  to	  
perform	  study	   II,	  where	  we	  addressed	  aberrancies	  during	  erythroid	  maturation	  of	  normal	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and	  MDS-­‐RS	  SF3B1	  mutated	  patients	  with	  regard	  to	  splicing	  and	  gene	  expression	  profile.	  In	  
fact,	   a	   very	   recent	   longitudinal	   transcriptome	   study	   of	   late	   human	   erythropoiesis,	   the	  
splicing	   in	   a	   differentiation	   stage-­‐specific	   context	   showed	   striking	   increases	   in	   levels	   of	  
intron-­‐containing	  transcripts	  in	  the	  final	  two	  steps	  of	  erythroid	  maturation	  (Pimentel	  et	  al.	  
2016).	  
In	   study	   II,	   the	   comparison	   of	  MDS-­‐RS	  SF3B1	  mutated	   and	  NBM	  CD34+	   cells	   during	   early	  
erythroid	  differentiation	  (day	  0	  and	  4)	  revealed	  a	  marked	  up-­‐regulation	  of	  genes	  involved	  in	  
the	  hemoglobin	  synthesis	  and	  the	  oxidative	  phosphorylation	  process	  and	  a	  down-­‐regulation	  
of	   the	   mitochondrial	   ABC	   transporters	   most	   likely	   as	   a	   compensatory	   reaction	   to	   the	  
defective	   terminal	   erythroid	   maturation	   with	   accumulation	   of	   iron	   in	   the	   mitochondria	  
instead	  of	  incorporation	  into	  heme.	  More	  importantly,	  we	  discovered	  that	  via	  mis-­‐splicing	  of	  
genes	   involved	   in	   the	  heme	  and	  hemoglobin	  synthesis,	  SF3B1	  mutation	  might	  disturb	   the	  
mitochondrial	   iron	   handling	   and	   the	   hemoglobinization	   process	   in	   MDS-­‐RS.	   Finally,	   we	  
found	   that	   SF3B1	   did	   not	   confer	   a	   growth	   disadvantage	   until	   terminal	   maturation	   into	  
reticulocytes,	   implying	   a	   reduced	   differentiation	   of	   SF3B1	   mutated	   erythroblasts	   into	  
mature	  erythrocytes	  and	  suggesting	  that	  in	  MDS-­‐RS,	  anemia	  develops	  during	  the	  late	  stages	  
of	  erythropoiesis.	  This	   finding	  provides	  a	   logical	   link	   to	  new	  compounds	  such	  as	  ACE	  536,	  
which	  targets	  the	  late	  stage	  of	  erythropoiesis	  and	  increases	  the	  levels	  of	  red	  blood	  cells	  and	  
hemoglobin	  (Attie	  et	  al.	  2014,	  Suragani	  et	  al.	  2014).	  	  
Ultimately,	   in	   study	   III	  we	   evaluated	   the	  mechanistic	   effects	   of	   SF3B1	   K700E	  mutation	   in	  
myeloid	   cells	   and	   explored	   if	   the	   mutation	   confers	   a	   loss-­‐of-­‐function	   in	   regards	   of	   gene	  
expression	   and	   splicing	   of	   key	   genes	   in	   MDS-­‐RS.	   Unexpectedly,	   we	   observed	   that	   both	  
reduced	  and	  abrogated	  SF3B1	  protein,	  using	  CRISPR/Cas9	  technology,	  as	  well	  as	  expression	  
of	   SF3B1	   K700E	   mutation	   at	   physiological	   levels,	   resulted	   in	   a	   typical	   MDS-­‐RS	   gene	  
expression	  pattern	  with	  reduced	  levels	  of	  ABCB7	  and	  altered	  exon	  usage,	  increased	  ALAS2	  
expression	  and	  mis-­‐spliced	  TMEM14C.	  To	  this	  end,	  our	  preliminary	  results	  suggest	  that	  the	  
SF3B1	   mutation	   acts	   through	   a	   loss-­‐of-­‐function,	   however	   additional	   experiments	   are	  
needed	   to	   clarify	   the	   role	   of	   these	  mutations.	   Although	   initial	  mice	  models	   of	   several	   of	  
these	  mutations,	   as	   well	   as	  many	   insights	   into	   the	   global	   effects	   of	   SF3B1	   mutations	   on	  
splicing	  have	  been	  described,	  it	  remains	  to	  be	  clarified	  if	  SF3B1	  mutations	  are	  causative	  of	  
MDS-­‐RS	  or	  if	  they	  are	  passenger	  mutations	  only	  contributing	  to	  a	  small	  extent	  to	  the	  disease	  
progression.	   The	   answer	   may	   be	   found	   in	   targeted	   RNA	   sequencing	   using	   primary	  
genetically	   modified	   normal	   BM	   cells;	   however	   progress	   is	   limited	   by	   the	   difficulty	   of	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delivering	  the	  mutant	  and	  the	  wild-­‐type	  SF3B1	  in	  human	  progenitor	  cells.	  	  
Our	  and	  others	  studies	  have	  tried	  to	   identify	  pathways	  and	  key	  target	  genes	   linked	  to	  the	  
disease	  phenotype	  in	  order	  to	  understand	  the	  mechanisms	  of	  the	  ineffective	  erythropoiesis.	  
Along	  this	  line,	  functional	  studies	  should	  aim	  to	  validate	  findings	  and	  investigate	  further	  the	  
key	  genes	  pinpointed	  by	  several	  recent	  genome	  wide	  studies.	  Interestingly,	  the	  fact	  that	  the	  
Abcb7	  mouse	  model	  as	  well	  as	  Sf3b1	  knock-­‐in	  mice	  (Mupo	  et	  al.	  2016,	  Obeng	  et	  al.	  2016)	  
were	  unable	   to	  effectively	  generate	   ring	   sideroblasts	  may	  suggest	  an	  unknown	  difference	  
between	   human	   and	   murine	   erythroid	   precursors	   with	   respect	   to	   mitochondrial	   iron	  
metabolism.	  Also,	  common	  splicing	  events	   in	  MDS-­‐RS	  were	  not	  observed	   in	   these	  models	  
maybe	   because	   SF3B1	  mutations	   exert	   their	   effect	   on	  well-­‐conserved	   functions	   of	   SF3B1	  
unrelated	   to	  splicing.	  Alternatively,	   the	   iron	  accumulation	  may	  also	  be	   the	  effect	  of	  other	  
mutations	  or	  biological	  mechanisms.	  For	   instance,	  Obeng	  et	  al.	   reported	   that	   loss	  of	  Tet2	  
cooperates	  with	  Sf3b1K700E	  to	  worsen	  anemia,	  and	  causes	  an	  earlier	  expansion	  of	  long-­‐term	  
hematopoietic	   stem	   cells,	   but	   rescues	   the	   impaired	   competitive	   repopulating	   activity	  
conferred	  by	  Sf3b1K700E.	   The	  additive	  effect	  of	  Tet2	  may	  explain	  why	   these	  mutations	  are	  
well	  tolerated	  in	  MDS	  patients,	  thereby	  making	  this	  combinatorial	  model	  extremely	  useful	  
to	   recapitulate	   the	  mutational	  pattern	  of	  patients.	  Certainly,	   the	  high	   frequency	  of	  SF3B1	  
mutations	   in	  MDS-­‐RS	   patients	   have	   shifted	   the	   efforts	   towards	   the	   understanding	   of	   the	  
splicing	  mechanisms	  and	  how	  they	  contribute	  to	  disease	  pathogenesis.	  Indeed,	  considering	  
that	  SF3B1	  is	  acting	  within	  a	  complex,	  it	  would	  be	  crucial	  to	  understand	  in	  further	  detail	  how	  
mutations	  in	  SF3B1	  result	  in	  altered	  3ʹ′	  SS	  usage,	  how	  SF3B1	  is	  directed	  to	  their	  pre-­‐mRNA	  
targets,	  how	  other	  proteins	  are	  interacting	  with	  SF3B1,	  and	  the	  structural	  and	  biochemical	  
function	  of	  the	  HEAT	  domains	  of	  SF3B1,	  where	  the	  majority	  of	  SF3B1	  mutations	  are	  located.	  
Thus,	   a	   proteomic	   approach	   would	   provide	   a	   mechanistic	   link	   between	   the	   mutant	  
spliceosomal	   protein,	   alteration	   in	   the	   splicing	   and	   in	   impaired	   erythropoiesis,	   hence	  






  49 
6 ACKNOWLEDGEMENTS	  
I	  would	   like	   to	  express	  my	  sincere	  appreciation	   to	  all	  who	  supported	  me	  during	  my	  Ph.D.	  
First	   and	   foremost	   to	   my	   supervisors,	   who	   have	   taken	   the	   responsibility	   to	   guide	   me	  
throughout	  these	  years;	  each	  has	  contributed	  with	  their	  own	  perspective,	  experience	  and	  
skills	  to	  direct	  my	  development	  as	  a	  scientist.	  	  
	  
To	  my	  main	  supervisor,	  Eva	  Hellström-­‐Lindberg,	  for	  giving	  me	  the	  opportunity	  to	  pursue	  a	  
Ph.D.	   in	  your	  group,	   for	  your	  guidance	  and	  support	   throughout	  my	  years	  as	  a	   student.	   In	  
addition	  to	  your	  vast	  expertise	  on	  MDS,	  I	  have	  admired	  your	  enthusiasm,	  perseverance	  and	  
your	   optimism,	   all	   of	   which	   have	   been	   instrumental	   during	   this	   time.	   Thank	   you	   for	  
establishing	  such	  a	  warm,	  productive	  and	  creative	  research	  environment	  at	  HERM.	  
	  	  
My	  co-­‐supervisor	  Julian	  Walfridsson,	  for	  all	  the	  encouragement	  you	  have	  given	  me	  and	  for	  
literally	   shaping	   my	   Ph.D.	   Your	   trust,	   constructive	   criticism,	   optimism	   and	   your	   sense	   of	  
humor	  were	  greatly	  appreciated	  and	  always	  reassuring	  and	  made	  me	  feel	  like	  the	  confident	  
student	   that	   I	   am	   today.	   Thank	   you	   for	   showing	  me	   that	   science	   is	   fun	   and	   “not	   about	  
feelings”	  and	  for	  simply	  being	  an	  amazing	  co-­‐supervisor.	  	  
My	  co-­‐supervisor	  Liselotte	  Vesterlund,	  for	  always	  showing	  great	  interest	  in	  my	  projects	  and	  
giving	   me	   valuable	   inputs	   and	   ideas.	   Thank	   you	   for	   being	   always	   helpful	   and	   promptly	  
replying	   to	  my	  emails	  and	   for	  all	   the	  nice	  chats	  about	   life	  and	   future	  plans.	  You	  are	   truly	  
great!	  
Petter	  Woll	  and	  Sten	  Eirik	  Jacobsen,	  thank	  you	  for	  the	  interesting	  scientific	  discussions	  and	  
the	  constructive	  inputs	  during	  our	  joint	  meetings	  and	  MDS	  retreats.	  
Elli	   Papaemmanuil,	   it	   is	   no	   understatement	   to	   say	   that	   your	   work	   on	   SF3B1	   has	  
revolutionized	   the	  entire	   field	  of	  MDS	  and	  my	  Ph.D.	  Thank	  you	   for	  sharing	  your	  expertise	  
and	   knowledge	   throughout	   these	   years.	   All	   the	   encounters	   we	   had	   at	   conferences	   have	  
encouraged	  me	  to	  keep	  on	  going	  and	  were	  a	  true	  source	  of	  inspiration.	  
Seishi	  Ogawa	  for	  being	  a	  great	  collaborator	  and	  for	  sharing	  your	  vast	  expertise	  in	  genetics,	  
MDS	  and	  sequencing.	  	  Your	  help	  for	  my	  last	  manuscript	  is	  invaluable.	  
My	  co-­‐authors,	  Shintaro	  Katayama,	  for	  your	  patience	  and	  the	  enormous	  help	  with	  the	  RNA	  
sequencing	  data,	  Per	  Unneberg	  and	   Juha	  Kere	   for	   the	  assistance	  and	  the	  collaboration	   in	  
paper	  II.	  
A	  sincere	  gratitude	  to	  the	  MDS	  group,	  for	  sharing	  every	  part	  of	  this	  journey	  from	  the	  very	  
beginning,	   with	   its	   ups	   and	   downs.	   A	   special	   thanks	   to	   Christian	   Scharenberg,	   Edda	  
Elvarsdottir,	  Marios	  Dimitriou,	  Mohsen	  Karimi	  and	  Teresa	  Mortera-­‐Blanco	  for	  the	  scientific	  
inputs,	  the	  support	  and	  your	  cheerful	  attitude,	  Magnus	  Tobiasson,	  for	  all	  the	  NBMs	  I	  asked	  
you	  to	  take,	  Lalla	  Forsblom,	  Maryam	  Nikpour	  for	  welcoming	  me	  to	  the	  MDS	  group,	  Asmaa	  
Ben	   Azenkoud,	   for	   your	   kindness,	   Annette	   Engström	   for	   your	   continuous	   help	   and	   for	  
making	  sure	  that	  everything	  was	  ready	  for	  my	  defense	  way	  in	  advance.	  To	  Gunilla	  Walldin,	  
for	   impeccably	  coordinating	  and	  arranging	  samples	  and	   for	  not	  giving	  up	  on	  my	  Swedish!	  
Last	  but	  not	   least,	   to	  Monika	  Jansson,	   for	  your	  thoughtfulness,	  your	  generous	  help	   in	  the	  
lab	  and	  for	  having	  a	  solution	  to	  almost	  all	  my	  problems.	  	  
 50 
Thanks	   to	   Johanna	   Ungerstedt,	   for	   your	   enthusiasm,	   your	   positive	   energy	   and	   your	  
commitment	  in	  providing	  samples;	  Martin	  Jädersten,	  for	  your	  kindness,	  your	  interest	  in	  my	  
projects	  and	  your	  valuable	  advises	   for	  my	   future	  career;	  Evren	  Alici	   for	  your	  motivational	  
and	   friendly	   guidance	   since	   the	   very	   beginning	   of	   my	   Ph.D.;	   Hong	   Qian	   and	   Robert	  
Månsson,	   for	   answering	   to	   all	   my	   questions	   anytime	   I	   knocked	   on	   your	   door;	   Sören	  
Lehman,	   for	   the	   scientific	   inputs	   you	  have	   given	  me	  at	  my	  half	   time;	   Petter	  Höglund	   for	  
accepting	  to	  be	  the	  chairman	  at	  my	  defense;	  Iyadh	  Douagi	  for	  helping	  me	  with	  the	  FACS	  and	  
the	   sorting;	   Katarina	   Le	   Blanc	   for	   supporting	   a	   great	   research	   environment;	   Cecilia	  
Götherström	  for	  kindly	  providing	  cord	  blood	  samples	  and	  Nina	  Heldring,	  for	  taking	  care	  of	  
the	  SAP	  seminars	  and	  for	  always	  giving	  me	  constructive	  feedback.	  
From	   Lund	  University,	   thanks	   to	  Niels	   Bjarne	  Woods,	   for	  welcoming	  me	   in	   your	   lab	   and	  
introducing	  me	  to	  the	  iPS	  cells;	  Jonas	  Larsson	  for	  providing	  us	  with	  indispensable	  vectors	  to	  
paper	   III;	  Sofie	  Singbrant,	   for	  your	  kindness	  and	  your	  genuine	   interest	   in	  my	  projects	  and	  
Johan	  Flygare,	  for	  accepting	  to	  be	  part	  of	  my	  half	  time	  committee	  and	  to	  critically	  revise	  my	  
thesis.	  Your	  expertise	  on	  erythropoiesis	  will	  add	  a	  great	  value	  to	  my	  defense.	  
To	  Astrid	  Olsnes	  Kittang	   for	  warmly	  welcoming	  me	  in	  Bergen	  six	  years	  ago	  and	  for	  all	  the	  
nice	  chats	  at	  the	  NMDS	  meetings.	  
To	  Anethe	  Mansen	   and	  Tina	  Persson	   at	   the	  KI	  Career	  Service,	   for	   the	  hard	  work	  and	   the	  
strong	  commitment	  in	  helping	  students	  with	  their	  first	  career	  steps	  after	  PhD.	  Thank	  you	  for	  
organizing	   the	   Career	   Skills	   for	   Scientist	   course,	   thanks	   to	   which	   I	   had	   the	   pleasure	   to	  
interview	  Maria	  Kakoulidou	   and	  Andreas	  Lennartsson	   and	   to	   learn	   from	  their	   interesting	  
and	  inspiring	  career	  stories.	  	  
To	  the	  Department	  of	  Medicine,	  and	  especially	  to	  Jan	  Bolinder,	  Anastasia	  Urban,	  Therese	  
Lind,	  Elenor	  Nyman,	  Klas	  Karlsson	  and	  Edgardo	  Faune	  for	  easing	  the	  long	  bureaucracy	  and	  
for	  helping	  me	  with	  any	  kind	  of	  technical	  issue.	  
I	  want	   to	  express	  my	  heartfelt	  appreciation	   to	   the	  members	  of	  HERM.	  You	  all	  have	  been	  
part	  of	   this	   thesis	   in	  one	  way	  or	  another,	   thank	  you	  for	  bettering	  my	  day-­‐to-­‐day	   life	  even	  
with	  a	  simple	  smile	  in	  the	  corridor	  and	  for	  sharing	  lunches,	  fika,	  julbord,	  afterworks,	  dinners,	  
parties,	  tears,	  frustration	  and	  so	  many	  laughs!	  You	  all	  made	  this	  journey	  memorable!	  Thanks	  
in	  particular	  to:	  	  
Adil	   Doğanay	   Duru,	   Ayla	   De	   Paepe,	   Carin	   Dahlberg,	   Caroline	   Gavin,	   Makoto	   Kondo,	  
Thibault	   Bouderlique	   the	   best	   chef	   of	   HERM	   and	   Sridharan	   Ganesan,	   the	   true	   soul	   of	  
HERM,	   for	   having	   been	   part	   of	   fun	   afterworks,	   parties	   and	   beautiful	   Swedish	   summer	  
evenings;	  my	   “sister”	  Monika	   Dolinska	   for	   all	   the	   enjoyable	   conversation	   we	   had	   in	   the	  
corridor	  and	  over	  a	  glass	  of	  wine;	  Erle	  Refsum,	  Aleksandra	  Krstić	  and	  Eva	  Hellqvist	  for	  your	  
nice	  company	  at	  lunch	  and	  on	  the	  train;	  Stephan	  Meinke	  my	  spiritual	  supporter	  during	  the	  
FACS	  staining;	  Thuy	  Luu	  Thanh,	  for	  your	  concern	  for	  others	  and	  for	  being	  always	  so	  positive;	  
Anton	  Törnqvist	  and	  Srinivasa	  Rao	  Nagubothu	  for	  our	  nice	  encounters	  in	  the	  corridor	  and	  
your	  genuine	  smiles;	  Charlotte	  Gustafsson,	  Xiaoze	  Li,	  Lakshmi	  Sandhow,	  Pignan	  Xiao	  and	  
Anne-­‐Sofie	  Johansson,	  for	  all	  the	  fun	  in	  the	  molecular	  lab	  and	  the	  good	  music;	  Nadir	  Kadri,	  
for	   cheering	   me	   up	   with	   all	   your	   jokes	   and	   your	   loud	   and	   deep	   laughs;	   Esmat	   Kamali	  
Dolatabadi,	   for	   the	   nice	   time	  we	   spent	   in	   the	   culture	   room	   and	   for	   letting	  me	   taste	   the	  
amazing	   Persian	  poolaki;	   Shabnam	  Kharazi,	   for	   thinking	   of	  me	   even	   on	   vacation	   and	   for	  
bringing	  me	  delicious	   jam;	  Allegra	  Matheson	  Lord	  and	  Christer	  Nilsson	   for	  keeping	  a	  nice	  
atmosphere	  in	  the	  office;	  Mari	  Gilljam,	  Birgitta	  Stellan	  and	  Tolga	  Sütlü	  for	  being	  wonderful	  
neighbors	  at	  KFC	  and	  for	  your	  help	  whenever	  I	  had	  questions;	  Inger	  Vedin,	  for	  your	  kindness	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and	  wisdom;	  Alf	  Grandien	  and	  Kari	  Högstrand,	   for	  helping	  me	  with	  cloning	   issues;	  Minna	  
Suomela,	  kiitos	  for	  being	  always	  so	  smiley	  and	  baking	  amazing	  cookies;	  Karin	  Mellström	  for	  
giving	  me	   the	   chance	   to	   follow	   the	  GMP	  course;	  Ann	  Wallblom,	   Sofia	  Bengtzen,	  Dimitra	  
Vasileiadi,	   Lili	   Andersson	   and	   Linnea	  Acaralp	   for	   your	   continuous	   assistance	   and	   help	   at	  
HERM.	  To	   the	  new	  Hermi’s	  Giovanna	  Perinetti	  Casoni,	   Lamberto	  Torralba	  Raga,	  Martha-­‐
Lena	  Müller,	  Matthias	  Voss,	  Hongya	  Han,	   Lucia	  Pena	  Perez,	   Stina	  Virding	  and	  Desmond	  
Chin	   and	   the	   former	   graduate	   students	   Lisamarie	   Roch,	   Athina	   Totomi,	   Flavia	   Peci,	  
Kathleen	  Heck	  and	  David	  Chang,	  that	  even	  only	  for	  short	  time,	  have	  largely	  contributed	  to	  
the	  nice	  atmosphere	  at	  HERM.	  	  
	  
A	  special	  thanks	  to	  the	  V.I.P.	  members	  of	  the	  “Oompa	  Loompa	  Virus	  Factory”…	  
Yaser	  Heshmati,	  my	  favorite	  young	  scientist!	  I	  truly	  admire	  your	  scientific	  independency	  as	  
well	  as	  your	  positive	  energy	  and	  perseverance.	  Thank	  you	  for	  your	  constant	  support,	  your	  
friendship	  and	  for	  teaching	  me	  so	  much	  in	  the	  lab.	  I	  am	  so	  “felice”	  to	  have	  worked	  with	  you.	  
In	  a	  few	  years	  you	  will	  be	  a	  great	  PI	  with	  an	  amazing	  group!	  Best	  of	  luck	  Prof!	  	  
Aditya	  Harisankar,	   for	  your	  “contagious”	  positive	  energy,	  your	  help	  and	  kindness,	   for	   the	  
loud	  metal	  music	  in	  the	  lab,	  for	  a	  culture	  room	  in	  the	  darkness,	  for	  thousands	  of	  after-­‐works	  
and	  coffees,	  for	  teaching	  me	  the	  rudiments	  of	  cloning	  and	  for	  wiping	  my	  sweat	  during	  the	  
trans	  Blot.	  	  
Gözde	  Türköz,	   for	  your	  kindness	  and	  your	  genuine	  concern	   for	  others,	   for	  brain-­‐storming	  
with	  me	  during	  our	  CRISPR/Cas9	  sessions,	   for	  our	  “tap-­‐tap”	  trip	   to	  Lund…	  and	  for	  sharing	  
the	  long	  days	  in	  the	  virus	  lab.	  	  
	  
To	  my	  dear	  colleagues…	  
Hani	  Abdulkadir	  and	  Deepika	  Nair	  for	  your	  continuous	  support,	  for	  cheering	  me	  up	  anytime	  
I	  needed,	  for	  the	  long	  and	  nice	  chats	  on	  our	  commute	  home,	  for	  being	  simply	  amazing	  and	  
for	  reminding	  me	  this:	  “Everything	  will	  be	  fine	  in	  the	  end,	  if	   it’s	  not	  fine,	  it’s	  not	  the	  end”.	  
Huthayfa	  Mujahed	  it	  was	  great	  share	  the	  office	  with	  you,	  thank	  you	  for	  making	  our	  corner	  
paper-­‐free	  and	  for	  keeping	  the	  plants	  alive. Hero	  Nikdin,	  my	  beautiful	  “sare	  piaz”,	  I	  am	  so	  
grateful	   for	   the	   time	   we	   have	   spent	   at	   HERM.	   Thank	   you	   for	   your	   friendship	   and	   for	  
accepting	  to	  be	  my	  toastmaster!	  It’s	  finally	  time	  to	  celebrate	  my	  dear!!!	  Michael	  Chrobok,	  
my	   favorite	   German	   and	   SFI	   buddy!	   This	   PhD	   was	   just	   the	   beginning	   of	   a	   beautiful	  
friendship.	  Ying	  Qu,	  we	  have	  come	  a	  long	  way	  since	  you	  used	  to	  silently	  come	  to	  our	  office	  
on	  the	  6th	  floor.	  Thank	  you	  for	  having	  been	  there,	  “for	  better	  or	  for	  worse”	  and	  for	  all	  the	  
times	  you	  have	  helped	  me	  with	  statistics	  and	  bioinformatics.	  Stephanie	  Darmanin,	  my	  true	  
mentor!	  Grazie	  di	  cuore	  for	  the	  millions	  of	  times	  you	  have	  listened	  to	  me,	  encouraged	  me	  
and	  given	  me	  precious	  advises. 
	  
…and	  my	  wonderful	  friends	  
Ivana	  Bulatović,	  when	   I	   first	  met	   you	   in	   the	   quiet	   corridor	   at	   KFC,	   I	   did	   not	   imagine	   you	  
would	  have	  become	  one	  of	  the	  most	  important	  people	  of	  my	  life.	  I	  cannot	  imagine	  my	  time	  
in	   Stockholm	   and	   my	   PhD	   without	   you	   on	   my	   side.	   They	   say,	   “hardship	   make	   or	   break	  
people”,	  but	  I	  can	  say	  that	  I	  made	  it	  thanks	  to	  you,	  my	  draga	  prijateljice!	   
Valentina	  Giai,	  I	  cannot	  express	  how	  much	  I	  value	  your	  friendship	  and	  how	  grateful	  I	  am	  for	  
all	  you	  have	  done	  for	  me	  when	  I	  first	  arrived	  in	  Stockholm.	  August	  20th	  2010,	  through	  a	  big	  
wall-­‐glass	  in	  Arlanda	  was	  not	  only	  the	  beginning	  of	  my	  adventure	  in	  Stockholm,	  but	  the	  day	  I	  
met	  an	  amazing	  friend.	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Erica	   Miraglia,	   Lorenza	   Capantini,	   Elisa	   Dioguardi,	   Valeria	   Messina	   and	   Valentina	  
Pampanini	  a.k.a	  Miranda,	   Lorenz,	   Fitu,	  Messina	   and	   Pampas,	   for	   your	   constant	   presence	  
throughout	   these	  years.	  You	  have	  truly	  created	  a	  sense	  of	  belonging	   for	  which	   I	   feel	  very	  
fortunate.	  Grazie	  bimbe	  per	  aver	  condiviso	  davvero	  di	  tutto!	  
Paola	  Violi	  and	  Giuseppe	  Cappellano,	   for	  helping	  me	  settle	  down	  at	   the	  beginning	  of	  my	  
Swedish	  adventure.	  I	  will	  never	  forget	  our	  fun	  times	  in	  Flempan.	  	  
Paola	  Longati	  and	  Rainer	  Heuchel,	  it	  has	  always	  been	  a	  pleasure	  bumping	  into	  you	  two	  at	  
NOVUM.	  Thank	  you	  for	  being	  there	  for	  me.	  
Thanks	  to	  my	  Finnish	  friends,	  Fanni	  Salmela	   for	   the	   laughs	  and	  the	  beers,	  and	  Niklas	  von	  
Lüders	   for	   your	   bone	  marrow	   donations	  ☺	   and	   for	   entertaining	  me	  with	   your	   incredible	  
stories.	  	  
Gitta	   and	   Jarmo,	   kiitos	   for	   being	   part	   of	   my	   family	   in	   Stockholm,	   for	   your	   concern	   and	  
kindness.	  
	  
Thanks	  to	  my	  friends	  in	  Italy,	  for	  making	  me	  feel	  like	  if	  I	  had	  never	  left	  Turin…	  	  
Elisa	  Migliore,	  for	  being	  probably	  one	  of	  the	  reasons	  why	  I	  ended	  up	  in	  Sweden,	  Costanza	  
Frari,	   Corrado	   Laronga,	   Fiorella	   Ballerini,	   for	   your	   authentic	   and	   precious	   friendship	   and	  
Leone	  Gioria,	  for	  the	  unforgettable	  time	  in	  Göteborg	  with	  Bruce.	  	  
	  
A	  Michele	  Aliberti,	  perché	  oggi	  potresti	  finalmente	  dire	  che	  “quella	  di	  Torino”	  è	  davvero	  una	  
dottoressa.	  
To	  Victor,	  for	  being	  my	  biggest	  fan	  despite	  my	  emotional	  storms.	  Thank	  you	  for	  your	  love,	  
patience	  and	  understanding.	  	  
A	  Ilaria,	  mamma	  e	  papà,	  dedico	  il	  lavoro	  e	  il	  successo	  di	  questa	  tesi.	  Non	  avrei	  mai	  raggiunto	  
questo	  traguardo	  senza	  di	  voi.	  In	  questi	  ultimi	  anni	  abbiamo	  affrontato	  tante	  sfide,	  ma	  voi	  
non	   avete	   mai	   perso	   il	   coraggio,	   anzi,	   siete	   stati	   la	   mia	   forza.	   Mi	   avete	   insegnato	   ad	  
affrontare	   gli	   ostacoli	   e	   a	   rialzarmi	   più	   forte	   di	   prima.	   Sebbene	   la	   distanza	   che	   ci	   tiene	  
separati	  l’uno	  dall’altra	  sia	  enorme,	  il	  vostro	  amore	  e	  supporto	  sono	  stati	  e	  saranno	  sempre	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